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Abstract 
Introduction: Epilepsy is a common serious neurological disorder affecting approximately 50 million 
people worldwide. The mainstay of treatment is the use of antiepileptic drugs (AEDs), to which 
approximately 70% of people with epilepsy respond.1, 2 
Lamotrigine (LTG) was first licensed for use in the UK in 1991 and has become one of the most 
commonly prescribed AEDs in the developed world. It has proven efficacy for various epilepsy types, 
is employed at first-line treatment for partial-onset and generalised seizures, may be used for atonic, 
tonic, and atypical absence seizure types, and also has licensing for the treatment of Lennox-Gastaut 
syndrome.1, 2 The individual dose of LTG required to achieve seizure freedom varies considerably,3 
which may be at least partially explained by inter-individual variation in pharmacokinetic and 
pharmacodynamic profiles. 
Two proteins appear to be involved in the pharmacokinetics of LTG. UDP-glucuronosyl-transferase 
1A4 (encoded by UGT1A4) is the enzyme responsible for the hepatic metabolism of LTG and organic 
cation transporter 1 (OCT1; encoded by SLC22A1) has very recently been implicated in the transport 
of LTG at the level of hepatocytes and the blood-brain-barrier. The pharmacodynamic profile of LTG 
is characterised by inhibition of neuronal voltage-gated sodium channels. The three predominant 
sodium channel alpha-subunits in mammalian brain are encoded by the genes SCN1A, SCN2A and 
SCN3A. We have assessed whether genetic variation in these five genes is associated with the 
maintenance dose of LTG when successfully employed as monotherapy in people with newly-
diagnosed epilepsy. 
Methods: A total of 96 individuals with newly diagnosed epilepsy (50% male, mean age 42 years, 
range 9 to 83 years) who had been seizure-free for at least 12 months on an unchanged dose of LTG 
(median dose = 200 mg/day, range = 50 to 675 mg/day) were included in the analysis. A total of 173 
single nucleotide polymorphisms (SNPs) across five genes (SCN1A, SCN2A, SCN3A, UGT1A4, SLC22A1) 
were genotyped and subjected to univariate and multivariate-regression analyses to identify 
associations with LTG maintenance dose. Multiple demographic factors (including age, gender, 
epilepsy type, previous AED use, and number of seizures prior to treatment) were also included as 
co-variates. 
Results: Univariate analyses revealed associations between maintenance dose and genotype at 
fourteen SNP loci, although these did not remain significant after correction for multiple comparisons 
using false-discovery rate. Multivariate regression analysis generated several models that associated 
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with the observed variation in LTG maintenance dose. The most explanatory of these accomplished 
an r2-value of 0.606 (p<0.001) incorporating polymorphisms from SLC22A1, SCN1A, SCN2A and 
SCN3A. 
Conclusions: Genetic variation in SLC22A1, SCN3A and SCN2A, and to a lesser extent SCN1A, affect 
LTG maintenance dose requirement. These results require validation in a larger, independent cohort. 
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Chapter 1: Introduction 
1.1. Epilepsy 
The signs and symptoms of epilepsy have been described by scholars since ancient times, with the 
word ‘epilepsy’ derived from the Greek verb ελαµβανειν (epilamvanein) meaning “to be seized”, “to 
be taken hold of” or “to be attacked”.4 
One of the earliest descriptions of epilepsy was recorded over 3,000 years ago, and was attributed to 
actions of the god of the moon.5 Since then, beliefs surrounding the cause of epilepsy have 
developed from notions such as ‘divine punishment for sinners’ by the ancient Greeks, to the first 
formal description of epilepsy as a disease by Hippocrates some 2,500 years ago.6  
Theories regarding divine aetiologies have waxed and waned over time. However, by the late 19th 
century, investigations into the aetiology of epilepsy had found that epileptic seizures could be 
recorded and evoked in the cerebral cortices of animals.5 This marked a movement towards modern-
day thinking about epilepsy, and by 1929 there were reports of using scalp-electrodes to measure 
brain electrical activity and classify epileptic seizures.7  
Today, epilepsy is considered not as a single disease or syndrome, but rather as a broad category of 
symptom complexes that arise from disordered brain functions of multiple aetiologies.4 A seizure is 
the manifestation of abnormal, synchronous mal-coordinated discharges of cortical neurones, and 
epilepsy is the predisposition for recurrence of such seizures. 
Epilepsy can affect all members of society, with significant implications for sufferers’ psychological, 
physical and social wellbeing. Epilepsy has been shown to carry a heightened risk of injury and 
sudden death,8 in addition to widely-acknowledged psycho-social problems resulting from prejudice, 
stigma and discrimination.9  
1.1.1. Incidence 
In industrialised countries, the annual incidence rate of epilepsy is estimated at 40-70 per 100,000 
people.10-12 Epilepsy has been shown to have a predilection for lower-socioeconomic groups, 
although the true extent of this relationship remains unclear, as does the directionality of any 
association.13-15 The age-distribution of epilepsy follows a bimodal distribution, with higher rates in 
the extremities of age. During recent years, a decreasing incidence in children has been observed, 
along with a simultaneous increase in the elderly population.16, 17 In children, this trend is not fully 
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understood, although there is speculation that healthier lifestyles by expectant mothers, improved 
perinatal care, and enhanced immunisation programmes are responsible.18 The increasing incidence 
in the elderly is a likely consequence of improved longevity, with independent risk factors for 
epilepsy, such as cerebrovascular disease, more prevalent with advancing age.19 
1.1.2. Prevalence 
Epilepsy is a common neurological disorder that affects in excess of 50-million people worldwide.20 
Estimates suggest that 5% of the population will experience non-febrile seizures at some point in 
life.21 The global prevalence of active epilepsy (a seizure within the last five years) is approximately 
0.5-1%.21 The prevalence of epilepsy is highest in the elderly population, affecting up to 1.5% of those 
over 75-years of age.22 
1.1.3. Diagnosis 
The diagnosis of epilepsy in adults should be established by a specialist medical practitioner with 
training and expertise in epilepsy; similarly, epilepsy in children should be diagnosed by a 
paediatrician with specialist epilepsy training. Diagnosis is usually clinical following a detailed history 
from the individual and eye-witnesses (where possible), and requires at least two unprovoked 
seizures separated by a period greater than 24-hours.23 
Neurological imaging investigations are increasingly used when making a diagnosis of epilepsy to 
help identify the aetiology. It is recommended that imaging is undertaken in all patients presenting 
with a first seizure aged 25 years and over, in addition to all patients presenting with apparent 
partial-onset seizures to identify the aetiology and to rule out treatable or progressive cerebral 
lesions.24 
1.1.4. Seizure Classification 
Seizures can be classified according to the origin of the abnormal electrical activity in the brain.  
Partial (also termed focal or localised) seizures result from abnormal electrical activity originating 
from a focal brain region. When a partial seizure affects the consciousness of an individual, it is 
termed a ‘complex partial seizure’; when consciousness is unaffected, the seizure is termed a ‘simple 
partial seizure’. Both simple and complex partial seizures arise from only one hemisphere of the 
brain. If the electrical activity spreads to involve the opposing hemisphere, it is termed a ‘partial 
seizure with secondary generalisation’. 
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Generalised seizures are the result of widespread abnormal electrical activity affecting both 
hemispheres of the brain simultaneously. They always distort consciousness, and are classified into 
six main categories according to the resulting behavioural effects. 
The International League Against Epilepsy (ILAE) criteria of 1981 provides a widely-accepted means 
of seizure classification based upon clinical manifestation25 (Table 1.1). 
 
There have been revisions of the ILAE seizure classification criteria to include various epilepsies and 
syndromes that do not fit into the 1981 framework. Not only do the 1981 criteria classify according 
to clinical signs and symptoms, the majority of clinical trials into drug efficacy identified seizure-type 
according to the same criteria. As a consequence, clinicians have a useful classification tool that 
allows evidence-based medicine to be implemented, hence its widespread use throughout the UK. 
In addition to the above, seizures can be further classified according to whether there is an 
established causal factor. If there is a known underlying cause, this is denoted by the term 
‘symptomatic’, whereas ‘idiopathic’ refers to cases where a causal factor cannot be established. The 
term ‘cryptogenic’ is used when there is a presumed underlying cause that has failed to be identified 
during evaluation. 
1.1.5. Seizure Pathophysiology 
A seizure results when there is an imbalance between inhibitory and excitatory forces within a 
network of neurones in the brain such that there is overall excessive excitability.26 The clinical 
manifestation of a seizure is dependent upon the affected brain regions, either directly at the seizure 
focus, or indirectly through localised spreading. 
Table 1.1: ILAE seizure classification criteria, 1981 
Seizure Classification Type of Seizure 
Partial (focal) seizures 
 Simple partial seizures 
 Complex partial seizures 
 Partial seizures with secondary generalised seizures 
Generalised seizures 
 Tonic-clonic (formerly ‘grand mal’) 
 Absence seizures (formerly ‘petit mal’) 
 Tonic 
 Clonic 
 Atonic 
 Myoclonic 
Unclassifiable seizures  
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Epilepsy is the predisposition for recurrent seizures, yet there are many known aetiologies that lead 
to its development. Perhaps unsurprisingly, the pathophysiological mechanisms that result in partial-
onset seizures differ considerably from those that underlie generalised-onset seizures.26 
1.1.5.1. Partial-Onset Seizures 
The pathophysiology underlying the hyper-excitable state that results in partial-onset seizures can be 
split into two broad categories; mechanisms leading to decreased inhibition, and mechanisms 
leading to increased excitation. The main mechanisms leading to decreased inhibition primarily 
involve -aminobutyric acid (GABA) receptors, whilst ion channels and glutamate are related to 
increased excitation. 
GABA is the principal inhibitory neurotransmitter in the human brain.27 It binds to two major classes 
of receptor; GABAA and GABAB.
28 Upon synaptic excitation, GABAA receptors act to oppose the action 
potential through decreasing membrane resistance and promoting membrane hyperpolarisation 
back towards the resting potential.26 Overall, this makes it more difficult for the membrane to reach 
the threshold potential required to generate an action potential, thereby acting as an inhibitory 
force. GABAB receptors act to suppress synaptic neurotransmitter release from the presynaptic 
terminal, thereby increasing the initial stimulus required for neuronal firing to occur.26 Overall, 
GABAA and GABAB receptor stimulation results in inhibition of neuronal action potentials. A lack of 
this inhibition is believed to be one of the mechanisms underpinning development of partial-onset 
seizures.29 
Voltage-gated sodium channels (VGSCs) cycle through three states; open, closed, and inactivated.30 
When open, sodium ions pass through the membrane, creating an electrical current that leads to 
depolarisation. The VGSC then enters an inactivated state for a period of time before returning to a 
functioning state; this period of inactivation is termed the ‘refractory period’, during which re-
opening of a VGSC is not possible.26 The refractory period serves to prevent excessive action 
potential propagation, with neuronal hyper-excitability avoided as a result. Genetic variants have 
been implicated in seizure pathogenesis by interfering with this mechanism, and extension of the 
VGSC refractory period is believed to be the mechanism of action of several antiepileptic drugs 
(AEDs).30 
Glutamate is the major excitatory neurotransmitter in the human brain.27 There are three types of 
ionotropic glutamate receptors named after agonists that bind to them with high specificity; NMDA-, 
kainate- and AMPA-type receptors. Fast neurotransmission is achieved through activation of AMPA- 
and kainate-type receptors, whilst slow excitation involves NMDA receptors. AMPA and kainate 
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receptors allow passage of monovalent cations such as sodium and potassium, whereas NMDA 
receptors additionally allow passage of divalent cations such as calcium.26 Although complex and not 
fully understood, it is possible that subtle alterations in receptor properties could ultimately result in 
elevated sensitivity to glutamate, with neuronal hyper-excitability and seizure genesis a likely 
consequence.  
1.1.5.2. Generalised-Onset Seizures 
The pathogenesis of generalised-onset seizures remains poorly understood, perhaps due to the 
variety of seizure types encompassed by this umbrella term. The best understood example of 
generalised-onset seizure pathogenesis is observed in typical absence seizures.26 The thalamocortical 
circuit has normal oscillatory rhythms that govern the sleep-wake cycle; alterations in this rhythm 
have been implicated in generalised-onset seizures, specifically involving T-type calcium channels and 
the T-calcium current they generate in the nucleus reticularis of the thalamus.26 Although not fully 
understood, this serves to illustrate that generalised-onset seizures may be the result of deep-lying 
and often genetically determined neuronal idiosyncrasies, whereas partial-onset seizures are more 
likely the result of cortical-based neuronal pathology. 
1.1.6. Pharmacological Management 
AEDs form the mainstay of treatment for people with epilepsy. The goal of AED therapy is to achieve 
seizure freedom whilst minimising adverse effects associated with treatment.31 An estimated 70% of 
sufferers respond well to AEDs, while the remaining 30% respond poorly and continue to experience 
seizures.32, 33 
In the past twenty years there has been a dramatic increase in the number of licensed AEDs, with 
currently in excess of 20 agents in the clinicians’ arsenal. Although all AEDs aim to offer seizure 
freedom, the mechanisms through which individual agents achieve this are variable, which in turn 
reflects the complexities of seizure pathogenesis. 
1.1.6.1. Choice of AED 
The National Institute for Health and Clinical Excellence (NICE) is an independent special health 
authority of the National Health Service (NHS) responsible for providing national guidance on 
promoting good health and preventing and treating ill health.34, 35 The most recent NICE guidelines 
pertaining to the pharmacological management of epilepsy were published in October 2004 (Table 
1.2). 
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Initiation of AED therapy is recommended once a diagnosis of epilepsy has been made by a specialist 
clinician.36 As shown in Table 1.2 there are often several recommended first-line agents for 
management of a given seizure type. The final choice of AED is made by the prescribing clinician, 
whose decision is guided by factors such as patient age, comorbidities and concurrent medications, 
as well as their knowledge of agent-specific adverse-effects and mechanism of action.  
It is estimated that 50-65% of patients respond well to first-line AED monotherapy.33 If the first-line 
monotherapy proves ineffective, it is recommended that an alternative first-line monotherapy agent 
be trialled before considering add-on therapy. Approximately 13% of individuals respond to this 
alternative first-line AED monotherapy,33 with the remainder requiring polytherapy with one or more 
AEDs in an attempt to achieve adequate control. Polytherapy patients suffer higher rates of adverse 
effects associated with treatment, and evidence suggests this subgroup has a poorer prognosis in 
comparison to monotherapy responders.37, 38 
Table 1.2: NICE recommendations – drug options by seizure type.36 
Seizure Type First-line agents Second-line agents Other agents 
Contra-indicated 
agents 
Generalised 
tonic-clonic 
Carbamazepine a 
Lamotrigine 
Sodium Valproate 
Topiramate a 
Clobazam 
Levetiracetam 
Oxcarbazepine a 
Acetazolamide 
Clonazepam 
Phenobarbital a 
Phenytoin a 
Primidone a 
Tiagabine 
Vigabatrin 
 
Absence 
Ethosuximide 
Lamotrigine 
Sodium Valproate 
Clobazam 
Clonazepam 
Topiramate a 
 
Carbamazepine a 
Gabapentin 
Oxcarbazepine a 
Tiagabine 
Vigabatrin 
Myoclonic Sodium Valproate 
Clobazam 
Clonazepam 
Lamotrigine 
Levetiracetam 
Piracetam 
Topiramate a 
 
Carbamazepine a 
Gabapentin 
Oxcarbazepine a 
Tiagabine 
Vigabatrin 
Tonic 
Lamotrigine 
Sodium Valproate 
Clobazam 
Clonazepam 
Levetiracetam 
Topiramate a 
Acetazolamide 
Phenobarbital a 
Phenytoin a 
Primidone a 
Carbamazepine a 
Oxcarbazepine a 
Atonic 
Lamotrigine 
Sodium Valproate 
Clobazam 
Clonazepam 
Levetiracetam 
Topiramate a 
Acetazolamide 
Phenobarbital a 
Primidone a 
Carbamazepine a 
Oxcarbazepine a 
Phenytoin a 
Focal 
with/without 
secondary 
generalisation 
Carbamazepine a 
Lamotrigine 
Oxcarbazepine a 
Sodium Valproate 
Topiramate a 
Clobazam 
Gabapentin 
Levetiracetam 
Phenytoin a 
Tiagabine 
Acetazolamide 
Clonazepam 
Phenobarbital a 
Primidone a 
 
a – hepatic enzyme-inducing agents 
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1.2. Lamotrigine 
Lamotrigine (LTG) was first developed as an AED in the 1970s as a result of its weak inhibitory activity 
on dihydrofolate reductase, following the hypothesis that folate was epileptogenic.39 This mechanism 
of action has since been dismissed following a lack of supporting evidence,40 however LTG remains 
one of the most commonly employed AEDs in the developed world. 
LTG was first licensed in the UK for the treatment of refractory partial epilepsy in 1991. At present, it 
is employed as first-line treatment for partial-onset and generalised seizures, may be used for atonic, 
tonic, and atypical absence seizure types, and also has licensing for the treatment of Lennox-Gastaut 
syndrome (Table 1.2). In addition to its antiepileptic activity, LTG is indicated for the maintenance 
treatment of bipolar disorder; however its effectiveness in the treatment of acute mood disorders 
remains to be established.41 LTG also appears to have some efficacy in the treatment of migraine 
aura42 and neuropathic pain.43 
1.2.1. Chemistry 
LTG [3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine] is a phenyltriazine derivative that is 
chemically unrelated to other AEDs.44, 45 It is a white powder with a molecular weight of 259.1 and is 
poorly soluble in water or ethanol.46 
In the UK, LTG is available in both tablet and chewable / dispersible forms. Tablets are available in 25, 
50, 100 and 200mg strengths, while chewable / dispersible forms come in 2, 5, 25 and 100mg 
preparations.47 The active compound is combined with several inactive ingredients to form each 
preparation. The utilised ingredients have no known effect on LTG pharmacokinetics, and include 
lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, 
denatured alcohol and purified water.44 
1.2.2. Pharmacodynamics 
LTG is thought to exert its antiepileptic effects primarily through its action on VGSCs.48 Studies 
suggest this occurs as a result of binding to sodium channels during their refractory period; the result 
is a stabilisation of the pre-synaptic membrane and a decrease in excitatory neurotransmitter 
release.49-51 
In addition to the well-established effects on VGSCs, LTG has also been shown to interfere with 
neuronal calcium currents through blockade of voltage-gated calcium channels,52-54 and potassium 
currents.55 
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In terms of blocking calcium channels, LTG has been shown to block N-, P/Q-, T-, and R-type 
channels. LTG blockade of N- and P/Q-type calcium channels in cortical neuronal cells has been 
shown to inhibit glutamate release from presynaptic terminals.52, 53 Through inhibiting glutamate 
release, a greater stimulus is required in order to achieve excitation in the postsynaptic terminal.56 T- 
and R-type voltage-gated calcium channels are predominantly expressed in the thalamocortical 
circuitry in the brain, and both have been shown to be targets for LTG.57 This effect, and the 
anatomical location of these channels, could explain the efficacy of LTG in the treatment of 
generalised absence seizures.58 
LTG has also been shown to modulate intracellular neuronal calcium levels in neocortical slices from 
rats. Transient elevations in calcium have been correlated with epileptiform discharges; because of 
the antagonistic effect of LTG on intracellular calcium levels, this has been hypothesised as at least a 
contributing source of its anticonvulsant efficacy.54 
Finally, LTG has been shown to modulate potassium-mediated hyperpolarisation currents in slices of 
rat cerebral cortex. This mechanism has also been postulated as a contributing factor to its efficacy 
as an anticonvulsant, although the extent to which these currents contribute to the generation of 
seizures in humans is a topic of discussion.55 
Overall, the pharmacodynamic profile of LTG is complex and not yet fully understood, although it is 
generally accepted that LTG’s antiepileptic efficacy is primarily mediated through blockade of VGSCs. 
While there is growing evidence that subsidiary mechanisms may contribute to the efficacy of LTG, 
the extent of this contribution remains to be elucidated.  
1.2.3. Pharmacokinetics 
Pharmacokinetics is a branch of pharmacology that studies the course of externally administered 
compounds as they travel through the body. It focuses on four main areas: absorption, distribution, 
metabolism, and excretion.  
Absorption: LTG is available in both tablet and chewable / dispersible forms, and it has been shown 
that no significant differences exist between them in terms of rate and extent of absorption.3 LTG 
does not undergo first-pass metabolism, and has an absolute oral bioavailability in excess of 98%46 
which is not affected by food.59 Following oral administration, it is rapidly and completely absorbed, 
achieving a peak plasma concentration within in 1-3 hours.45 The peak plasma concentration has 
been shown to follow a linear relationship with dose in several small-scale trials in both healthy 
volunteers and epilepsy patients.60-62 
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Distribution: LTG is uniformly distributed throughout the body following oral administration.63 The 
volume of distribution is independent of dose, and is similar between single- and multiple-dose 
administration.44, 59 LTG has been shown to be approximately 55% bound to human plasma proteins, 
primarily albumin, at plasma LTG concentrations of 1-10µg/ml in vitro.44 Plasma protein binding of 
LTG has been shown in vitro to be unaffected by therapeutic concentrations of other AEDs such as 
phenytoin (PHT), phenobarbital (PB) or valproic acid (VPA).45 Furthermore, LTG did not displace the 
AEDs carbamazepine (CBZ), PHT or PB from their protein-binding sites.44 LTG has few, if any, clinically 
significant drug-interactions at the level of distribution because of this relatively-low plasma protein 
binding, with competition for protein-binding sites unlikely as a consequence.3 
Metabolism: The 1A4 isoform of the uridine diphosphate glycosyltransferase (UGT) family of 
enzymes is believed to be responsible for the majority of LTG glucuronidation. Remmel and Sinz were 
the first to identify the N2-glucuronide product as a metabolite of LTG in 1991 following animal 
studies.64, 65 Since then, it has been estimated that 75% of LTG is metabolised to the N2-glucuronide 
form, and an additional  10% to the N5-glucuronide form, neither of which are metabolically active.66 
It is widely assumed that UGT1A4 is the enzyme responsible for N2-glucuronidation given its broad 
role in amine glucuronidation, although data to support this notion is scarce. There has been recent 
speculation that other UGT isoforms may have the capacity to produce LTG N2-glucuronide 
products.67 Rowland and colleagues propose that, in addition to UGT1A4, at least one other UGT is 
involved in LTG N2-glucuronidation, and roles for several additional isoforms cannot be excluded.67 
Excretion: Both unconjugated LTG and its metabolites are excreted from the body primarily via the 
urinary system.63 In a study on six healthy volunteers, 240mg of radio-labelled LTG was orally-
administered, with 94% of the radioactivity recovered in the urine, and 2% in the faeces.44 Of the 
radioactivity recovered in the urine, 76% was in the N2-glucuronide form, 10% was in the N5-
glucuronide form, and 0.14% was a N2-methyl metabolite.44 
Elimination half-life is a measure of the time taken for the blood concentration of a substance to 
reduce to half of its steady state. LTG shows considerable inter-individual variation in terms of 
elimination half-life, but little intra-individual variability.63 In healthy volunteers, the half-life of LTG 
has been shown to range from 25.4-32.8 hours in monotherapy, 48.3-70.3 hours when comedicated 
with VPA, and 12.6-14.4 hours when comedicated with enzyme-inducing AEDs.58  
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1.2.3.1. Interactions 
LTG appears to have little effect on the pharmacokinetics of other AEDs with the exception of 
clonazepam (CNZ) where co-administration has been shown to reduce serum CNZ concentrations by 
20-38%.68 The pharmacokinetics of LTG however appears to be influenced by many other 
antiepileptic agents. In 2005, Weintraub and colleagues investigated the effects of AED comedication 
on LTG clearance by measuring serum LTG levels. Sixteen different regimens of LTG comedication 
were identified; fourteen dual-therapies and two triple-therapies. A total of 570 patients were 
included in the analysis aged 12 years and older, the results of which are illustrated graphically in 
Figure 1.69 
Weintraub concluded that both PHT and CBZ increase LTG clearance by approximately 125% and 30-
50%, respectively. In addition to this, VPA was found to decrease LTG clearance by approximately 
60%.69 None of the other comedications investigated were found to result in a statistically significant 
change in LTG clearance. 
Alternative studies have identified PB, oxcarbazepine (OXC) and primidone (PRM) as inducers of LTG 
metabolism, resulting in increased LTG clearance by approximately 34-52%.70-72 The findings relating 
to PB, OXC and PRM were not initially identified by Weintraub et al, most probably due to small 
numbers of patients.  
There has also been recent investigation of pharmacokinetic interactions between LTG and oral 
contraceptives. LTG has been found to cause a small (19%) decrease in the progesterone component 
of the oral contraceptive pill, with no effect on oestrogen (ethinyl estradiol [EE]) levels.73 Conversely, 
progesterone has been shown to have no affect on LTG pharmacokinetics, yet EE leads to a reduction 
in serum LTG levels in excess of 50%.74, 75 This means that, although LTG is unlikely to affect women’s 
risk of pregnancy (apart from a slight increase in risk for women taking progesterone-only oral 
contraception), the increased levels of EE associated with oral contraceptives is likely to interfere 
with plasma LTG concentrations to the extent that efficacy may be compromised.58 
Auto-induction is the process where a molecule induces the enzymes that are responsible for its own 
metabolism. LTG has been shown to induce its own metabolism, resulting in a steady state half-life 
decrease of 25%, and a clearance increase of 37%.44 This degree of auto-induction is not considered 
to impact upon the use of LTG in clinical practice as it is overcome by the dose-titration process.45 
  
 
1
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Figure 1 - Effect of drug combinations on lamotrigine clearance.69 
Asterisk indicates drug combinations with clearance significantly different from monotherapy (P<0.05) 
n = number of distinct lamotrigine clearances, including the drug listed and other drugs without significant effects on lamotrigine clearance 
Bars = 95% confidence intervals 
Percentage = ratio of mean clearance in given combination as a percentage of mean clearance with monotherapy 
Monotherapy data are bolded for clarity 
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1.2.4. Clinical Efficacy and Tolerability 
The clinical efficacy and tolerability of LTG in the treatment of partial-seizures and generalised-onset 
seizures is reviewed below. Although LTG is often used as an adjunctive AED, in the interests of 
specificity and brevity, LTG monotherapy alone will be considered.  
1.2.4.1. Partial Seizures 
Studies investigating the efficacy of LTG monotherapy in the treatment of partial seizures are 
summarised in Appendix I. Various dosing regimens of LTG were administered to people diagnosed 
with partial-onset seizures, and its efficacy determined through comparison to other AEDs including 
PHT, CBZ and gabapentin (GBP). 
Brodie et al compared the efficacy and safety of LTG against CBZ in a cohort of 146 patients with 
partial-onset seizures and 122 with primary generalised tonic-clonic seizures.76 Dosing regimens were 
as follows; LTG 50mg/day, titrated up to 150mg/day over a 4 week period; CBZ 200mg/day, titrated 
up to 600mg/day over a 4 week period. Dose remained fixed until 24-weeks, at which point it could 
be adjusted, if clinically indicated, for the remaining 24-weeks. The study showed that for patients 
with partial-onset seizures, 35% were fully controlled on LTG in comparison to 37% on CBZ, indicating 
no significant difference in efficacy between the two agents. However, LTG was shown to be better 
tolerated than CBZ overall; more patients withdrew due to adverse effects  on CBZ (21%) than LTG 
(11.5%), and a comparison of the areas under the Kaplan-Meier curve (for time to withdrawal) 
supported a significant difference in favour of LTG (hazard ratio 1.57 [95% confidence interval 1.07-
2.31]).76 In addition to time to withdrawal, 15 specific adverse effects were screened for and 
analysed, with a statistically significant difference shown between groups for levels of ‘sleepiness’. 
The LTG group was shown to have significantly lower levels of withdrawal due to sleepiness than CBZ 
(12% vs 22% respectively [95% CI -28 to -1]), although this should be interpreted with caution as data 
was obtained from patient reports, was not standardised, and as such may be susceptible to recall 
bias. 
In a different trial, Reunanen and colleagues also found no statistically significant difference between 
LTG and CBZ in terms of efficacy, although the authors felt that LTG 200mg/day (LTG-200) was the 
most effective regimen when compared with LTG 100mg/day (LTG-100) and CBZ 600mg/day (CBZ-
600). For LTG-200, 60.4% of participants achieved seizure freedom during the 24-week study period 
in comparison to 51.3% of LTG-100 and 54.7% of CBZ-600. Although a significant difference in 
efficacy was not demonstrated, both dosage regimens of LTG were better tolerated than CBZ-600; 
53% of patients reported adverse experiences attributable to treatment in the CBZ-600 group in 
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comparison to 23% (LTG-100) and 28% (LTG-200). Overall, LTG appeared equally effective but better 
tolerated when compared with CBZ.77 
Arm A of the Standard and New Antiepileptic Drugs (SANAD) trial concluded that, for time to 12-
month remission, CBZ was significantly better than GBP (hazard ratio 0.75 [95% confidence interval 
0.63-0.90]) and showed a non-significant advantage for CBZ against LTG (0.91 [0.77-1.09]), 
topiramate (0.86 [0.72-1.03]) and OXC (0.92 [0.73-1.18]).2 There was a significant difference between 
the CBZ and LTG groups for treatment failure owing to unacceptable adverse events throughout the 
study duration. At six-years, 78% of LTG patients were without failure in comparison to 68% of CBZ 
patients; a significant difference of 10% [95% CI 3 to 17].2  
Another study conducted by Brodie and co-workers was designed to assess tolerability differences 
between LTG and CBZ in 150 elderly patients (mean age 77 years) with newly diagnosed epilepsy.78 
Median daily doses of LTG and CBZ in patients completing the study were 100mg (range: 75-300mg) 
and 400mg (range: 200-800mg), respectively. The main difference between the groups was the rate 
of drop-out due to adverse events (LTG 18% versus CBZ 42%). In addition, a statistically significant 
difference between LTG and CBZ was identified (p<0.001), with more patients completing the study 
on LTG (71%) in comparison to CBZ (42%), which the authors attributed to the superior tolerability of 
LTG. 
A more recent study undertaken by Steiner and colleagues attempted to quantify adverse effects by 
using the ‘Side Effects and Life Satisfaction’ (SEALS) inventory;79 a tool for measuring the effects AEDs 
have on health-related aspects of quality of life.80 Comparison of pre-treatment SEALS scores with 
scores obtained at pre-determined points throughout the 48-week trial was performed, and found 
that scores decreased (meaning improvement) in the LTG group but increased in a matched PHT 
group.79 This is likely to reflect, at least in part, the fewer drug-related adverse effects experienced 
with LTG monotherapy as compared to PHT. 
Although these studies show the efficacy of LTG in the treatment of partial-onset seizures, there are 
several limitations which mean that results should be interpreted with caution. The randomised, 
double-blind study by Brodie and colleagues76 was designed to include patients with ‘partial-onset 
seizures with or without generalisation’, as well as patients with ‘primary generalised tonic-clonic 
seizures’. Although the primary outcome analysis was separated according to seizure type, it failed to 
fully differentiate between them as evident by a number of participants included in both these 
categories due to mixed seizure types. A greater proportion of these ‘mixed’ patients were included 
in the CBZ arm of the study (n=6) in comparison to LTG (n=2) and the responsiveness of these 
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patients to their respective AEDs has the potential to skew the reported efficacy. This could have 
been avoided by excluding patients with mixed seizure types, or at least ensuring an even 
distribution between the LTG and CBZ groups. Nonetheless, these were a minority of the total 
number of participants (n=260), meaning the majority of participants in the LTG (129/131) and CBZ 
(123/129) groups were successfully classified to only one of the seizure type sub-classifications. 
Therefore, the results can reasonably be assumed to be a true reflection of efficacy, and they are 
arguably more indicative of effectiveness in a clinical setting. 
Throughout the studies, measures have been taken to ensure treatment and control groups are as 
similar as possible to minimise the effects of confounding factors. Although Brodie and colleagues76 
attempted this through stratification according to seizure type, they failed to remove other elements 
of bias from the study. The investigators acknowledged that disproportionately more patients were 
assigned to the LTG group with more than 100 seizures before recruitment; this was later identified 
to be of significant prognostic value (p=0.04) with ‘the more seizures reported before randomisation, 
the greater the likelihood of a seizure after 6-weeks of treatment or premature withdrawal’.76 As a 
consequence, the true efficacy of LTG might in fact be higher than reported, although this effect may 
again be negligible owing to the large sample size (n=260). 
Overall, clinical studies suggest that LTG is efficacious in the treatment of partial onset seizures. It has 
been repeatedly shown that no significant difference exists between LTG and the historical first-line 
drug CBZ,76-78 and LTG was most recently shown to be non-inferior to CBZ by Marson and colleagues.2 
In addition to these reports,  Steiner and colleagues found PHT to be comparable to LTG in terms of 
seizure freedom at 48-weeks (48% and 41% respectively),79 and Brodie et al concluded that GBP and 
LTG were similarly effective at the end of a 24-week maintenance dose period.81  
1.2.4.2. Generalised-onset seizures 
There have been many investigations of the efficacy of LTG in the treatment of generalised-onset 
seizures, the results of which are arguably inconclusive.  
Several studies have suggested the efficacy of LTG in the treatment of childhood absence epilepsy. 
Frank and colleagues evaluated the efficacy of LTG in a cohort of 45 children (3-15 years) with newly 
diagnosed absence seizures in a placebo-controlled double-blind trial.82 Following an initial dose-
escalation period where all participants received LTG monotherapy, participants were randomised to 
receive either LTG or placebo, with treatment success defined as complete freedom from seizures 
confirmed by 24-hour and hyperventilation electroencephalogram (EEG). A total of 62% of patients 
receiving LTG achieved successful treatment, significantly more than in the placebo group (21%).  
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LTG and VPA monotherapies were compared in the treatment of newly-diagnosed absence seizures 
by Coppola and colleagues in a randomised, un-blinded parallel-group study design.83 Thirty-eight 
children (17 boys, 21 girls) aged from 3 to 13 years (mean 7.5 years) were enrolled in the study, and 
efficacy was determined by seizure freedom at predetermined assessment points of 1, 3 and 12 
months. Efficacy was comparable at 12-months, with 13 children taking VPA and 10 taking LTG 
remaining seizure free. VPA achieved a faster onset of action at the 1 and 3 month assessments, an 
effect attributed to a shorter titration schedule in the VPA group. In this study, side effects were 
found to be more common in the LTG group (31.8%, n=6) than VPA (10.6%, n=2), although these 
were mostly mild and transient. 
Most recently, Glauser and colleagues undertook a double-blind, randomised, controlled trial to 
compare the efficacy, tolerability and neuropsychological effects of ethosuximide (ESM), VPA and 
LTG in children with newly diagnosed childhood absence epilepsy.84 The trial recruited a total of 453 
children who were randomised to receive either ESM (n=156), LTG (n=149) or VPA (n=148). After 16-
weeks of treatment, ESM and VPA were found to be similar in terms of freedom-from-failure rates 
(53% and 58% respectively, odds ratio VPA vs ESM 1.26 [95% CI 0.80-1.98]), however both achieved 
significantly higher rates than LTG at 29% (VPA vs LTG; odds-ratio 3.34 [95% CI 2.06-5.42], p<0.001), 
(ESM vs LTG; odds ratio 2.66 [95% CI 1.65 to 4.28], p<0.001). In terms of tolerability, there were no 
significant differences in drop-out rates due to adverse effects between groups, however the 
incidence of attentional dysfunction in children receiving VPA was found to be significantly higher 
than those receiving ESM (49% and 33%, respectively) (odds ratio 1.95 [95% CI 1.12 to 3.41], 
p=0.03).84 Although these results undeniably show LTG to be inferior to ESM and VPA, a longer-term 
follow-up period will be required to determine whether ESM remains non-inferior to VPA in terms of 
efficacy. 
Prasad and colleagues evaluated whether LTG monotherapy could prove an effective treatment of 
juvenile myoclonic epilepsy (JME) in a retrospective study.85 Seizure outcome was found not to differ 
between patients receiving VPA monotherapy (n=36) and LTG monotherapy (n=14). The withdrawal 
rate per patient-year of treatment with VPA was lower than that with LTG (p=0.12), which, although 
not statistically significant, suggests VPA may be superior in terms of adverse effects. The results of 
this trial should be interpreted with caution due to its small patient cohort; VPA may have been 
shown to be significantly better than LTG had the study been better powered. 
In addition, there have been reports of worsening of myoclonus with the administration of LTG. In a 
study by Guerrini and co-workers, a total of 21 patients diagnosed with severe myoclonic epilepsy of 
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infancy were treated with LTG, with 80% of participants experiencing a deterioration in seizure 
control.86 
In the aforementioned study by Brodie and colleagues, 122 newly-diagnosed patients with primary 
generalised tonic-clonic seizures were assigned to either LTG or CBZ over a 48-week study period. 
The study failed to identify any difference in efficacy between LTG and CBZ for the treatment of 
primary generalised tonic clonic seizures, with the percentage of patients reporting seizure-freedom 
during the last 24-weeks of the trial almost identical LTG (39%) and CBZ (38%). As mentioned 
previously, fewer patients on LTG withdrew from the study due to adverse effects than on CBZ (11.5 
vs 21%, p<0.05), and patients were more likely to complete the study if randomised to LTG rather 
than CBZ (65 vs 51%, hazard ratio 1.57 [95% CI 1.07-2.31], p=0.018]).  
Most recently, Arm B of the SANAD trial recruited 716 patients with newly diagnosed generalised or 
unclassifiable epilepsy in a randomised, unblinded, pragmatic study design. Patients were randomly 
assigned on a 1:1:1 basis to receive LTG (n=239), TPM (n=239) or VPA (n=238), and efficacy was 
measured using time to 12-month remission. VPA was found to be significantly better than LTG 
overall (hazard ratio 0.76 [95% CI 0.62-0.94]), as well for the subgroup with an idiopathic generalised 
epilepsy (0.68 [0.53-0.89]). In terms of failure due to adverse effects at 6-years, LTG showed a 
favourable 7% difference in comparison to VPA (95% CI -1 to 14), whilst TPM showed an additional 
14% decrease in numbers in comparison to VPA (95% CI -30 to 1).1 Although the 95% confidence 
intervals failed to show statistically significant differences, the data suggests LTG is a favourable AED 
in terms of adverse events in comparison to other AEDs. 
Overall, there is conflicting evidence surrounding the use of LTG in the treatment of generalised-
onset seizures. LTG appears to have some efficacy in the treatment of generalised-onset seizures in 
general; however it appears inferior to other AEDs when certain seizure types are assessed in 
isolation. In addition, it is not clear whether LTG is as well tolerated by patients with generalised-
onset seizures as other AEDs. Overall, the evidence suggests VPA should remain first-line treatment 
for patients with generalised-onset seizures, although there may be some instances where LTG 
should be considered a viable alternative. 
1.2.4.3. Cost Effectiveness 
The recent SANAD trial concluded that LTG is a cost-effective alternative to CBZ for patients 
diagnosed with partial-onset seizures.2 The quality adjusted life year (QALY) is a broad measure of 
benefit that measures health-related quality of life. It is affected not only by clinical outcome 
measure, but also other factors such as the consequences of drug side-effects on patients’ health. 
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The SANAD trial issued quality-of-life questionnaires (EQ-5D) at baseline and 2-year follow up, and 
used that information to calculate the cost-effectiveness of each of the AEDs in comparison to CBZ in 
terms of cost-per-QALY (Table 1.3). Two separate analyses were undertaken; one excluding OXC 
(n=636) and one including OXC (n=414). Each analysis was restricted to adult patients since the EQ-
5D questionnaire was not validated for use in children, and only included patients who provided 
complete EQ-5D responses. 
Table 1.3: Incremental cost-effectiveness ratios versus carbamazepine- cost per QALY (SANAD) 
 
 
For the analysis that excluded OXC, GBP has a positive incremental cost and a negative incremental 
QALY gain and is therefore dominated by LTG. Because LTG has a lower incremental cost-effective 
ratio than TPM, TPM is ruled out on the grounds of extended dominance. The incremental cost-
effectiveness ratio for LTG relative to CBZ is £11,851.2 
The analysis that included OXC showed TPM and GBP have positive incremental costs and negative 
incremental QALY gains and are therefore dominated by OXC and LTG respectively.2  
Overall, the results of the SANAD analyses show LTG is a cost-effective alternative to CBZ in the 
treatment of partial-onset seizures. Further analyses showed the probabilities that LTG is cost-
effective at ceiling ratios of £10,000, £30,000, and £50,000 per QALY were 0.42, 0.82, and 0.89 
respectively when OXC was excluded from the analysis, and 0.36, 0.66, and 0.73 respectively when 
OXC was included.2 
 Cost (£) QALYs Incremental 
Cost (£) 
Incremental 
QALYs 
Incremental 
cost-
effectiveness 
ratio (£/QALY) 
Comparison Excluding OXC 
CBZ 1226 1.477 - - - 
TPM 2009 1.501 783 0.024 Extended 
Dominance 
LTG 2257 1.564 248 0.063 11851 
GBP 2561 1.491 304 -0.073 Dominated 
Comparison Including OXC 
CBZ 1095 1.491 - - - 
OXC 1839 1.611 744 0.12 6200 
TPM 1930 1.541 91 -0.07 Dominated 
LTG 2078 1.563 148 0.022 Extended 
Dominance 
GBP 2573 1.480 495 -0.083 Dominated 
QALYs = quality-adjusted life years, OXC = oxcarbazepine, CBZ = carbamazepine, TPM = topiramate, 
LTG = lamotrigine, GBP = gabapentin.  
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1.2.4.4. Interpretation 
Overall, no significant difference has been shown between LTG and other AEDs such as PHT, TPM and 
the current first-line drug CBZ for the treatment of partial-onset seizures. In addition to this, it has 
been shown to have some efficacy in terms of seizure control in generalised-onset seizures, although 
it is not as efficacious as the current first-line agent VPA. Regardless of efficacy in the treatment of 
specific seizure-types, LTG has been shown to be better tolerated than many other first-line AEDs 
including VPA, CBZ, PHT and TPM. In situations where efficacy in terms of seizure control has been 
shown to be at least non-inferior, LTG should be considered first-line therapy owing to its evidently 
more desirable adverse events profile. 
However, treatment with LTG is not without challenges. As with all AEDs, the effective dose of LTG 
varies widely from patient to patient, and finding the optimum dose can be difficult.3 When used as 
monotherapy, some individuals require only 50mg/day to achieve seizure freedom, whereas others 
need as much as 800mg/day. Current practice involves titration of LTG over a six to eight week 
period until a pre-determined target dose is achieved; dose titration is required to minimise the risk 
of recognised side effects such as rash (including the life-threatening Stevens-Johnson syndrome) 
which is more likely to occur with quicker dose escalation. Once the pre-determined target dose is 
reached, dose adjustments are made thereafter according to the extent of efficacy and occurrence of 
adverse effects. Although this method has withstood the test of time, it remains sub-optimal for a 
large number of patients. If we consider those patients with a low dose requirement, the standard 
titration process may result in intolerable adverse effects necessitating drug withdrawal due to the 
excessively high target dose. Alternatively, patients with an unusually high dose requirement may be 
required to undergo successive increases in LTG dose over many months before the optimum dose is 
found, during which seizure activity persists. This unpredictability in dose requirement, coupled with 
the lengthy titration period, makes LTG a less attractive choice than some rival AEDs. 
 
  
 19 
 
1.3. Pharmacogenetics 
The term ‘pharmacogenetics’ was first used by Vogel in 1958 to describe the impact genetic variation 
can have on an individual’s response to drug therapy.87 Pharmacogenetic studies aim to determine 
whether observed differences in drug response within a population can be explained by underlying 
genetic variation between individuals. 
One method of assessing the impact of genetic variation is through a candidate gene approach. Using 
knowledge of the pharmaokinetic and pharmacodynamic profiles of a given drug, proteins are 
identified that have the potential to affect the drug as it passes through the body. Once candidate 
genes encoding these proteins have been identified, the variation across those genes is determined 
through genotyping members of the study population. Subsequent statistical analyses are performed 
to identify significant associations between genetic variation and a predetermined clinical outcome 
measured in the study population. 
Early pharmacogenetic trials focussed on rare outcomes such as adverse drug reactions (ADRs) 
associated with specific drug compounds. An early example of this was the occurrence of acute 
haemolysis in a minority of recipients of the anti-malarial drug, primaquine.88 Initial studies 
concluded that acute haemolysis resulted from the deficiency of an enzyme (glucose-6-phosphate 
dehydrogenase [G6PD]) found in red blood cells,89 and this was later attributed to genetic variation in 
the G6PD gene.90 
The scope of pharmacogenetic research has expanded during the past fifty years to incorporate 
various aspects of drug response. In addition to ADRs, pharmacogenetic studies now seek to predict 
drug effectiveness, tolerability, and/or efficacy. Pharmacogenetic studies can also be used to 
investigate the genetic influences on serum concentrations and effective and maximally-tolerated 
doses. Patient characteristics such as body mass index (BMI), gender and age are recognised to 
influence dosing requirements of most drugs; combining patient characteristics and 
pharmacogenetic variation helps to build up a picture of the true influences on drug-dose 
requirements, ultimately striving towards stratified prescribing.  
Genetic variants that are known to influence drug response have the potential to form an important 
clinical tool. If it is possible to predict drug response according to an individual’s genetic make-up, 
then screening for genetic variants prior to drug initialisation may allow an individually-tailored 
therapeutic approach to be employed.  
 20 
 
Warfarin is the most commonly prescribed vitamin-K antagonist worldwide because of its 
anticoagulant properties.91 Serum concentrations of warfarin can be difficult to maintain within 
therapeutic limits, requiring serial monitoring of coagulation time via INR. Polymorphisms in two 
genes, VKORC1 and CYP2C9, have been associated with inter-individual variability in warfarin 
metabolism, with over 30% of the variance in warfarin dose explained by polymorphisms in these 
genes.92 Recent studies suggest that pharmacogenetics-guided dosing algorithms can accurately 
predict warfarin dosage,93-96 and as a result genetic testing is now recommended in the United States 
to predict warfarin response.  
1.3.1. Single Nucleotide Polymorphisms 
The human genome is comprised of twenty-three pairs of chromosomes (twenty-two autosomal 
chromosome pairs, and one sex-determining pair), with each chromosome consisting of a coiled 
strand of DNA. Four different nucleotides join together to form a strand of DNA; adenine (A), 
thymine (T), cytosine (C), and guanine (G). The structure of DNA is a double-stranded helix; A and T 
form complementary base pairs (bp) on opposing strands, as do C and G. The human DNA sequence 
contains an estimated 3,100,000,000 bp,97 and consists of approximately 20,000 – 25,000 genes.98 
A genetic polymorphism is defined as the occurrence, together in the same population, of more than 
one allele or genetic marker at the same locus with the least frequent allele or marker occurring 
more frequently than can be accounted for by mutation alone.99 Single nucleotide polymorphisms 
(SNPs) are DNA sequence variations that occur when a single nucleotide in the genome is altered. By 
definition, the frequency of this sequence variant must be ≥ 1% in a given population to be termed a 
SNP; a lower frequency is considered a mutation. 
There are in excess of 2.3 million common SNPs (ie, minor allele frequency ≥ 0.05) across the human 
genome in persons of Caucasian European descent,100 the majority of which do not have functionally 
significant effects. SNPs are classified according to their functional significance on protein 
transcription. There are five main categories of SNP, listed in descending order of perceived 
functional significance: 
- Coding non-synonymous 
o Nonsense, missense, regulatory 
- Splice site 
o 5’ splice site, 3’ splice site 
- Messenger-RNA untranslated-region (mRNA UTR) 
o 5’ UTR, 3’ UTR 
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- Coding synonymous 
- Intronic 
Nonsense SNPs result in a premature stop-codon in the transcribed mRNA sequence, producing a 
truncated, incomplete and usually non-functional protein product. A missense SNP occurs when a 
codon is produced that encodes a different amino acid. Depending on the substituted amino acid, 
the resultant protein can range from non-functional to normal functioning; the effect of such amino 
acid substitutions depends upon the position within the translated protein. Regulatory SNPs lie in 
regions of DNA that directly or indirectly affect protein expression; alterations in regulatory regions 
may lead to a change in protein amount, structure and/or function.  
Splice site SNPs can occur upstream (5’) or downstream (3’) to regions of transcribed DNA. Splicing 
occurs after RNA transcription, and is the process whereby introns are removed and exonic 
sequences are joined together. SNPs in splice sites may result in splicing errors, including loss of 
function at that site, reduced specificity, or displacement, with effects on translated amino acid 
sequences a common consequence. 
mRNA UTR SNPs can also occur either 5’ or 3’ to regions of transcribed DNA. DNA regions encoding 
mRNA UTRs are transcribed into mRNA, and the 5’ UTR contains several regulatory sequences 
including binding sites that may regulate gene expression. 3’ UTR also contain binding sites for 
proteins and elements that lead to stabilisation or location of the mRNA sequence within a cell. For 
synonymous SNPs, the nucleotide substitution results in a codon-triplet that encodes the same 
amino acid as before. These were previously assumed to be ‘silent’ with no effect on protein 
function, however, because certain codons are translated more efficiently than others, this may not 
be entirely the case. Due to the complex, intricate nature of protein transcription/translation, subtle 
changes such as a relative delay in amino acid incorporation at the ribosome may impact upon the 
final structure of the protein. Intronic SNPs are in the non-coding regions of DNA (i.e. not in exons). 
They may have a role in gene expression but are not directly implicated in protein structure. 
There are sixty-four possible triplet-combinations of nucleotides; with three exceptions, each codon 
encodes for one of the twenty amino acids used in protein synthesis. A table of the possible DNA 
codon combinations and the resultant amino acids is shown in Appendix II. 
1.3.2. Tagging SNPs and Linkage Disequilibrium 
Linkage disequilibrium (LD) is the non-random association of alleles at two or more loci. When a 
particular allele at one locus is found together on the same chromosome with a specific allele at a 
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second locus more often than expected if the loci were segregating independently in a population, 
the loci are in disequilibrium.101 Numerically, it is defined as the difference between observed and 
expected allelic distributions (assuming random distributions).101 The degree of LD between SNPs is 
determined by the r2-value. r2 values range from 0 to 1 and are directly proportional to the 
percentage of the non-centrality parameter shared between a pair of loci.101 The non-centrality 
parameter is a measure of how different the true distribution is from the assumption that SNPs are 
independent events occurring by chance. Thus, for association tagging, r2 is a measure of power, with 
values closer to 1 representing more power. 
A common approach to LD gene mapping involves firstly identifying a gene region of interest and the 
degree of LD between SNPs in that region. Next, a subset of highly informative SNP markers (tagging-
SNPs [tSNPs]) is identified at a pre-determined r2 value (usually r2 ≥ 0.8) that will capture the majority 
of genetic variation across that gene region of interest. The tSNPs are supplemented by significant / 
putatively functional SNPs that are of particular interest and therefore warrant direct genotyping. 
Finally, the tSNPs and supplementary SNPs are typed in the clinical material. 
When undertaking an association study to identify polymorphisms that influence genetically complex 
traits such as disease or response to treatment, the use of LD and tSNPs has several advantages. It 
allows for more efficient genotyping protocols, promotes cost-effectiveness, and the data requires 
less rigorous correction for multiple comparisons given the smaller number of individual tests which 
effectively leads to an increase in study power. An r2 ≥ 0.8 is usually employed in such studies. When 
an r2 ≥ 0.8 is applied, the majority of SNPs will be in LD at a level of r2 = 1, some will have an r2 
between 0.9 and 1, and the remainder will have an r2 between 0.8 and 0.9. This means that, although 
a given pair of SNPs may only be in LD 80% of the time (ie, r2 = 0.8), the amount of genetic variation 
accurately captured by a set of tSNPs is much higher than 80%. Therefore, although an r2 ≥ 0.8 may 
appear lax on an individual SNP basis, the overall ability of a set of tSNPs to capture genetic variation 
is much higher, and is likely to provide an overall power in the region of 95%. 
1.3.3. Genome-wide association studies 
A genome-wide association study (GWAS) is an approach to genotyping that involves scanning 
markers across the whole genome, usually involving two cohorts of patients in a case-control 
manner. The principle of LD is used to infer haplotypes that capture the majority of common 
variation across the human genome, allowing for the maximal acquisition of genetic information 
through a manageable number of tests. Genome-wide association studies are useful in identifying 
genes associated with a given disease that were perhaps previously unknown to researchers. 
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Identifying new genetic associations serves to advance knowledge through two main routes; firstly, 
current understanding is challenged, forcing researchers to re-evaluate the knowledgebase to 
incorporate the genetic association. Secondly, it identifies gene-regions of particular interest, 
necessitating further analyses through candidate-gene approaches. This non-hypothesis driven 
approach to research is not without drawbacks. The massive numbers of tests required to cover the 
entire genome inevitably leads to false positive associations (type 1 errors). When statistical 
measures are employed to account for type 1 errors, the result may, somewhat paradoxically, 
produce a false negative association (type 2 error), which is again a consequence of the vast numbers 
of individual tests employed. In addition to this, GWAS is expensive to perform; money that could be 
spent performing hypothesis-driven candidate-gene analyses that are arguably more likely to yield 
significant results. Nonetheless, GWAS is a useful tool. 
1.3.4. AED pharmacogenetics 
Epilepsy is an ideal area for systematic pharmacogenetic research. The pharmacokinetic pathways in 
particular are well described, it is a common disorder, and its management is complicated by 
unpredictable efficacy, ADRs, and variability in inter-individual dose requirements. The optimal doses 
of some AEDs may differ more than ten-fold between individuals,102 and even when factors known to 
influence dose requirement such as age, sex and weight have been accounted for, there is still a 
considerable unexplained variability in dose. 
Previous investigations have demonstrated clear genetic influences on AED dosing. A splice site 
variant (rs3812718) in the SCN1A gene encoding the α1-subunit of the neuronal VGSC has been 
shown to correlate with maximal doses of PHT and CBZ.103 Dose and DNA information for 425 
patients treated with CBZ was analysed; the allelic distribution for these participants was AA = 112, 
AG = 220, and GG = 93. The mean maximal dose of CBZ for each of these genotypes was 1313, 1225, 
and 1083mg/day, respectively. Considering arbitrary effects for each genotype, a significant 
difference between the means was established with an uncorrected p-value of 0.0051. When 
modelled as an additive effect, the significance increased (uncorrected p-value 0.0014), both of 
which remained significant after conservative Bonferroni correction for multiple tests.103  
In the same study, a similar association was established between the SCN1A splice site variant and 
PHT maximal dose. Dose and DNA information for 281 participants was analysed; the distribution of 
genotypes among these was AA = 73, AG = 109, and GG = 60, which corresponded to mean maximal 
doses of 373, 340, and 326mg/day, respectively. An unrestricted model revealed a significant 
association (p = 0.014, uncorrected), and an additive model again revealed a stronger association (p = 
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0.0045, uncorrected). After Bonferroni correction for seven independent tests, the additive model 
remained significant, whereas the unrestricted model showed only a trend.103  
Another study by Makmor-Bakry and colleagues found that maintenance dose of CBZ is associated 
with the genotype of two known functional variants in the EPHX1 gene which encodes microsomal 
epoxide hydrolase.104 This study analysed 70 patients who were deemed to be well controlled (≥50% 
reduction in seizure frequency) on CBZ monotherapy. None of the seven genotyped variables or 
demographic variables was of sufficient strength to influence CBZ dosing in isolation. However, when 
EPHX1 c.337T>C (rs1051740) and EPHX1 c.416A>G (rs2234922) were entered into a multivariate 
model with age as a covariate, a significant association with the maintenance dose of CBZ was 
revealed (r2 = 0.362, p = 0.002).104 
These studies show that a pharmacogenetic approach to AED dosing can explain at least some of the 
observed variation. By taking a similar approach, this project aims to determine whether LTG dosing 
in epilepsy is influenced by genetic variation in five candidate genes; SLC22A1, UGT1A4, SCN1A, 
SCN2A and SCN3A, each of which is discussed in more detail below. 
1.3.4.1. SLC22A1 
The solute carrier (SLC) family of membrane transport proteins can be divided into 47 subfamilies 
according to their solute-specificity. Each of these subfamilies can be further separated into various 
isoforms, giving rise to more than 300 SLC family members in total.105 
SLC22 is one subfamily of the SLC family, the corresponding genes for which are found on the long 
arm of chromosome 6.106 The first transporter of the SLC22 subfamily was initially reported by 
Grundemann and colleagues in 1994; the rat organic cation transporter OCT1, encoded for by the 
SLC22A1 gene.107 In rats, OCT1 is expressed in the liver, kidney and intestine, whereas in humans it is 
expressed primarily in the liver where it is responsible for the entry of organic cations into 
hepatocytes.108 Since the discovery of OCT1, further investigation has revealed more SLC22 isoforms. 
These include two additional organic cation transporters, OCT2 and OCT3 (encoded by SLC22A2 and 
SLC22A3, respectively), four organic anion transporters, OAT1 to OAT4 (encoded by SLC22A6, 7, 8, 
11, respectively), three transporters for carnitine and/or cations, OCTN1, OCTN2 and hCT2 (encoded 
by SLC22A4, SLC22A5, SLC22A16, respectively), and one urate transporter, URAT1 (encoded by 
SLC22A12).109-114  
The OCTs have been extensively studied in order to clarify their physiological functions. OCT1 to 
OCT3 proteins are known to transport a multitude of endogenous compounds in vitro, with varying 
substrate specificity between each isoform. In humans, OCT1 has been shown to transport the 
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neurotransmitter acetylcholine,115, 116 as well as the metabolite guanidine.117-122 In comparison, OCT3 
has been shown to transport a wider array of neurotransmitters including epinephrine,115 
histamine115, 121-123 and norepinephrine,115, 123, 124 but lacks the ability to transport metabolites. OCT2 
has a wider spectrum of substrates; the neurotransmitters acetylcholine,115, 116 dopamine,115, 119, 123 
epinephrine,115 histamine,115, 121-123 norepinephrine,115, 123, 124 and serotonin,115, 119, 121, 125 and the 
metabolites choline,120, 121, 125-129 creatinine,118 and guanidine117-122 All three OCTs have also been 
shown to transport the amino acid metabolite and putative neurotransmitter agmatine.130 
In addition to their aforementioned endogenous substrate specificity, the OCTs are also known to 
transport a wide array of xenobiotics and pharmaceutical drugs. Both OCT1 and OCT2 have been 
shown to transport the histamine H2 receptor antagonist cimetidine,
118, 120, 121, 127, 128, 131-133 the 
antimalarial quinine,118, 120, 131, 132, 134 and the antidiabetic compound metformin.118, 121, 135, 136 As with 
the endogenous compounds, there are inter-isoform substrate specificity variations, with OCT1 
involved in the transport of the sodium channel blocker quinidine,118, 120, 125, 127, 129, 131, 132 in addition to 
the antiviral agents aciclovir and ganciclovir.137 OCT2 is believed to transport a minimum of eight 
additional drugs, and OCT3 is known to transport at least two further pharmaceutical compounds.138 
There has been substantial research into the impact of variation within the SLC22A1 gene on the 
function of OCT1. Kerb and colleagues identified five polymorphisms that result in altered amino acid 
sequence across SLC22A1 in a population of 57 Caucasians; Arg61Cys (rs12208357), Cys88Arg 
(rs55918055), Phe160Leu (rs683369), Gly401Ser (rs34130495) and Met420del (rs35167514), with 
reported minor allele frequencies (MAFs) of 0.091, 0.006, 0.22, 0.032 and 0.16 respectively.139 They 
showed that the variants of Arg61Cys, Cys88Arg and Gly401Ser reduced uptake of 0.1µM [3H] 1-
methyl-4-phenylpyridinium ([3H]MPP), a known substrate for OCT1, to 30, 1.4 and 0.9% respectively 
in comparison to wild-type. Furthermore, the Cys88Arg and Gly401Ser mutants were also found to 
exhibit altered substrate selectivity.139 
Shu and colleagues140 have further investigated human variants of OCT1. They expanded upon the 
findings of an earlier study on 247 ethnically diverse participants, in which 15 protein variants in 
OCT1 were detected, with observed changes in both loop (nine variants) and transmembrane 
domains (six variants).141 Shu and co-workers determined the impact of these variants on protein 
function, and observed that five exhibited decreased function (Arg61Cys (rs12208357), Gly220Val 
[rs36103319], Pro341Leu [rs2282143], Gly401Ser (rs34130495), and Gly465Arg [rs34059508]), and 
one had increased function (Ser14Phe [rs34447885]), through quantifying transport of [3H]MPP.140 
These findings were in keeping with those of Kerb and colleagues, aside from the failure to replicate 
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reduced function of Cys88Arg (rs55918055) due to its absence from the study population; perhaps 
unsurprising given its relative scarcity (MAF = 0.006). 
The high variability of OCT1 may have implications for drug response. The transporter interacts with 
a variety of structurally diverse compounds, and controls access to drug metabolising enzymes in the 
liver.114, 126, 132, 142, 143 It is possible that genetic variation in the SLC22A1 region may influence either 
expression or function of the resultant OCT1 protein. Variation in the SLC22A1 gene has been shown 
to influence protein function in vitro; six amino acid alterations have been shown to result in reduced 
transport activity, and one produces a phenotype with increased action.139, 140 In addition to this, 
altered substrate selectivity has been observed in two of these variants.139  
These in vitro observations may provide an explanation for clinically observed differences in response 
to drugs. Variability in the SLC22A1 region could impact upon the kinetics of substrates for OCT1, 
altering the duration of exposure or volume of distribution of substrate drugs, with implications for 
drug efficacy, safety, and tolerability. OCT1 has very recently been implicated in the transport of LTG 
both into hepatocytes and at the blood-brain-barrier (BBB) (unpublished data, University of 
Liverpool), and so poses an ideal target for candidate gene analysis in this project. 
1.3.4.2. UGT1A4 
UGTs are reticulum-bound enzymes found throughout the human hepato-gastrointestinal tract, and 
are considered major determinants in phase II drug metabolism.144 There are many known substrates 
for UGT1A4, including amitriptyline,145 clozapine,146 tamoxifen,147 and LTG.59 
The UGTs are a superfamily of enzymes, and can be classified into two families; UGT1 and UGT2. 
Eight UGT1 proteins have been identified in humans, to date; UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 
1A9, 1A10. UGT2 can be subdivided into UGT2A and UGT2B according to evolutionary divergence 
and homology; UGT 2A1, 2B4, 2B7, 2B10, 2B11, 2B15, 2B17, 2B28.148, 149 Together, these 16 proteins 
act to catalyse the glucuronidation process in humans. 
Inherited deficiencies of the UGTs are known to result in genetic disorders associated with 
hyperbilirubinaemia. Gilbert’s syndrome is characterised by mild unconjugated non-haemolytic 
hyperbilirubinaemia that affects approximately 5% of the population.150 The genetic basis for the 
disease is a TA insertion polymorphism into the promoter region of the UGT1A1 gene, which has a 
MAF of 0.4 in the Caucasian population.150 Gilbert’s syndrome exists on a spectrum of severity 
ranging from mild hyperbilirubinaemia to life-threatening jaundice, and although it fails to become 
clinically apparent in a majority of patients, it illustrates how genetic variation in the UGTs can affect 
phenotype. 
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The UGT1 locus, which is located on chromosome 2q37, encodes for all UGT1 family members. There 
are nine functional members of the UGT1A subfamily,151 with varying tissue-specific expression 
throughout the hepato-gastrointestinal tract. Strassburg and colleagues have investigated tissue-
expression of UGTs extensively, and have concluded that UGT1A1, UGT1A3, UGT1A4, UGT1A6, and 
UGT1A9 are present in human liver, whereas UGT1A7 (oesophagus and stomach), UGT1A8 
(oesophagus and colon), and UGT1A10 (oesophagus, bile ducts, stomach and colon) are found 
predominantly in extra-hepatic epithelial tissues.152-157  
Human UGT1A4 was first cloned in the early 1990s.158 It is expressed predominantly in the liver, but 
also in the bile ducts, colon and small intestine.152, 153 UGT1A4 has become of increasing interest in 
recent years, with various polymorphisms resulting in altered enzyme activity. Ehmer and co-workers 
identified two variants that changed both the catalytic activity and specificity of UGT1A4 towards 
substrates.159 Both were in the first exon of UGT1A4; at codon 24 a C>A transversion at position 1 
(rs6755571) was observed leading to a proline to threonine amino acid change (P24T), and at codon 
48 a T>G transversion at position 1 (rs2011425) produced a leucine to valine amino acid change 
(L48V). P24T has a reported MAF of 0.05-0.09 in Caucasian populations, and L48V has a MAF of 0.14 
in Caucasians.  In addition, there have been reports of variants in the 5’-upstream region of UGT1A4 
in Japanese patients, although their functional relevance has yet to be established.160 The presence 
of SNPs within the coding regions of UGT genes may lead to alteration of specific catalytic activities. 
UGT1A4 is believed to be responsible for 75% of LTG glucuronidation;66 polymorphisms within the 
UGT1A4 gene may result in alteration of enzyme activity, and as a result explain at least part of the 
observed inter-individual variation in response to LTG.  
1.3.4.3. SCN1A, SCN2A, SCN3A 
In the brain, VGSCs are complexes of a 260-kDa α-subunit in association with auxiliary β-subunits (β1-
β4) of 33 to 36kDa.161 The α-subunit contains the voltage sensor and the ion-conducting pore in four 
internally repeated domains (I-IV), each consisting of six α-helical transmembrane segments (S1-S6) 
and a pore loop connecting S5 and S6.161 The β-subunits are known to modify the kinetics and 
voltage dependence of gating, serving as cell-adhesion-molecules that interact with the extracellular 
matrix, other cell-adhesion molecules, and the cytoskeleton.162, 163 
There are nine functional VGSC α-subunits in the human genome.161 The proteins of these channels 
are named Nav1.1 through to Nav1.9, each of which is encoded by a corresponding SCN- gene. Nav1.1, 
Nav1.2 and Nav1.3 are encoded by SCN1A, SCN2A and SCN3A, respectively. Together with Nav1.6 
(SCN8A), these three -subunit proteins (Nav1.1, Nav1.2 and Nav1.3) represent the primary sodium 
channels in the mammalian central nervous system.161, 164-166 
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Genetic variation in SCN1A has been implicated in the pathogenesis of severe myoclonic epilepsy of 
infancy (SMEI) as well as generalised epilepsy with febrile seizures plus (GEFS+).167 More than 600 
mutations in SCN1A have been identified, accounting for in excess of 70% of all cases of SMEI.168 
Approximately half the SMEI-causing mutations in SCN1A are nonsense or frameshift mutations that 
result in protein truncation, and are found randomly distributed throughout the gene.168 The 
remaining SMEI-causing SCN1A mutations are predominantly missense mutations located in 
transmembrane segments of the protein where they may prevent channel expression or severely 
impair channel function.168  The 30% of SMEI cases for which a genetic basis has yet to be established 
could, in theory, result from mutations in regulatory regions that govern SCN1A transcription.167 
More than 20 different SCN1A mutations have been identified in people with GEFS+, accounting for 
approximately 10% of cases.167 The majority of these are missense mutations located primarily within 
transmembrane segments of Nav1.1 channels.
168 As in SMEI,  sodium channel β-subunit mutations 
have been shown to cause GEFS+ through indirect impairment of the expression and function of 
Nav1.1 -subunit containing channels.
169 
As discussed previously, genetic variation in SCN1A has been associated with maximum doses of CBZ 
and PHT.103 A splice-site variant (rs3812718) showed significant associations with doses of both 
agents, in particular when analysed in additive models which remained statistically significant after 
Bonferroni correction for multiple comparisons. There is evidence to suggest that variation in SCN2A 
may affect response to AED therapy. Recently, in a study by Kwan and colleagues, an association was 
suggested between an SCN2A polymorphism (SCN2A IVS7-32A>G, rs2304016) and AED 
responsiveness. A-alleles were found to be associated with drug resistance (odds ratio = 2.1, 95% CI 
1.2-3.7, p=0.007) in the 471 Chinese epilepsy patients analysed. In addition to this, a weak 
association was reported by Sills and colleagues in abstract form between the R19K polymorphism of 
SCN2A and resistance to AED treatment.170  Finally, genetic variations in SCN2A have been reported 
in benign familial neonatal infantile spasms (BFNIS), with at least eight families now reported with 
missense mutations causative of BFNIS.171 
Evidence of genetic variation in SCN3A resulting in epilepsy or having an impact on AED dosing is 
scarce. A single patient with partial epilepsy and a mutation in SCN3A has been described, resulting 
from a heterozygous K354Q missense mutation.172 Despite this, SCN3A expression appears 
widespread throughout in the human adult brain,173 and as such it proves a candidate for genotype 
analysis. 
Overall, SCN1A, SCN2A, and SCN3A provide ideal targets for genotyping in this project. Genetic 
variation across these genes has been shown to result in various epilepsy syndromes, and 
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considering that the VGSC is its primary pharmacodynamic target, variation in these genes could 
theoretically influence dose requirement of and response to LTG. Moreover, variation in SCN1A has 
been shown to influence dosing of CBZ and PHT, both of which exert their anticonvulsant effects via 
sodium channels;103 plausibly, LTG dosing could be affected in a similar manner. 
 
1.4. Aims of Study 
The aim of this project was to determine whether genetic variation is responsible for the observed 
variability in effective doses of LTG in a well-characterised, prospectively followed cohort of patients 
with newly-treated epilepsy. Five genes were selected for analysis as a result of their involvement in 
the pharmacokinetic and pharmacodynamic profiles of LTG; SLC22A1, UGT1A4, SCN1A, SCN2A, and 
SCN3A. The study involved patients enrolled on the SANAD trial which randomised two-thousand, 
four-hundred and thirty-seven patients with newly diagnosed epilepsy from Jan 12, 1999 to Aug 31, 
2004. Participants that achieved seizure freedom for a period of at least twelve-months on a stable 
dose of LTG monotherapy were selected for analysis. Maintenance dose was used as the outcome 
measure as it reflects a combined measure of efficacy and tolerability, both of which are required in 
order for an AED to be clinically acceptable. Genotype data from a recent GWAS on the SANAD 
cohort of patients was supplemented with additional tSNP genotype data to capture all putatively 
functional variants in the five genes of interest. It was anticipated that a set of reliable genetic 
markers would be identified that explained a large percentage of inter-individual dose requirement 
for LTG. Ultimately, these markers may be employed prospectively to determine optimum doses for 
effective seizure control in individual patients. 
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Chapter 2:  – Methods 
2.1. Patient Selection 
2.1.1. Patient Cohort 
Participants were from the SANAD trial174 which randomised two-thousand, four-hundred and thirty-
seven newly-diagnosed epilepsy patients between January 12th 1999 and August 31st 2004, and 
collected follow up data where possible until January 13th 2006. The decision to collect DNA samples 
from SANAD participants was taken after commencement of the trial, resulting in 985 DNA samples 
being successfully obtained.  
2.1.2. Eligible Participants 
During the SANAD trial, the clinician recorded information regarding patient demographics and 
seizure history at recruitment, with details of treatment regimen and effectiveness documented at 
subsequent follow-up appointments. Patients were to be seen for follow-up at three, six, and twelve 
months and at successive yearly intervals from the date of randomisation. More frequent 
appointments were made if clinically indicated. Where patients failed to attend clinic appointments, 
follow up was achieved through directly contacting patients by telephone, or indirectly via the 
general practitioner.  
Following completion of the trial in 2006, an electronic database of the dosing data for all 
participants was assembled. This database was manually filtered to include only those participants 
with available DNA samples, and a shortlist compiled of those who appeared to have taken a stable 
dose of LTG monotherapy for a period of at least 12 consecutive months.  
These shortlisted participants subsequently had their case-notes reviewed to determine whether 
they met the following inclusion criteria: 
- Seizure free for a period of 12 consecutive months 
- Stable dose of LTG throughout this period 
- LTG monotherapy 
A total of 104 participants met the above inclusion criteria, having achieved seizure freedom for a 
period of at least 12 consecutive months on a stable dose of LTG monotherapy, and were therefore 
selected for genotype analysis. 
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2.1.3. Data Collection 
For each eligible participant, details of the following factors were collected from the patient notes 
and assembled into an electronic database: 
- Maintenance dose of LTG 
- Epilepsy type 
- Sex 
- Number of seizures before randomisation 
- Age at which maintenance dose was initiated 
- Previous AED use 
Maintenance dose:  Maintenance dose is a reflection of drug effectiveness. In turn, drug 
effectiveness is a combined measure of efficacy and tolerability. The efficacy of an AED is judged on 
its ability to prevent seizures, whilst tolerability is a reflection of how acceptable a drug is in terms of 
side-effects. Maintenance dose was chosen to reflect drug dosing in a clinical setting. For each 
participant, this was the stable daily dose administered during the period of seizure-freedom. During 
the SANAD trial, AEDs were prescribed as per everyday clinical practice; for LTG, standard practice is 
to initiate treatment at a low starting dose and to titrate up over a period of 6-8 weeks until a pre-
determined target dose is reached. Dose adjustments occur thereafter according to persistence of 
seizures or emergence of adverse effects.  
Epilepsy Type: Participants were classified into one of three categories according to the clinicians’ 
notes on epilepsy type: 
- Idiopathic generalised epilepsy (IGE) 
- Localisation-related epilepsy (LRE) 
- Unclassifiable epilepsy (UNC) 
Sex: Participant sex had been documented in the notes and was subsequently extracted. 
Number of seizures before randomisation: Prior to randomisation into the SANAD trial, details of 
previous seizures had been documented, including number of episodes of each type of seizure. The 
total number of previous seizures was calculated from these data. 
Age at which maintenance dose initiated: Documented within the patient notes were details of the 
dosing regimen at each follow-up appointment. Once a 12 month seizure-free period on a stable 
dose of LTG had been identified, the date at which this maintenance dose had been initiated was 
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recorded. Subsequently, using each patient’s date of birth, the age at maintenance dose initiation 
was calculated. 
Previous AED use: The SANAD trial did not exclude participants if they had received a single AED on a 
monotherapy dosing regimen before the trial commenced. This information had been recorded in a 
‘yes/no’ format by the clinician at randomisation. In addition to this, participants may have been 
randomised to receive a different AED from LTG at the start of the SANAD trial but were ultimately 
controlled on LTG after failure of the originally assigned drug. Regardless of when exposure occurred, 
participants who had received an alternative AED prior to achieving seizure-freedom with LTG were 
identified and “previous treatment” noted in the study database. 
2.2. SNP Identification 
2.2.1. HapMap 
The International HapMap project was launched in 2002 with the aim of providing a public resource 
to accelerate medical genetic research.175 The objective was to genotype at least one common SNP 
every 5 kilobases (kb) across the euchromatic portion of the genome in 270 individuals from four 
geographically diverse populations.176, 177 Since completion, this information has been made 
publically available, and was utilised to identify SNPs in the gene regions of interest. 
Each individual gene was searched using the HapMap search tool using the Hapmap Genome 
Browser (Phase 1 & 2, full dataset) accessible via http://hapmap.ncbi.nlm.nih.gov/. The chromosome 
positions were noted, and then the search criteria for each gene expanded manually by 10kB both 
upstream and downstream to capture the 5’ and 3’ flanking regions for each gene (Table 2.1). 
Table 2.1: Position and expanded search criteria for each gene 
 
Once the relevant gene regions had been identified, the SNP genotype data for these regions was 
downloaded using the ‘Reports and Analysis’ utility, ensuring the following parameters were 
selected: 
- Population – CEU (Caucasian-European) 
Gene Search Gene Position Expanded Search Criteria 
SLC22A1 Chr6:160,462,853..160,499,740 Chr6:160,452,853..160,509,740 
UGT1A4 Chr2:234,292,177..234,346,684 Chr2:234,282,177..234,356,684 
SCN1A Chr2:166,553,917..166,638,395 Chr2:166,543,917..166,648,395 
SCN2A Chr2:165,804,158..165,957,066 Chr2:165,794,158..165,967,066 
SCN3A Chr2:165,652,286..165,768,799 Chr2:165,642,276..165,778,823 
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- Strand – rs (SNP reference number) 
- Output format – save to disk 
This resulted in the download of all SNPs with a known frequency in a Caucasian European 
population in the gene regions of interest. 
 
2.2.2. Haploview 4.2 
Haploview 4.2 is a bioinformatics software tool that can analyse patterns of LD in a given set of 
genetic data. Once a set of genetic data has been analysed, Haploview is able to provide a set of 
tSNPs that will capture the genetic variation across the specified region(s).  
2.2.2.1. Tagging SNPs 
The principle of LD was used to generate a list of tSNPs that would allow for inference of all identified 
SNPs across the gene regions of interest. Haploview was instructed to analyse the downloaded SNP 
genotype data files from HapMap and generate a list of tSNPs for each. Under ‘HapMap Format’ of 
the Haploview start-up menu, each SNP genotype data file was opened and following parameters 
entered on the ‘Check Markers’ tab: 
- HW (Hardy-Weinberg) p-value = 0.001 
- Minimum genotype = 75% 
- Max# Mendelian errors = 1 
- Minimum MAF = 0.05 
The following limits were selected under the ‘tagger’ tab: 
- Pairwise tagging only 
- r2 threshold = 0.8 
- LOD threshold for multi-marker tests = 3.0 
- Min distance between tags = 0bp 
- Max distance between tags = blank 
The Haploview programme was instructed to execute the ‘Run Tagger’ function. This grouped SNPs 
that were in LD together, and generated a list of tSNPs with a minimum MAF of 5% which captured 
approximately 95% of the genetic variation across each gene region at the r2 = 0.8 level of certainty. 
The tSNP data for each of the five gene regions of interest has been included in Appendix III and is 
summarised in Table 2.2. 
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Overall, 587 SNPs in the five gene-regions of interest were identified from the HapMap database. 
Following LD grouping, 118 tSNPs were identified that would allow inference of all 587 SNP 
genotypes.  
 Table 2.2: Summary of tSNP data for each gene 
 
2.2.3. GWAS data 
Genotype data was available from a recent GWAS analysis on the SANAD cohort of patients. 
Genotyping was performed at the Wellcome Trust Sanger Centre (Hinxton, UK) on an Illumina 660k 
SNP chip with the aim of identifying genome-wide associations with response to AED treatment in 
the SANAD cohort as a whole. At this time, that analysis is ongoing, but the availability of GWAS-
derived genotypes made a significant contribution to this project and limited the number of novel 
genotypings that were required to complete the tSNP analysis of the five candidate genes of interest.  
The GWAS genotyped 47,993 and 58,599 SNPs across chromosomes 2 and 6, respectively. A list of 
these GWAS SNPs was available for chromosomes 2 and 6, along with details of SNP position, and the 
minor and major alleles at each SNP locus (Appendix IV). 
The GWAS SNPs were sorted by ascending chromosome position, and the same search criteria used 
for SNP identification on HapMap applied. Any SNPs that lay between the upper and lower 
chromosome position boundaries were selected, the results of which are shown in Table 2.3. Overall, 
this resulted in the identification of 166 GWAS SNPs within the gene-regions of interest.  
 
Table 2.3: GWAS SNP identification 
Gene Number of tSNPs Total number of SNPs captured 
SLC22A1 27 54 
UGT1A4 20 141 
SCN1A 16 116 
SCN2A 35 193 
SCN3A 20 83 
Total 118 587 
Gene Gene Location Lower Search 
Boundary 
Upper Search 
Boundary 
Number of 
GWAS SNPs 
SLC22A1 Chr6:160,462,853..160,499,740 160,452,853 160,509,740 37 
UGT1A4 Chr2:234,292,177..234,346,684 234,282,177 234,356,684 38 
SCN1A Chr2:166,553,917..166,638,395 166,543,917 166,648,395 27 
SCN2A Chr2:165,804,158..165,957,066 165,794,158 165,967,066 45 
SCN3A Chr2:165,652,286..165,768,799 165,642,286 165,778,799 19 
Total    166 
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2.2.4. Identification of Outstanding tSNPs 
Genotype data were available for the identified 166 GWAS SNPs. The next stage was to determine 
whether these GWAS SNPs were in LD with any SNPs from the tSNP identification process. The tSNP 
identification process had discovered that 118 tSNPs could capture the majority of the genetic 
variation across the five gene-regions of interest at an r2=0.8. If a GWAS SNP was found to be in LD 
with one of the tSNPs, genotyping of that tSNP was no longer required.  
For each gene region, the identified GWAS SNPs were checked against the corresponding output 
from Haploview. Overall, the GWAS SNPs were in LD with 81 of the 118 tSNPs previously identified. 
This left 37 outstanding tSNPs that required genotyping in order to capture approximately 95% of the 
genetic variation across the five gene-regions of interest (Table 2.4). 
Table 2.4: Summary of outstanding tSNPs 
 
2.2.5. Supplementary SNPs 
In addition to the 37 outstanding tSNPs, supplementary SNPs were selected for novel genotyping 
following a literature search. Putatively functional variants were selected for direct genotyping if they 
had not yet been captured by the GWAS and were absent from the devised list of outstanding tSNPs. 
SNPs were manually selected for genotyping if they met all the inclusion criteria shown in Table 2.5 
and excluded if they met any of the exclusion criteria. This process resulted in the inclusion of an 
additional nine SNPs, bringing the total number of SNPs for novel genotyping to 46. 
Table 2.5: Inclusion / exclusion criteria for supplementary SNPs 
Gene Number of identified 
tSNPs 
Number of tSNPs in LD with 
GWAS SNPs 
Number of outstanding 
tSNPs 
SLC22A1 27 20 7 
UGT1A4 20 13 7 
SCN1A 16 10 6 
SCN2A 35 24 11 
SCN3A 20 14 6 
Total 118 81 37 
Inclusion Criteria Exclusion Criteria 
Located within a gene-region of interest  In LD with a GWAS SNP 
Known MAF > 0.01 in a Caucasian population In LD with an outstanding tSNP 
Known functional SNP or significant association 
mentioned in literature 
 
 
Abbreviations: MAF = minor allele frequency; SNP = single nucleotide polymorphism; tSNP = tagging 
SNP; GWAS = genome-wide association study; LD = linkage disequilibrium 
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2.3. Experimental Design 
2.3.1. MySequenom® 
Once a list of SNPs had been compiled, an experiment was designed to genotype them using a 
Sequenom iPLEX® matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-TOF MS) platform. This was achieved through use of the MySequenom® ‘human genotyping 
tool’ utility accessible via http://www.mysequenom.com and consisted of five steps: 
rs-Sequence Retriever: The list of SNPs to be genotyped was entered into the first stage of the tool. 
This electronically retrieved the DNA sequence for each SNP from NCBI dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP), retrieving approximately 200kB both upstream and 
downstream from each SNP. 
ProxSNP®: The data obtained from the rs-sequence retriever was inputted into the ProxSNP® 
application. This re-formatted the SNP sequences to ensure any proximal SNPs near to the assay SNP 
were marked and accounted for accordingly. Any sequence with one or more proximal SNPs too 
close to the assay SNP was rejected at this stage. The output from ProxSNP® consisted of a list of rs-
numbers with their corresponding 100kB flanking regions; any unsuitable SNPs were reported 
separately and excluded from future stages. 
PreEXTEND®: The output of successful SNPs from ProxSNP® was entered into the PreEXTEND® 
application; this modelled each SNP sequence as a potential primer, validating each sequence to 
ensure that only the region of the SNP of interest would be amplified. SNPs were rejected if their 
primers were found to anneal to multiple sites.  
Assay Design: Primers were designed for the SNPs which remained after the PreEXTEND® process. 
For each SNP, the assay design application created a forward PCR primer, a reverse PCR primer, and 
an extension primer. 
PleXTEND®: After assay design, the assays were checked by the PleEXTEND® application to ensure 
that no unintended amplification products would be produced. 
2.3.2. Finalised Experimental Design 
A total of 46 SNPs were identified as candidates for novel genotyping, however 7 SNPs were excluded 
at various stages during the experimental design process as shown in Table 2.6. This resulted in a 
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final experimental design consisting of 39 SNPs spread across two plexes; 21 SNPs in plex 1, and 18 
SNPs in plex 2 (Table 2.7). 
Table 2.6: Excluded SNPs 
 
Table 2.7: Final plex design 
Plex 1  Plex 2 
rs-number: Gene 
Region 
Identification 
Method: 
rs-number: Gene 
Region 
Identification 
Method: 
rs12151636 SCN1A HapMap rs13406905 SCN1A HapMap 
rs478389 SCN1A HapMap rs1461195 SCN1A HapMap 
rs17791817 SCN1A HapMap rs6751613 SCN2A HapMap 
rs7566636 SCN2A HapMap rs6705474 SCN2A HapMap 
rs2060199 SCN2A HapMap rs16850317 SCN2A HapMap 
rs17183814 SCN2A HapMap rs353116 SCN2A HapMap 
rs6741147 SCN2A HapMap rs2228988 SCN2A Literature Search 
rs1368234 SCN2A HapMap rs3213904 SCN3A HapMap 
rs7573433 SCN2A HapMap rs2028364 SCN3A HapMap 
rs7600082 SCN2A HapMap rs6719780 SCN3A HapMap 
rs1946892 SCN3A HapMap rs7596422 SCN3A HapMap 
rs11677254 SCN3A HapMap rs3771342 UGT1A4 HapMap 
rs3806591 UGT1A4 HapMap rs45621441 UGT1A4 Literature Search 
rs6431633 UGT1A4 HapMap rs10203853 UGT1A4 HapMap 
rs35956182 SLC22A1 Literature Search rs929596 UGT1A4 HapMap 
rs619598 SLC22A1 HapMap rs12208357 SLC22A1 Literature Search 
rs34059508 SLC22A1 Literature Search rs644992 SLC22A1 HapMap 
rs9456505 SLC22A1 HapMap rs7773429 SLC22A1 HapMap 
rs10455864 SLC22A1 HapMap    
rs10455868 SLC22A1 HapMap    
rs461473 SLC22A1 HapMap    
 
SNP Gene 
Region 
Stage of Exclusion Reason for Exclusion 
rs76921794 SCN1A rs-Sequence 
Retriever 
Cannot get document summary 
rs78391141 SCN1A rs-Sequence 
Retriever 
Cannot get document summary 
rs77216276 SCN1A rs-Sequence 
Retriever 
Cannot get document summary 
rs78675912 SCN3A rs-Sequence 
Retriever 
Cannot get document summary 
rs2011404 UGT1A4 PreEXTEND® Multiple eXTEND hits for scanned primer triplets 
rs28946889 UGT1A4 PleXTEND® High dimer potential (0.67) for forward extend 
primer 
rs17744737 SCN1A PleXTEND® Could not multiplex SNP to minimum 
multiplexing level 
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Primers for the finalised experimental design across two plexes were ordered from Metabion® 
(Martinsried, Germany); forward and reverse primers were both at 50µM concentrations, and 
extension primers were supplied at a concentration of 300µM. 
2.3.3. Experimental Design Overview 
 
  
Primers ordered for 39 SNPS 
46 SNPs identified for genotyping 
39 Suitable SNPs 
2 SNPs excluded 
41 suitable SNPs 
Assay Design 
4 SNPs excluded 
1 SNP excluded 
41 suitable SNPs 
42 suitable SNPs 
42 rs-sequences retrieved 
rs-Sequence Retriever 
PleXTEND® 
PreEXTEND® 
ProxSNP® 
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2.4. Genotyping 
2.4.1. Primers 
A primer is a strand of nucleic acid that serves as a starting point for DNA synthesis. Typically they are 
approximately twenty bases in length, and are designed to be complementary to the sequence that is 
upstream to the DNA region of interest. PCR primers are designed to anneal upstream of a gene 
region of interest to allow amplification of the gene region containing a SNP. In contrast, extension 
primers are designed to anneal to the template DNA directly 5’ to a variant loci so that a mutant DNA 
polymerase can carry out single-base extension (SBE). 
2.4.1.1. PCR Primer Mix Preparation 
Primers were required at a working concentration of 0.5µM for optimal activity. For each plex, the 
following quantities of reagents were combined in 1000µl eppendorfs: 
Plex 1: 
- 290µl Nanopure water 
- 5µl of each forward primer (21 forward primers in total) 
- 5µl of each reverse primer  (21 reverse primers in total) 
Plex 2:  
- 320µl Nanopure water 
- 5µl of each forward primer (18 forward primers in total) 
- 5µl of each reverse primer (18 reverse primers in total) 
For each plex, this resulted in a total PCR primer mix volume of 500µl, with each primer at a 
concentration of 0.5µM. 
 
2.4.1.2. Extension Primer Mix Preparation 
For each plex, the extension primers were arranged in ascending order of weight and assigned a 
number accordingly; there were 21 extension primers for plex 1 (numbered 1-21) and 18 extension 
primers for plex 2 (numbered 1-18). 
For each plex, the primers were split into four groups depending on their weights as per the four-
step adjustment protocol. For plex 1, primers 1-6 were assigned to group 1, primers 7-11 to group 2, 
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primers 12-16 to group 3, and primers 17-21 to group 4. A 11.67µl volume of each of the group 1 
primers were mixed in an eppendorf, along with 15.50µl of each of the group 2 primers, 19.43µl of 
each of the group 3 primers, and 23.33µl of each of the group 4 primers. This resulted in primer 
concentrations of the group 1, 2, 3, and 4 primers of 7.00µM, 9.30µM, 11.67µM, and 14.00µM 
respectively.  
The assembly of the plex 1 primer mix is summarised in Table 2.8 along with the quantities required 
for assembly of plex 2. According to which of the four groups they had been assigned, pre-
determined volumes of each primer were used to assemble each primer mix to achieve desired 
concentrations; this is the essence of the four-step adjustment protocol.  
Table 2.8: Extension primer mix preparation summary 
 
2.4.2. Plating out the DNA 
The SANAD DNA stock-aliquot was available at a concentration of 20ng/µl, which is the standard 
concentration used on the Sequenom MassARRAY® platform. DNA samples for 27 of the identified 
participants were unavailable due to inadequate volume of existing DNA holding, resulting in 77 DNA 
samples being available for genotyping. 
A working-aliquot of these 77 DNA samples was assembled containing a maximum of 3µl of each 
sample. The aliquot was stored in the freezer at -20°C, and when required was allowed to thaw at 
room temperature, centrifuged at 2000 RPM for 2 minutes, and then stored on ice whilst samples 
were transferred to the final plate design. 
A 1µl volume of each DNA sample at the 20ng/µl concentration was transferred into a 384-well PCR 
plate according to the plate design in Appendix V. The 384-well PCR plate was then covered with 
tissue and allowed to evaporate. 
Extension 
Primer Group 
Final 
Concentration/ 
Primer 
Volume/ 
Primer 
Number of Primers 
per Group (primer 
numbers) 
Total volume of 
primer group 
Plex 1 Plex 2 Plex 1 Plex 2 
1 7.00µM 11.67µl 6 (1-6) 5 (1-5) 70.02µl 58.35µl 
2 9.30µM 15.50µl 5 (7-11) 5 (6-10) 77.50µl 77.50µl 
3 11.66µM 19.43µl 5 (12-16) 4 (11-14) 97.15µl 77.72µl 
4 14.00µM 23.33µl 5 (17-21) 4 (15-18) 116.65µl 93.32µl 
Nanopure 
Water 
    138.68µl 193.11µl 
Total volume     500µl 500µl 
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2.4.3. Polymerase Chain Reaction 
2.4.3.1. Polymerase Chain Reaction Mix Preparation 
Using the quantities of reagents outline in Table 2.9, a polymerase chain reaction (PCR) mix was 
prepared for each plex. 
Table 2.9: PCR reagents 
 
The PCR buffer, MgCl2 and deoxyribonucleotide triphosphate (dNTP) mix were removed from the 
freezer and allowed to thaw at room temperature. Once defrosted, they were mixed using a 
Whirlimixer® for 10 seconds each, and then centrifuged for two minutes at 2000 RPM. 
The PCR enzyme was removed from the freezer, mixed for 10 seconds using a Whirlimixer®, 
centrifuged for two minutes at 2000 RPM, and stored on ice throughout the PCR mix process. 
The primer mix was removed from the fridge, mixed for 10 seconds using a Whirlimixer®, and 
centrifuged for two minutes at 2000 RPM. 
The reagents were combined in a 1000µl eppendorf, sealed and centrifuged for 2 minutes at 2000 
RPM, and the reagents returned to their respective storage locations after use. 
The above process was repeated, substituting the plex 2 primer mix instead of plex 1, resulting in two 
eppendorfs containing PCR mix; one for plex 1 and the other for plex 2. 
2.4.3.2. Transfer of PCR Mix to 384-well PCR plate 
A 60µl volume of the plex 1 PCR mix was transferred into each of the wells in the first column of a 
96V microwell plate, and 60µl of the plex 2 PCR mix was transferred into each of the wells of the 
second column. The plate was then sealed and centrifuged for 2 minutes at 2000 RPM to remove any 
air bubbles. A 96V well plate was used ahead of a standard 96-well plate because the ‘V’ shaped 
wells minimised the volume errors often encountered when using a multi-channel pipette. 
Reagents Storage (temperature) Volume Required 
Nanopure water Sterile sealed container (room 
temperature) 
342µl 
Plex 1 primer mix (0.5µM) Fridge (5°C) 120µl 
PCR Buffer (10x) Freezer (-20°C) 75µl 
MgCl2 (25mM) Freezer (-20° C) 39µl 
dNTP mix (25mM) Freezer (-20° C) 12µl 
Hot Star Taq (5U/µl) Freezer (-20° C) 12µl 
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An 8-tip multi-channel pipette was used to transfer 5µl of the PCR mix from the first column of the 
96V microwell plate into each of the wells of columns 1-6 of the 384-well PCR plate containing 
evaporated DNA. Similarly, 5µl of PCR mix from the second column of the 96V microwell plate was 
transferred into each of the wells of columns 7-12 of the 384-well PCR plate. 
2.4.3.3. PCR Reaction 
The 384-well PCR plate was sealed using an Adhesive PCR Seal (AB-0558), centrifuged for 2 minutes 
at 2000 RPM, and then transferred to the G-Storm® Thermocycler GS4 apparatus (Gene Technologies 
Ltd, UK). A thermal cycler compression pad was placed on top of the 384-well PCR plate, and the 
thermocycler instructed to run the ‘PCR iPLEX’ programme for a reaction volume of 5µl. The PCR 
process selectively amplified the sequences of DNA containing the identified SNPs, and can be 
summarised as follows: 
Initialisation: The PCR mix was heated to 94.0°C and held for a period of 15 minutes. 
Denaturation: The PCR mix was heated to 94°C for a period of 20 seconds, disrupting the hydrogen 
bonds between complementary bases and separating the double-stranded DNA-complex to yield two 
single DNA strands. 
Annealing: Once the strands had been separated, the reaction temperature was lowered to 56°C for 
30 seconds to allow the primers to anneal to their respective single-stranded DNA targets. 
Simultaneously, the Taq polymerase enzyme bound to the primer-template hybrid in preparation for 
the elongation phase. 
Elongation: The reaction was then heated to 72°C for a period of 60 seconds, providing optimum 
conditions for the activity of the Taq polymerase enzyme. Taq polymerase synthesised 
complementary strands of DNA in the 5’ to 3’ direction through addition of complementary dNTPs 
with hydrogen bonds.  A complementary DNA strand was formed in the 5’ to 3’ direction from each 
point at which a primer had annealed to the template DNA strand. 
Repetition: The denaturation, annealing and elongation steps were repeated 45 times, with the 
products of each cycle becoming the template for subsequent cycles, theoretically producing an 
exponential increase in the quantity of relevant DNA per cycle.  
Final Elongation: After 45 cycles, the reaction temperature was held at 72°C for three minutes to 
ensure that any remaining single-stranded DNA was fully extended. 
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Final hold: The temperature of the reaction was reduced to 5°C, which provided suitable storage 
conditions for up to a 12-hour period. 
The PCR iPLEX® required approximately 2.5 hours to reach the final hold stage at which point the 
384-well PCR plate was removed, centrifuged at 2000RPM for 2 minutes, and stored in the cold room 
at 0°C.  
2.4.4. Shrimp Alkaline Phosphatase 
The unincorporated dNTPs from the PCR amplification process were removed to avoid interference 
with reagents added at subsequent stages. This was achieved through the addition of shrimp alkaline 
phosphatase (SAP), an enzyme which resulted in the dephosphorylation of any excess dNTPs, thereby 
rendering them inactive in future reactions. 
2.4.4.1. SAP Preparation 
The reagents and volumes listed in Table 2.10 were required for SAP-mix preparation. 
Table 2.10: SAP reagents 
 
The hME buffer was removed from the freezer and allowed to thaw at room temperature. The SAP 
and hME buffer were then mixed for 10 seconds each using the Whirlimixer®, and centrifuged for 2 
minutes at 2000 RPM, with the SAP stored on ice thereafter. 
The SAP reagents were mixed in a 1000µl eppendorf, centrifuged for 2 minutes at 2000 RPM, and 
then 66µl of the SAP solution was transferred into each well of the first column of a new 96V 
microwell plate. An 8-tip multichannel pipette was then used to transfer 10µl of the SAP solution 
from column 1 into each of columns 2-6 of the 96V microwell plate. The plate was then sealed and 
centrifuged for 2 minutes at 2000 RPM to remove any bubbles. 
2.4.4.2. Addition of SAP to 384-well PCR plate 
The Matrix Liquid Handler (MLH) was used to add 2µl of SAP solution to each of the wells containing 
DNA in the 384-well PCR plate. Prior to using the MLH, the 384-well PCR plate and the 96V microwell 
plate were sealed and centrifuged at 2000 RPM for 2 minutes, and their seals removed upon 
completion. 
SAP Reagents Storage Volume Required 
Nanopure water Sterile sealed container 
(room temperature) 
405.39µl 
hME buffer (10x) Freezer (-20°C) 45.04µl 
Shrimp Alkaline Phosphotase (SAP) Freezer (-20°C) 79.49µl 
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Once the weekly maintenance protocols had been adhered to, as per the manufacturer’s guidelines, 
a new magazine of tips was inserted into the MLH and the “tip wash” programme initiated using the 
ControlMate software. 
Once the “tip wash” programme had completed, the “SAP addition (96 to 384).cms” programme was 
selected. This prompted onscreen instructions for positioning of 384-well PCR plate and 96V 
microwell plate. Upon completion, the 384-well PCR plate was sealed using an adhesive PCR seal (AB-
0558) and centrifuged for 2 minutes at 2000 RPM.  
2.4.4.3. SAP Reaction 
The 384-well PCR plate was placed in the G-Storm® Thermocycler GS4 apparatus with a thermal 
cycler compression pad on top, and the programme ‘SAP iPLEX’ selected for a reaction volume of 7µl. 
The programme consisted of the following steps: 
Temperature increased to 37.0°C for 40 minutes. This provided optimum temperature conditions for 
the SAP to undertake its activity. 
Temperature increased to 85.0°C for 5 minutes. This step served to irreversibly denature the SAP, 
removing any chance of interaction with subsequent reagents.  
Storage at 10°C. The reaction products were held at this temperature indefinitely until removed from 
the thermocycler. 
The SAP-iPLEX reaction required approximately 50 minutes to complete, after which the 384-well 
PCR plate was removed from the apparatus, sealed using AB-0558, and centrifuged for 2 minutes at 
2000 RPM. 
2.4.5. iPLEX® Gold 
After PCR cleanup, the iPLEX® Gold reaction was performed. The reagents in Table 2.11 and Table 
2.12 were required to assemble the iPLEX® Gold reaction cocktail solutions for plexes 1 and 2, 
respectively. 
Table 2.11: Plex 1 iPLEX reagents 
Plex 1 Reagents Storage (Temperature) Volume 
Nanopure Water Sterile sealed container (room 
temperature) 
100.02µl 
iPLEX®-Buffer (10x) Freezer (-20°C) 26.50µl 
iPLEX®-Termination mix Freezer (-20°C) 26.50µl 
Plex 1 Primer mix Fridge (5°C) 106.51µl 
iPLEX®-Enzyme Freezer (-20°C) 5.30µl 
Total  264.83µl 
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Table 2.12: Plex 2 iPLEX reagents 
 
2.4.5.1. iPLEX® Reaction Cocktail Solution 
The iPLEX®-buffer and iPLEX®-termination mix were allowed to thaw at room temperature. Each 
reagent apart from the Nanopure water was mixed using a Whirlimixer® for 10 seconds each, and 
then centrifuged for 2 minutes at 2000 RPM. The iPLEX®-enzyme was stored on ice throughout 
preparation, while the other reagents were stored at room temperature. The reagents for plex 1 and 
plex 2 were combined separately in 1000µl eppendorfs, mixed using a Whirlimixer® for 10 seconds 
each, and then centrifuged for 2 minutes at 2000 RPM.  A 2µl volume of primer extension reaction 
cocktail solution was added to each well of the 384-PCR reaction plate containing PCR amplification 
products. This was then placed in the G-Storm® GS4 thermocycler and exposed to the necessary 
conditions (section 2.4.5.4.) for SBE to occur. 
2.4.5.2. Addition of iPLEX® Reaction Cocktail Solution to 384-well PCR Plate 
The MLH was used to add 2µl of iPLEX® Reaction Cocktail solution to each of the wells containing 
DNA in the 384-well PCR plate. As per SAP addition, weekly maintenance and tip wash protocols 
were followed prior to use of the MLH for iPLEX® reaction cocktail solution addition. Using a new 96V 
microwell plate, 33µl of the plex 1 iPLEX® reaction cocktail solution was transferred into each well of 
the first column, and 33µl of the plex 2 iPLEX® reaction cocktail solution into each well of the fourth 
column. Using an 8-tip multichannel pipette, 10µl of plex 1 cocktail solution was transferred from 
column 1 into columns 2 and 3, and similarly 10µl of plex 2 cocktail solution was transferred from 
column 4 into columns 5 and 6. The 384-well PCR plate and the 96V microwell plate were sealed and 
centrifuged at 2000 RPM for 2 minutes, and their seals removed upon completion. The programme 
“cocktail addition (96 to 384).cms” was initiated, and the onscreen instructions followed for 
positioning of the 384-well PCR plate and the 96V microwell plate. Upon completion, the 384-well 
PCR plate was sealed with an adhesive seal (AB-0558) and centrifuged for two minutes at 2000 RPM.  
  
Plex 2 Reagents Storage (Temperature) Volume 
Nanopure Water Sterile sealed container (room 
temperature) 
100.02µl 
iPLEX®-Buffer (10x) Freezer (-20°C) 26.50µl 
iPLEX®-Termination mix Freezer (-20°C) 26.50µl 
Plex 2 Primer mix Fridge (5°C) 106.51µl 
iPLEX®-Enzyme Freezer (-20°C) 5.30µl 
Total  264.83µl 
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2.4.5.3. iPLEX® Reaction 
The 384-well PCR plate was placed in the G-Storm® Thermocycler GS4 apparatus with a thermal 
cycler compression pad on top, and the programme ‘extend iPlex.scr’ initiated for a reaction volume 
of 9µl per well. This programme consisted of the following stages, required approximately 4 hours, 
and upon completion the plate was centrifuged for 2 minutes at 2000 RPM and stored in the cold 
room at 0°C: 
Temperature 94°C for 30 seconds. 
50 cycles of the following: 
Temperature 94°C for 5 seconds 
Temperature 52°C for 5 seconds 
Temperature 80°C for 5 seconds 
Temperature 52°C for 5 seconds 
Temperature 80°C for 5 seconds 
Temperature 52°C for 5 seconds 
Temperature 80°C for 5 seconds 
Temperature 52°C for 5 seconds 
Temperature 80°C for 5 seconds 
Temperature 72°C for 3 minutes 
Temperature 4°C for 5 minutes 
Stored at 5°C indefinitely. 
During the SBE process outlined above, each extension primer anneals to its target directly 5’ to the 
SNP locus. A mutant DNA polymerase (iPLEX®-enzyme) then incorporates a single terminator 
nucleotide (iPLEX®-termination mix) that is complementary to the base at the variant locus. This 
results in elongation of the extension primer by a single base unit, with a corresponding mass 
increase dependent upon which terminator nucleotide has been incorporated. The mass increase can 
be measured using MALDI-TOF MS, with SNP genotype interpreted accordingly. 
2.4.6. Sample Conditioning 
Upon completion of the Extend-iPLEX reaction, unincorporated products were desalted via cation 
exchange through addition of SpectroCLEAN® resin. This step was performed in order to maximise 
the MALDI-TOF MS resolution, in turn minimising false-positive results.  
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2.4.6.1. Preparation of SpectroCLEAN® Resin 
Resin was spread over the first 12 columns of a 384-well dimple plate using a bevelled Perspex 
applicator, and allowed to dry for approximately 10 minutes. During this time the 384-well PCR plate 
was centrifuged for 2 minutes at 2000 RPM and the seal removed. 
2.4.6.2. Addition of Nanopure Water 
The MLH was used to add 16µl of Nanopure water to each well of the 384-well PCR plate. Using the 
ControlMate® software, the programme ‘16µl water addition.cms’ was selected and the onscreen 
instructions followed for placement of the 384-well PCR plate and water bath filled with Nanopure 
water. Once complete the 384-well PCR plate was sealed, centrifuged for 2 minutes at 2000 RPM, 
and the seal removed again. 
2.4.6.3. Addition of SpectroCLEAN® Resin 
The 384-well PCR plate was inverted, placed on top of the resin dimple plate, then both were 
inverted to transfer the resin into the 384-well PCR plate. The plate was sealed again using Adhesive 
PCR Seal (AB-0558), secured between two polystyrene blocks in the Heidolph®-Reax 2 rotator, and 
set to rotate for 10 minutes on the lowest setting. 
Once completed, the 384-well PCR plate was removed and centrifuged for 5 minutes at 3000 RPM. 
The extended centrifuge duration and speed was necessary to settle down all CleanRESIN® so that it 
was not transferred onto the matrix during the next step; resin particles embedded in the matrix can 
be detrimental to the accuracy and success of the MALDI-TOF analysis. 
2.4.7. Dispensing 
A MassARRAY® nanodispenser was used to dispense 15-25nl of the samples onto a 384 
SpectroCHIP®. The samples were embedded into the 3-hydroxypicolinic acid matrix of the 
SpectroCHIP® where they underwent co-crystallisation in preparation for MALDI-TOF MS. 
2.4.7.1. Transfer of iPLEX® Reaction Products onto a SpectroCHIP® 
Per protocol steps were taken to prepare the nanodispenser for operation, including pin conditioning 
of the main head and single head, cleaning the main head and single head, and running the volume 
check programme to avoid poor dispensing quality. Once the nanodispenser had been prepared for 
use, the Spectropoint® programme was used to initiate the ‘384-384.tmf’ command, with the 
appropriate dispensing speed values entered in order to achieve a spotting volume of 15-25nl. This 
programme transferred 15-25nl of each sample onto the SpectroCHIP®. MassARRAY Calibrant® was 
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removed from the freezer and allowed to thaw at room temperature before being centrifuged for 30 
seconds at 2000 RPM. A 70µl volume was transferred into the calibrant reservoir of the 
nanodispenser, and the programme ‘calibrant.tmf’ initiated. This transferred calibrant onto the 
SpectroCHIP® to optimise performance of the MALDI-TOF apparatus.  
2.4.8. Mass Spectrometry 
The general principle of MS is to produce, separate, and detect gas phase ions (Figure 2). This was 
achieved through the following stages: 
Irradiation of the matrix crystals. The matrix crystals were exposed to an ultraviolet laser of 
wavelength 337nm for 1 nanosecond. The matrix acted as a buffer, absorbing much of the energy 
supplied by the laser to prevent degradation of the single-base extended primers whilst allowing 
enough energy for them to become ionised. The result was structural decomposition of the 
irradiated crystal and the generation of a particle cloud. 
Acceleration through an electrical field. An electrical field accelerated the charged ions to separate 
them from the particle cloud. Following separation, they were allowed to drift through a vacuum 
towards the detector apparatus. 
Detection of ions and TOF measurement. The accelerated ions were detected by the secondary 
electron multiplier (SEM) apparatus, which measured the TOF for each particle and allowed for 
subsequent calculation of ionic mass.  
 
Figure 2: General schematic of a linear MALDI-TOF MS system178 
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2.4.8.1. Reading the SpectroCHIP® 
Once the calibrant and samples had been spotted onto the SpectroCHIP®, it was transferred to the 
MassARRAY® MALDI-TOF MS instrument using handling tongs to avoid contamination. Once inserted, 
the vacuum was activated and laser-desorption/ionisation process initiated. The SEM collected TOF 
data for all ions released from each individual sample. The spectrum of detected particles were 
processed and smoothed with a digitiser (Typer® software program) and the interpreted genotypes 
assigned on the basis of predetermined values uploaded into a relational database (Typer® 
database). 
2.4.8.2. Genotype Quality Control 
The ‘MassARRAY® Caller’ software package was used to display the genotype data determined by the 
MALDI-TOF MS process. The following steps were taken to ensure accuracy of data: 
Contamination: The plate design incorporated multiple wells that did not contain a DNA sample yet 
were still analysed for genetic content; any contamination of these blank wells would result in false-
positive calls. 
Consistency between repeats: Where sufficient volumes of DNA were available, repeats of samples 
were used to ensure consistency of genotype calls. Twenty-two of the seventy-seven available DNA 
samples (29%) were repeated across either plex 1 or plex 2, the calls of which were compared, and 
any anomalies corrected / excluded accordingly. 
Manual calls: Where the software was unable to assign a genotype, it was labelled as a ‘no call’. The 
spectra for these were reviewed, and genotypes manually assigned, where possible. 
2.5. Data Assembly 
The GWAS dataset consisted of genotype data for 166 SNPs across 96 patients. A total of 104 
participants were originally selected for inclusion, however the GWAS-genotyping process was 
deemed to have failed for 8 of them, decreasing the dataset to 96 patients overall. 
A further 39 tSNPS were selected for genotyping to capture the outstanding genetic variation. This 
was undertaken on only 77 of the identified 104 eligible participants due to DNA stock depletions. 
All of the available genotype data was assembled into a master database, representing 100 DNA 
samples and up to 205 SNP genotypes per sample. 
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2.5.1. Data Quality Control 
Before any statistical analyses could be carried out on the data, the following quality control 
procedures were performed: 
Genotyping Completeness: For each DNA sample, at least 80% of all SNPs must have been 
successfully genotyped for that DNA sample to be included in that analysis. This resulted in exclusion 
of 4 DNA samples, reducing the total number of samples to 96. 
SNP Success: For each SNP, a genotype must have been established in at least 70% of the DNA 
samples for that SNP to be included the analysis. This resulted in exclusion of 21 SNPs, reducing the 
total number of SNPs to 184. 
Hardy-Weinberg Equilibrium (HWE): SNPs that failed to meet HWE (p-value = 0.001) were excluded 
from further analysis. This resulted in exclusion of a further 11 SNPs, reducing the total number of 
SNPs to 173.  
Overall, following data quality control measures, 96 DNA samples with genotype data for 173 SNPs 
were put forward for statistical analyses. 
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2.5.2. Data Assembly Overview: 
 
 
 
  
104 participants meeting the inclusion criteria 
104 participants with 
GWAS data for up to 
166 SNP genotypes 
104 participants with 
additional genotyping data 
for up to 39 SNP genotypes 
8 participants 
exclude due to 
failed samples 
27 participants 
excluded due to DNA 
stock depletions 
100 remaining participants with up to 205 SNP genotypes per sample 
- 92 participants with both GWAS and additional genotype data 
- 4 participants with GWAS genotype data only 
- 4 participants with additional genotype data only 
96 participants with up to 205 SNP genotypes per sample 
- 92 participants with both GWAS and additional genotype data 
- 4 participants with GWAS genotype data only 
4 participants excluded; 
those with additional 
genotype data only 
SNP success > 70% 21 SNPs excluded 
96 participants with up to 184 SNP genotypes per sample 
- 92 participants with both GWAS and additional genotype data 
- 4 participants with GWAS genotype data only 
Hardy-Weinberg Equilibrium testing 11 SNPs excluded 
96 participants with up to 173 SNP genotypes per sample 
- 92 participants with both GWAS and additional genotype data 
- 4 participants with GWAS genotype data only 
96 participants with 
GWAS data for up to 
166 SNP genotypes 
77 participants with 
additional genotyping data 
for up to 39 SNP genotypes 
Genotype Completeness > 80% 
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2.6. Statistics 
SPSS (version 17) was used to perform various analyses on the collated data.  
2.6.1. Data Coding 
Following collection, data were coded according to the format in Table 2.13. 
Table 2.13: Summary of data coding prior to analysis 
2.6.2. Descriptive Analyses 
Descriptive analyses of each variable were performed. A mean, standard deviation, and range were 
calculated for normally-distributed continuous variables, and a median and range for skewed 
continuous variables. The distribution of participants among groups was compared. 
2.6.3. Univariate Analyses 
Following descriptive analyses, univariate analyses were undertaken for each variable in relation to 
maintenance dose according to the tests outlined in Table 2.14. Since the data for maintenance dose 
was found to have a skewed distribution, the natural log of maintenance dose (Ln Dose) was 
modelled as the dependent variable. Following completion of the univariate analyses, correction for 
multiple comparisons using false-discovery rate was performed. 
Table 2.14: Statistical tests performed on each variable 
Variable Coding References 
Maintenance Dose Daily dose in mg 
Epilepsy Type (0, UNC) (1, LRE) (2, IGE) 
Sex (0, Male) (1, Female) 
Number of Seizures before Randomisation Seizure number 
Age at which Maintenance Dose Initiated Age in years 
Previous AED use? (0, Yes) (1, No) 
Genotype (0, homozygous major allele) (1, heterozygous) (2, 
homozygous minor allele) 
IGE = idiopathic generalised epilepsy; LRE = localisation-related epilepsy; UNC = unclassifiable 
epilepsy; AED = antiepileptic drug 
Variable Statistics Test 
Epilepsy Type One-Way Analysis of Variance (ANOVA) 
Sex Student’s t-test 
Number of Seizures before Randomisation Linear regression 
Age at which Maintenance Dose Initiated Linear regression 
Previous AED use? Student’s t-test 
Genotype One-Way ANOVA 
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2.6.4. Multivariate Analyses 
Multivariate analysis was carried out using a stepwise linear regression model to identify any 
association with maintenance dose. Seven separate multivariate analyses were performed to include 
SNPs from the following gene(s); for each analysis, non-genetic factors were included as covariates 
and Ln dose was modelled as the dependent variable:  
- SLC22A1 alone 
- UGT1A4 alone 
- SCN1A alone 
- SCN2A alone 
- SCN3A alone 
- SCN1A, SCN2A, SCN3A combined 
- SLC22A1, UGT1A4, SCN1A, SCN2A, SCN3A combined 
Participants with missing data were excluded in a list-wise fashion to avoid skewing the model. The 
impact of each variable on the model was indicated by the β-coefficient, with the corresponding p-
value denoting the probability that the factor influenced LTG maintenance dose. The r2 value was 
used to indicate the goodness of fit of the overall model, and represented the degree of variation in 
LTG dosing that could be accounted for by that model. The p-residual value indicated the significance 
of the model overall; a threshold of 0.05 was set to identify statistical significance. 
Following successful generation of a multivariate model, a dose-predictive equation for determining 
the maintenance dose of LTG was constructed using the generated correlation coefficients. This 
equation was then used to generate predicted doses for each participant used in the generation of 
that particular model. 
Finally, the data was back-transformed from Ln-dose to maintenance dose, and the relationship 
between observed and predicted maintenance dose determined using Spearman’s correlation test 
on the non-parametric data. 
 
  
 54 
 
Chapter 3: Results 
3.1. Descriptive Statistics 
Ninety-six participants were included in the analysis; 48 male and 48 female. The age of participants 
ranged from 9 – 83 years, with a mean age of 43 years (standard deviation 18.8 years). A total of 
61.5% of participants were classified as having LRE, 11.5% with IGE, and the remaining 27.0% had an 
unclassifiable epilepsy type (Table 3.1). 
The median number of seizures before randomisation was 10 and ranged from 2 to approximately 
1800. For the majority of participants (61.5%), LTG was the first AED. 
Table 3.1: Patient demographics 
 
The maintenance dose ranged from 50-675mg/day, with a median dose of 200mg/day. Prior to 
statistical analyses, the distribution of the dose variable was explored and found to be positively 
skewed (Figure 3). The data was therefore transformed by taking the natural log, bringing the 
distribution closer to that of the normal to allow parametric tests to be carried out. 
  Patient Cohort (n=96) 
Sex Male 
Female 
50% 
50% 
Age in years Mean 
Minimum 
Maximum 
Standard Deviation 
43 
9 
83 
18.8 
Epilepsy type IGE 
LRE 
UNC 
11.5% 
61.5% 
27% 
Number of seizures Median 
Minimum 
Maximum 
10 
2 
1801 
Maintenance dose in mg/day Median 
Minimum 
Maximum 
200 
50 
675 
LTG first AED? Yes 
No 
61.5% 
38.5% 
IGE = idiopathic generalised epilepsy; LRE = localisation-related epilepsy; UNC = unclassifiable 
epilepsy; LTG = lamotrigine, AED = antiepileptic drug 
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 Figure 3: Distribution of LTG maintenance dose before and after log transformation 
 
3.2. Univariate Analyses 
Correction for multiple comparisons using false-discovery rate (FDR) was performed, taking into 
account 178 individual tests (173 genetic, 5 non-genetic); the corrected p-values are displayed in the 
final column of the relevant tables. 
3.2.1. Non-genetic factors 
3.2.1.1. Linear Regression 
A linear regression model was used to identify associations between maintenance dose and the 
following factors: 
- Number of seizures before randomization (seizure number) 
- Age at which maintenance dose was initiated (age) 
Ln Dose was modelled as the outcome variable; no significant associations were found between dose 
and either seizure number or age (Table 3.2). 
 
Table 3.2: Univariate Analyses - linear regression 
 
  
Predictor Coefficient r2 value p-value p-value rank FDR-corrected p-value 
Seizure number 0.100 0.010 0.335 72 0.828 
Age -0.038 0.001 0.712 132 0.960 
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3.2.1.2. Student’s t-test 
Student’s t-test was used to identify associations between Ln Dose and the following independent 
variables: 
- Sex 
- Previous AED use 
No statistically significant associations were identified (Table 3.3). 
Table 3.3: Univariate analyses: Student's t-test 
 
3.2.1.3. One-way Analysis of Variance 
ANOVA was performed to investigate any association between Ln Dose and epilepsy type; none was 
identified (Table 3.4). 
Table 3.4: Univariate Analyses: One-way analysis of variance 
 
3.2.2. Genetic Factors 
ANOVA was performed to investigate associations between Ln Dose and the three possible 
genotypes at each SNP locus; in situations where there were only two genotypes, Student’s t-test 
was performed. Overall, a total of 147 one-way ANOVAs and 26 Student’s t-tests were performed on 
genetic factors; these data are displayed in Appendix VI. Results with an uncorrected p-value <0.05 
are illustrated in Table 3.5 and Table 3.6; those with p<0.02 are explored in more detail thereafter, 
and the remaining results with a pre-corrected p-value between 0.02 and 0.05 have been included in 
Appendix VII. 
  
Variable t-
statistic 
Degrees of 
freedom 
p-
value 
Confidence interval p-value 
rank 
FDR-corrected 
p-value Lower Upper 
Sex -0.706 94 0.482 -0.25242 0.11993 91 0.943 
Previous 
AED Use 
-0.227 94 0.821 -0.21369 0.16976 153 0.955 
Variable F-
Statistic 
Degrees of Freedom p-
value 
p-value 
rank 
FDR-corrected p-
value Between 
Groups 
Within 
Groups 
Epilepsy 
Type 
2.305 2 93 0.105 31 0.603 
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Table 3.5: Summary of one-way ANOVA tests p<0.05 (uncorrected) 
SNP (Minor 
allele) 
Gene-
Region 
F-
Stat 
Degrees of Freedom p-
value 
p-value 
rank 
FDR-
corrected p-
value 
Between 
Groups 
Within 
Groups 
rs3798173 (A) SLC22A1 5.102 2 92 0.008 1 1.000 
rs628031 (A) SLC22A1 4.567 2 93 0.013 4 0.579 
rs456598 (A) SLC22A1 4.264 2 93 0.017 5 0.605 
rs806383 (A) SLC22A1 3.393 2 93 0.038 12 0.564 
rs12993173 (C) SCN2A 4.256 2 92 0.017 5 0.605 
rs1439805 (C) SCN2A 4.184 2 93 0.018 7 0.458 
rs9287856 (A) SCN2A 3.724 2 93 0.028 8 0.623 
rs9287857 (G) SCN2A 3.724 2 93 0.028 8 0.623 
rs1866603 (G) SCN2A 3.629 2 93 0.030 10 0.534 
rs17184707 (A) SCN2A 3.384 2 93 0.039 13 0.534 
rs10174400 (A) SCN2A 3.108 2 91 0.049 14 0.623 
rs11903851 (A) SCN3A 5.018 2 93 0.009 2 0.801 
SNP = single-nucleotide polymorphism; F-stat = F-statistic; FDR = False Discovery Rate 
 
Table 3.6: Student's t-test p<0.05 (uncorrected) 
SNP (Minor 
allele) 
Gene 
Region 
t-stat DF p-
value 
Mean 
Diff 
95% CI p-
value 
rank 
FDR-
corrected 
p-value 
Lower Upper 
rs461473 (A) SLC22A1 -2.575 67 0.012 -0.368 -0.654 -0.083 3 0.712 
rs34059508(A) SLC22A1 -2.151 69 0.035 -0.557 -1.074 -0.040 11 0.566 
SNP = single-nucleotide polymorphism; t-stat = t-statistic; DF = degrees of freedom; mean diff = mean 
difference; CI = confidence interval; FDR = False Discovery Rate. 
 
3.2.2.1. SLC22A1 
rs3798173 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.008, uncorrected). This intronic SNP in SLC22A1 tagged an additional seven SNPs 
(Appendix Table 3). The homozygous-minor allele group (AA) appeared to require a higher 
maintenance dose of LTG than either the heterozygous (AG) or homozygous-major allele group (GG) 
(Table 3.7 and Table 3.8) although there was no evidence of an allelic-specific effect on dose (Figure 
4). 
Table 3.7: Back-transformed dose data for rs3798173 
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
GG 60 190 100 675 
GA 32 165 50 300 
AA 3 368 200 500 
Total 95 185 50 675 
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Table 3.8: Back-transformed dose data for rs3798173 - between groups comparison 
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
GG GA 1.153 0.917 1.450 0.350 
AA 0.516* 0.278 0.958 0.032 
GA GG 0.867 0.690 1.091 0.350 
AA 0.447* 0.238 0.842 0.008 
AA GG 1.939* 1.044 3.601 0.032 
GA 2.235* 1.188 4.206 0.008 
* The mean difference is significant at the 0.05 level. 
Number of participants: GG = 60, GA = 32, AA = 3, Total = 95 
  
 
Figure 4: Dose distribution between rs3798173 genotype 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: GG = 60, GA = 32, AA = 3, Total = 95 
 
rs628031 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.013, uncorrected). This is a coding non-synonymous SNP in SLC22A1 that results in a 
M408V amino acid substitution in the OCT1 protein. The homozygous-major allele group (GG) 
appeared to require a higher maintenance dose of LTG than the heterozygous group (GA) and the 
homozygous-minor allele group (AA) (Table 3.9 and Table 3.10). There was some evidence of an 
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allele-specific effect on dose, with carriers of the A-allele requiring lower maintenance doses of LTG 
(Figure 5). 
Table 3.9: Back-transformed dose data for rs628031 
 
Table 3.10: Back-transformed dose data for rs628031 - between groups comparison 
 
 
 
Figure 5: Dose distribution between rs628031 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: GG = 33, GA = 47, AA = 16, Total = 96  
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
GG 33 224 100 675 
GA 47 175 50 500 
AA 16 157 100 200 
Total 96 187 50 675 
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
GG GA 1.280* 1.003 1.633 0.047 
AA 1.430* 1.031 1.984 0.027 
GA GG 0.781* 0.612 0.997 0.047 
AA 1.118 0.819 1.525 0.767 
AA GG 0.699* 0.504 0.970 0.027 
GA 0.895 0.656 1.221 0.767 
* The mean difference is significant at the 0.05 level. 
Number of participants: GG = 33, GA = 47, AA = 16, Total = 96 
 60 
 
rs456598 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.017, uncorrected). This SNP in the flanking region of SLC22A1 did not tag any 
additional SNPs. Upon scrutiny, the association was found to be based on the genotype of a single 
participant carrying the heterozygous-minor allele genotype (AA). Post-hoc tests were not performed 
as a consequence and no efforts were made to explore allele-specific effects on dose (Table 3.11).  
Table 3.11: Back-transformed dose data for rs456598 
 
rs461473 
Student’s t-test identified a significant association between maintenance dose and genotype at this 
SNP locus (p=0.012, uncorrected). This intronic SNP is found in SLC22A1 and did not tag any 
additional SNPs. The heterozygous group (GA, geometric mean = 246mg/day, n=11) appeared to 
require a higher maintenance dose of LTG than the homozygous-minor allele group (GG, geometric 
mean = 170mg/day, n=58) (Table 3.12). With only two genotypes at this locus, it was not possible to 
infer allele-specific effects. 
Table 3.12: Back-transformed dose data for rs461473 – between groups comparison 
 
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
GG 70 185 50 498 
GA 25 181 100 399 
AA 1 675 675 675 
Total 96 187 50 675 
Variable t-
statistic 
Degrees 
of 
freedom 
Ratio of 
Geometric 
means 
95% CI of Ratio of 
Geometric Means 
p-
value 
p-
value 
rank 
FDR-
corrected 
p-value Lower Upper 
rs461473 
(A) 
-2.575 67 0.692 0.520 0.921 0.012 3 0.712 
Number of participants: GG = 58, GA = 11, Total = 69 
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Figure 6: Dose distribution between rs461473 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: GG = 58, GA = 11, Total = 69 
 
3.2.2.2. SCN2A 
rs12993173 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.017, uncorrected). This intronic SNP is found in SCN2A and tagged an additional seven 
SNPs (Appendix Table 6). The homozygous-major allele group (AA) appeared to require a higher 
maintenance dose of LTG than the heterozygous group (AC) (Table 3.13 and   
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Table 3.14). Comparison with the homozygous-minor allele group (CC) failed to reach statistical 
significance and there no was no evidence of an allele-specific effect on dose (Figure 7). 
Table 3.13: Back-transformed dose data for rs12993173 
 
  
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
AA 26 229 100 675 
AC 50 171 100 500 
CC 19 171 50 500 
Total 95 185 50 675 
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Table 3.14: Back-transformed dose data for rs12993173 - between groups comparison 
 
 
Figure 7: Dose distribution between rs12993173 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: AA = 26, AC = 50, CC = 19, Total = 95 
rs1439805 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.018, uncorrected). This intronic SNP is found in SCN2A and tagged an additional four 
SNPs (Appendix Table 6). The homozygous-major allele group (AA) appeared to require a higher 
maintenance dose of LTG than the heterozygous group (AC) (Table 3.15 and Table 3.17). Comparison 
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Lower Boundary 
AA AC 1.339* 1.038 1.729 0.020 
CC 1.337 0.972 1.838 0.085 
AC AA 0.747* 0.579 0.964 0.020 
CC 0.998 0.751 1.327 1.000 
CC AA 0.748 0.544 1.029 0.085 
AC 1.002 0.754 1.331 1.000 
* The mean difference is significant at the 0.05 level. 
Number of participants: AA = 26, AC = 50, CC = 19, Total = 95 
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with the homozygous-minor allele group (CC) failed to reach statistical significance and there no was 
no evidence of an allele-specific effect on dose (Figure 8). 
Table 3.15: Back-transformed dose data for rs1439805 
 
Table 3.16: Back-transformed dose data for rs1439805 - between groups comparison 
 
 
  
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
AA 24 230 100 500 
AC 53 168 50 675 
CC 19 192 100 500 
Total 96 187 50 675 
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
AA AC 1.369* 1.030 1.820 0.028 
CC 1.200 0.858 1.677 0.392 
AC AA 0.731* 0.550 0.971 0.028 
CC 0.876 0.668 1.151 0.469 
CC AA 0.834 0.596 1.165 0.392 
AC 1.141 0.869 1.498 0.469 
* The mean difference is significant at the 0.05 level. 
Number of participants: AA = 24, AC = 53, CC = 19, Total = 96 
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Figure 8: Dose distribution between rs1439805 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: AA = 24, AC = 53, CC = 19, Total = 96 
 
3.2.2.3. SCN3A 
rs11903851 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.009, uncorrected). This intronic SNP in SCN3A tagged an additional fifteen SNPs 
(Appendix Table 7). The heterozygous group (GA) appeared to require a higher maintenance dose of 
LTG than the homozygous-major allele group (GG) (Table 3.9 and Table 3.18). As such, the data does 
not support an allele-specific effect on dose (Figure 9). 
Table 3.17: Back-transformed dose data for rs11903851 
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
GG 63 171 50 500 
GA 25 238 150 675 
AA 8 174 100 500 
Total 96 187 50 675 
 66 
 
 
Table 3.18: Back-transformed dose data for rs11903851 - between groups comparison 
 
 
Figure 9: Dose distribution between rs11903851 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: AA = 63, AC = 25, CC = 8, Total = 96 
 
  
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
GG GA 0.722* 0.561 0.930 0.007 
AA -0.985 0.659 1.471 1.000 
GA GG 1.385* 1.076 1.783 0.007 
AA 1.364 0.884 2.106 0.234 
AA GG 1.015 0.680 1.516 1.000 
GA 0.733 0.475 1.132 0.234 
* The mean difference is significant at the 0.05 level. 
Number of participants: AA = 63, AC = 25, CC = 8, Total = 96 
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3.2.3. Multivariate Analysis 
Multivariate analysis was carried out using a stepwise linear regression model with maintenance 
dose modelled as the dependent variable and the five identified non-genetic variables as covariates. 
Seven separate analyses were undertaken incorporating SNPs within the following gene groupings: 
- SLC22A1 alone 
- UGT1A4 alone 
- SCN1A alone 
- SCN2A alone 
- SCN3A alone 
- SCN1A, SCN2A and SCN3A combined 
- SCN1A, SCN2A, SCN3A, UGT1A4, SLC22A1 combined 
Following successful generation of a multivariate model, a dose-predictive equation for determining 
the maintenance dose of LTG was constructed using the generated correlation coefficients. This 
equation was then used to generate predicted doses for each participant used in the generation of 
that particular model. Finally, the data was back-transformed from Ln-dose to maintenance dose, 
and the relationship between observed and predicted maintenance dose determined using 
Spearman’s correlation test. 
 
3.2.3.1. SLC22A1 
Four models were generated following stepwise multivariate regression analysis of the SLC22A1 
gene, all of which had a p-residual value below the pre-determined threshold of 0.05 for a 
statistically significant result to be inferred (  
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Table 3.19). The most explanatory model (model 4) associated with 31.0% of the variation in 
maintenance dose, and was used to generate the following dose-predictive equation: 
LnODLTG = 5.133 + (0.265 x SNP 1) + (1.258 x SNP 2) – (0.554 x SNP 3) – (0.186 x SNP 4) 
(LnODLTG = Natural logarithm of daily lamotrigine maintenance dose (mg); SNP 1-4 = genotype at 
SNPs 1-4 scored as homozygous-major allele = 0, heterozygous = 1, homozygous minor allele = 2) 
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Table 3.19: Multiple linear regression models for SLC22A1 
 
Using the dose-predictive equation generated from model 4, predicted LTG maintenance doses were 
calculated and then correlated with the observed maintenance doses. The data was back-
transformed and the degree of correlation between the two variables determined using Spearman’s 
correlation test (correlation coefficient 0.403) which was statistically significant with a corresponding 
p-value < 0.001. 
 
3.2.3.2. UGT1A4 
A multiple linear regression model failed to identify any significant associations using SNP genotypes 
from UGT1A4. None of the variables were able to be incorporated into a model with a p-residual 
value of < 0.05. 
 
3.2.3.3. SCN1A 
A multiple linear regression model failed to identify any significant associations using SNP genotypes 
from SCN1A. None of the variables were able to be incorporated into a model with a p-residual value 
of < 0.05. 
 
3.2.3.4. SCN2A 
A singular model was generated from the SCN2A gene, with 24.2% of the variation in LTG 
maintenance dose explained by genotype at rs2119067 alone. This was found to be statistically 
significant with a p-residual value of 0.01 (Table 3.20), and the following dose-predictive equation 
was produced using the information: 
Variables (SNP number 
in predictive equation) 
Model 1 Model 2 Model 3 Model 4 
β p β p β p β p 
Constant 5.060 <0.001 5.018 <0.001 5.054 <0.001 5.133 <0.001 
rs806383 (SNP 1) 0.212 0.013 0.232 0.005 0.215 0.007 0.265 0.001 
rs34059508 (SNP 2)   0.644 0.010 1.134 0.001 1.258 <0.001 
rs6937722 (SNP 3)     -0.520 0.032 -0.554 0.019 
rs10455868 (SNP 4)       -0.186 0.033 
Model (r2, p-residual) 0.098, 0.013 0.192, 0.002 0.253, 0.001 0.310, <0.001 
β =  β coefficient 
p = p-value 
Models based on 63 participants 
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LnODLTG = 5.298 - (0.242 x SNP 1) 
(LnODLTG = Natural logarithm of daily lamotrigine maintenance dose (mg); SNP 1 = rs2119067; 
genotypes scored as homozygous-major allele = 0, heterozygous = 1, homozygous minor allele = 2) 
Using the generated equation, predicted LTG maintenance doses were calculated and then 
correlated with the observed maintenance doses. The data was back-transformed and the degree of 
correlation between the two variables determined using Spearman’s correlation test (correlation 
coefficient 0.219) which was statistically significant with a corresponding p-value of 0.032. 
 
3.2.3.5. SCN3A 
Three models were generated following stepwise multivariate regression analysis of the SCN3A gene, 
all of which had a p-residual value below the pre-determined threshold of 0.05 (Table 3.21). The 
most explanatory model (model 3, r2 = 23.5%) was used to generate the following dose-predictive 
equation: 
LnODLTG = 5.046 + (0.918 x SNP 1) – (0.692 x SNP 2) + (0.197 x SNP 3) 
(LnODLTG = Natural logarithm of daily lamotrigine maintenance dose (mg); SNP 1-3 = genotype at 
SNPs 1-3 scored as homozygous-major allele = 0, heterozygous = 1, homozygous minor allele = 2) 
The data was back-transformed and Spearman’s correlation test was used to determine the degree 
of correlation between observed and predicted maintenance doses (correlation coefficient 0.246). 
This was found to be statistically significant with a corresponding p-value of 0.016. 
Table 3.20: Multiple linear regression model for SCN2A 
Variables (SNP number in 
predictive equation) 
Model 1 
Β-coefficient p-value 
Constant 5.298 <0.001 
rs2119067 (SNP 1) -0.242 0.010 
Model (r2, p-residual) 0.094, 0.010 
Model based on 69 participants 
Table 3.21: Multiple linear regression models for SCN3A 
Variables (SNP number in 
predictive equation) 
Model 1 Model 2 Model 3 
Β-
coefficient 
p-
value 
Β-
coefficient 
p-
value 
Β-
coefficient 
p-
value 
Constant 5.090 <0.001 5.102 <0.001 5.046 <0.001 
rs11903851 (SNP 1) 0.242 0.005 0.912 0.002 0.918 0.002 
rs1982208 (SNP 2)   -0.698 0.017 -0.692 0.016 
rs17829596 (SNP 3)     0.197 0.040 
Model (r2, p-residual) 0.111, 0.005 0.184, 0.001 0.235, <0.001 
Models based on 70 participants 
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3.2.3.6. SCN1A, SCN2A and SCN3A 
The SCN1A, SCN2A and SCN3A genes were combined into a multiple linear regression model. Six separate models were produced, with r2 values ranging 
from 0.109 to 0.450 and significant p-residual values < 0.05 (Table 3.22). The most explanatory model (model 6, r2 = 45.0%) was used to generate the 
following dose-predictive equation: 
LnODLTG = 5.318 + (1.066 x SNP 1) – (0.361 x SNP 2) – (0.231 x SNP 3) – (0.544 x SNP 4) + (0.355 x SNP 5) – (0.379 x SNP 6) 
(LnODLTG = Natural logarithm of daily lamotrigine maintenance dose (mg); SNP 1-6 = genotype at SNPs 1-6 scored as homozygous-major allele = 0, 
heterozygous = 1, homozygous minor allele = 2) 
Spearman’s correlation test was used to determine the degree of correlation between observed and predicted maintenance doses (correlation coefficient 
0.626) and was found to be statistically significant with a corresponding p-value of <0.001. 
 
Table 3.22: Multiple linear regression models for SCN1A, SCN2A, and SCN3A 
Variables (SNP number in 
predictive equation) 
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
β p β p β p β p β p β p 
Constant 5.091 <0.001 5.207 <0.001 5.334 <0.001 5.330 <0.001 5.318 <0.001 5.318 <0.001 
rs11903851 (SNP 1) 0.245 0.006 0.286 0.001 0.431 <0.001 1.000 <0.001 1.022 <0.001 1.066 <0.001 
rs2119067 (SNP 2)   -0.295 0.001 -0.355 <0.001 -0.345 <0.001 -0.344 <0.001 -0.361 <0.001 
rs11677254 (SNP 3)     -0.198 0.013 -0.179 0.020 -0.228 0.004 -0.231 0.003 
rs1899013 (SNP 4)       -0.609 0.024 -0.587 0.025 -0.544 0.034 
rs2165208 (SNP 5)         0.318 0.038 0.355 0.019 
rs17242693 (SNP 6)           -0.379 0.047 
Model (r2, p-residual) 0.109, 0.006 0.243, <0.001 0.314, <0.001 0.369, <0.001 0.412, <0.001 0.450, <0.001 
β =  β coefficient 
p = p-value 
Models based on 67 participants 
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3.2.3.7. SLC22A1, UGT1A4, SCN1A, SCN2A and SCN3A 
All 178 variables were combined in a global stepwise multivariate regression analysis. Nine separate models were produced, with r2 values ranging from 
0.117 to 0.606 and significant p-residual values < 0.05 (Table 3.23). The most explanatory model (model 9, r2 = 60.6%) was used to generate the following 
dose-predictive equation: 
LnODLTG = 5.463 + (0.175 x SNP 1) + (1.021 x SNP 2) – (0.679 x SNP 3) – (0.465 x SNP 4) – (0.453 x SNP 5) + (0.269 x SNP 6) – (0.286 x SNP 7) – (0.258 x SNP 8) 
+ (0.339 x SNP 9) 
(LnODLTG = Natural logarithm of daily lamotrigine maintenance dose (mg); SNP 1-9 = genotype at SNPs 1-9 scored as homozygous-major allele = 0, 
heterozygous = 1, homozygous minor allele = 2) 
Spearman’s correlation test was used to determine the degree of correlation between observed and predicted maintenance doses (correlation coefficient 
0.686) and was found to be statistically significant with a corresponding p-value of <0.001. 
Table 3.23: Multiple linear regression model for SLC22A1, UGT1A4, SCN1A, SCN2A, and SCN3A. 
Variables (SNP 
numbers in 
predictive 
equation) 
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 Model 9 
β p β p β p β p β p β p β p β p β p 
Constant 5.069 <0.001 5.027 <0.001 5.065 <0.001 5.182 <0.001 5.288 <0.001 5.243 <0.001 5.333 <0.001 5.452 <0.001 5.463 <0.001 
rs806383 (SNP 1) 0.231 0.008 0.248 0.003 0.233 0.004 0.215 0.006 0.220 0.003 0.207 0.004 0.180 0.011 0.172 0.012 0.175 0.008 
rs34059508 (SNP 2)   0.629 0.013 1.134 0.001 1.134 0.001 1.134 <0.001 1.134 <0.001 1.134 <0.001 1.134 <0.001 1.021 <0.001 
rs6937722 (SNP 3)     -0.537 0.027 -0.649 0.007 -0.685 0.003 -0.618 0.006 -0.691 0.002 -0.713 0.001 -0.679 0.001 
rs2119067 (SNP 4)       -0.246 0.016 -0.312 0.003 -0.360 0.001 -0.427 <0.001 -0.452 <0.001 -0.465 <0.001 
rs1439806 (SNP 5)         -0.214 0.021 -0.267 0.005 -0.293 0.002 -0.355 <0.001 -0.453 <0.001 
rs484926 (SNP 6)           0.237 0.026 0.240 0.020 0.259 0.010 0.269 0.005 
rs3798174 (SNP 7)             -0.273 0.037 -0.306 0.016 -0.286 0.019 
rs4303727 (SNP 8)               -0.220 0.021 -0.258 0.006 
rs2165208 (SNP 9)                 0.339 0.023 
Model (r2, p-
residual) 
0.117, 0.008 0.210, 0.001 0.277, <0.001 0.352, <0.001 0.414, <0.001 0.468, <0.001 0.512, <0.001 0.562, <0.001 0.606, <0.001 
β =  β coefficient 
p = p-value 
Models based on 59 participants 
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Chapter 4: Discussion 
The ultimate aim of AED therapy is to achieve maximal seizure control in the absence of adverse 
effects. LTG is a commonly used AED with proven efficacy for various seizure types. It has been 
shown to be better tolerated than many other AEDs, and was recommended by the SANAD trial as an 
alternative to CBZ, the current first-line AED of choice in the treatment of partial-onset seizures.1, 2 As 
with all AEDs, the effective dose of LTG varies widely from patient to patient, and finding the 
optimum dose can be difficult.3 Current practice involves titration of LTG over a six- to eight-week 
period until a pre-determined target dose is reached, with dose adjustments made thereafter 
according to the extent of efficacy and occurrence of adverse effects. This ‘one size fits all’ approach 
to LTG dosing is sub-optimal for many patients. Persons who are particularly sensitive to LTG may 
require a low daily dose to achieve seizure control; however, without prior knowledge of this 
sensitivity, the standard titration schedule may excessively dose these patients to the extent that 
adverse effects necessitate drug withdrawal. The titration process may also fail to satisfy the needs 
of patients who require particularly high doses to achieve seizure control. In these patients, LTG may 
be perceived to be ineffective due to persistent seizures, even at the upper end of the supposed 
therapeutic dose range. Under these circumstances, where the titration rate is too slow and the 
initial target dose too low, there is a potential for the patient or clinician to lose confidence in the 
treatment and withdraw it before the optimal dose is reached. For such patients, the ability to 
predict the required maintenance dose would prove particularly beneficial, achieving optimal dosing 
where previously treatment would have been deemed to fail. In addition to this, the treatment of all 
patients with LTG could become more tailored to individual needs, alleviating the trial and error 
aspect of current dosing regimens through prediction of dose requirement prior to drug initiation. 
The observed variability in individual dose requirement of LTG may, at least in part, be the result of 
underlying variation in genes encoding proteins that are involved in its pharmacokinetic and 
pharmacodynamic pathways. LTG is primarily metabolised by the 1A4 isoform of the UGT family of 
enzymes which is encoded by the UGT1A4 gene.59 The organic cation transporter OCT1 has been 
implicated in the transport of LTG into hepatocytes and at the BBB (unpublished data, University of 
Liverpool) and is encoded by the gene SLC22A1. Finally, the primary mechanism of action of LTG is 
inhibition of neuronal VGSCs in the brain, the -subunits of which are encoded by three genes; 
SCN1A, SCN2A and SCN3A.48 
Previous AED pharmacogenetic studies have utilised candidate-gene approaches in their quest to 
explain inter-individual variation in dose requirement, with PHT and CBZ the most-extensively 
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studied drugs to date. Despite the current lack of translation into clinical practice, there have been 
several studies that have successfully identified associations between dose requirement and 
underlying genetic variation during the past 10 years.179-181 However, there is little or no information 
on the source of inter-individual variation in dose requirements of newer AEDs, such as LTG. This 
current study has attempted to address this gap in the knowledge-base through investigation of 
variation in five candidate genes (SLC22A1, UGT1A4, SCN1A, SCN2A, and SCN3A) that might explain, 
at least in part, the observed inter-individual variation in LTG dosing. 
Participants were selected retrospectively from the SANAD cohort of newly-diagnosed epilepsy 
patients. Analysis was undertaken on a total of 96 individuals with maintenance doses of LTG ranging 
from 50 to 675mg/day. A total of 178 univariate analyses were performed to investigate associations 
with LTG maintenance dose. Five demographic variables (age, sex, epilepsy type, previous AED use, 
and number of seizures before treatment) and genotypes at 173 SNP loci were analysed in isolation 
using various statistical techniques, resulting in 14 independent variables showing associations with 
dose (p<0.05, uncorrected). However, after correction for multiple comparisons using FDR, none of 
these variables remained significantly associated with LTG dose. Following univariate analyses, 
various multivariate models were constructed using stepwise linear regression to determine whether 
combinations of variables could explain the observed variation in maintenance dose. Significant 
multivariate models were generated within the SLC22A1 (  
 75 
 
Table 3.19), SCN2A (Table 3.20), and SCN3A (Table 3.21) genes. In addition, further models were 
generated through a combined analysis of the SCN1A, SCN2A, and SCN3A genes (Table 3.22) and in a 
global analysis of all variables examined in this study (Table 3.23). 
SLC22A1 
A total of 38 SNP genotypes across SLC22A1 were available for analysis; univariate analyses identified 
six SNPs that were significantly associated with LTG maintenance dose before correction for multiple 
comparisons (Table 3.5 and Table 3.6). Three of these are intronic SNPs (rs461473, rs806383, 
rs456598) that do not tag any further genetic variation; the mechanisms by which these might 
impact upon LTG maintenance dose remains unclear. An additional intronic SNP found to be 
associated with LTG maintenance dose was rs3798173 which tags a further six SNPs (Appendix Table 
3), none of which would be expected to have functional significance. The remaining two 
polymorphisms that achieved pre-correction significance in SLC22A1 were the missense SNPs 
rs34059508 and rs628031 that result in G465R and M408V amino acid substitutions, respectively. 
The G465R variant of OCT1 (rs34059508) has been shown to result in reduced transport of both 
[3H]MPP140 (a known substrate for OCT1) and the anti-diabetic agent metformin182 during in vitro 
studies. The overall effect of reduced LTG transport on maintenance dose requirement is likely to be 
dependent upon the site at which OCT1 is most functionally relevant. If OCT1 expression is of 
greatest functional relevance at the hepatic level, then impaired OCT1 function is likely to result in 
elevated plasma concentrations of LTG due to decreased cellular uptake and consequently reduced 
hepatic metabolism. Under these circumstances, the elevation in plasma concentrations might be 
expected to out-weigh the impairment of LTG transport across the BBB, resulting in elevated brain 
concentrations of LTG per unit dose and a lower maintenance dose requirement. Alternatively, if 
OCT1 were more functionally important at the BBB level, then reduced OCT1 function as a result of 
the G465R polymorphism might be expected to increase LTG dose requirements in order to 
overcome reduced BBB transport. In this case, impaired transport into the brain is anticipated to out-
weigh any increase in serum LTG concentrations arising from decreased transport into hepatocytes 
and, as a result, maintenance dose requirements would be higher.  
In the present study, the patients who were heterozygous for rs34059508 (G465R) appeared to 
require a higher maintenance dose of LTG than those who were homozygous for the major allele 
(Appendix Table 19 and Figure 11). This observation would suggest that OCT1 is of greater functional 
importance at the BBB than in hepatocytes. However, without adequate understanding of the 
anatomical distribution of OCT1 and its relative expression at different cell membranes, it is difficult 
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to draw any robust conclusions which would explain why this SNP is associated with an elevated dose 
requirement of LTG. In addition, the heterozygous group was comprised of just three participants 
and therefore the accuracy of the mean maintenance dose in those carrying variant genotypes might 
be considered questionable. Nonetheless, given the reduced function of OCT1 associated with 
rs34059508 and its pre-correction significance in univariate analysis (p=0.035), it is reasonable to 
suggest that this SNP influences LTG maintenance dose requirement, even if the mechanisms by 
which this occurs remains to be clarified. 
The M408V variant of OCT1 (rs628031) has previously been shown to possess similar activity wild-
type OCT1 in the transport of [3H]MPP in vitro.140 In the present study, patients who were 
homozygous for the major allele appeared to require a higher maintenance dose of LTG than either 
heterozygotes or those who were homozygous for the minor allele (Table 3.10) and there was some 
evidence for a gene-dose effect (Figure 5). Again, it is difficult to put the observed dosing trend into 
context given our lack of understanding of LTG transport by OCT1. For rs628031, it appears LTG 
maintenance dose requirement decreases when the variant allele is expressed. If OCT1 primarily 
transports LTG into the brain, this might indicate that the M408V variant results in increased activity 
of OCT1-mediated LTG transport. Conversely, if LTG is preferentially transported into hepatocytes for 
metabolism by UGT1A4, the observed trend would indicate that the M408V variant results in the 
decreased transport of LTG. Any change in LTG transport (either gain or loss of function) would, 
however, contradict previous data which suggests that this variant is without functional effect. The 
only possible explanation under those circumstances would be a substrate-specific effect of the 
polymorphism on the transport of LTG but not on that of MPP. This speculative hypothesis requires 
further detailed investigation in appropriately-designed drug transport assays.  
A stepwise linear regression model was constructed using the 38 SNP genotypes in the SLC22A1 gene 
in addition to the five demographic variables (Table 3.1). Four significant models were generated 
from these variables, the last of which comprised four SNP genotypes that collectively explained 
31.0% of the observed variation in LTG maintenance dose (p<0.001,   
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Table 3.19). Of the SNPs included in the model, two were intronic (rs806383, rs6937722), one was in 
the upstream flanking sequence (rs10455868) and the remaining SNP was the putatively functional 
G465R variant (rs34059508) discussed above. None of these polymorphisms were identified as being 
in LD with other SNPs, suggesting that they were not surrogates for an unidentified causal variant. 
It is somewhat surprising that 31.0% of the total variation in LTG maintenance dose can be accounted 
for by genetic variation in these four SNPs alone. However, the fact that six separate SLC22A1 
polymorphisms were found to be associated with LTG maintenance dose in the univariate analysis 
(albeit prior to correction for multiple testing), none of which were in LD with one another, would 
suggest that OCT1 has a significant role in the pharmacokinetics of LTG and in determining its dose 
requirements. This proposition is arguably supported by a dose-predictive equation based on the 
multivariate model, which showed a reasonable correlation between observed and predicted 
maintenance doses of LTG (Spearman’s correlation coefficient = 0.403, p=0.001). However, these 
results must be interpreted with caution owing to the small number of participants in some of the 
genotype groups. In particular, the reliability of the rs34059508 (G465R) component of the model is 
questionable, with only three heterozygotes in the study population. All three of these individuals 
had a relatively high LTG dose requirement which, if coincidental, might have over-estimated the 
relative importance of this polymorphism. By comparison, rs806383 showed a more even genotype 
distribution amongst the study population and its contribution to LTG dose requirements can be 
concluded with more confidence. In summary, genetic variants in SLC22A1 appear to have a 
significant influence on LTG dose requirement but it is questionable whether this study has reliably 
quantified the extent of that influence. Validation of these findings in a separate and substantially 
larger cohort of patients is required.  
UGT1A4 
Following univariate and multivariate analyses, no significant associations between LTG maintenance 
dose and genetic variation in UGT1A4 were identified. Two polymorphisms in UGT1A4 have 
previously been shown to reduce catalytic activity and alter substrate specificity.159 The first of these 
is rs6755571, a missense SNP in which a C>A transversion at codon 24 results in a proline to 
threonine amino acid change (P24T). This SNP was tagged in the current study by rs11568318 (r2 = 
1.0) (Appendix Table 4), but univariate analysis failed to detect any significant association with dose 
(p=0.830, Appendix Table 10). The second SNP is another missense polymorphism where a T>G 
transversion at codon 48 (rs2011425) produces a leucine to valine amino acid change (L48V) 159. This 
SNP has recently been shown by Gulcebi and colleagues to be associated with significantly lower 
plasma LTG levels in a cohort of 35 Turkish epilepsy patients.183 The mean plasma LTG level was 
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found to be 29.4% lower in participants who were heterozygous at this locus (p<0.01). Mean plasma 
levels were 2.4mg/L for participants carrying the minor allele (n=11) and 3.4mg/L for the 
homozygous-major allele group (n=24); none of the participants were homozygous for the minor 
allele. These results should, however, be viewed with caution; partly because the patient cohort was 
small (n=35) but, more importantly, because the authors apparently failed to correct their data for 
either dose or response to treatment. Nonetheless, these results suggest that the L48V variant in 
UGT1A4 can influence plasma LTG concentrations, presumably by modifying its metabolism, and 
would thereby be expected to influence dose requirement. Unfortunately, rs2011425 was not typed 
in the current study because, at the time of SNP selection, a MAF for this polymorphism could not be 
established in a Caucasian population. Furthermore, rs2011425 was neither genotyped directly or 
represented by a tSNP in the GWAS data. Thus, it is not possible to confirm the influence of this 
polymorphism on LTG dose requirement or on LTG pharmacokinetics in general without further 
investigation.  
SCN1A 
Neither univariate nor multivariate analyses identified any significant associations between LTG 
maintenance dose and genetic variation in SCN1A. Tate et al reported an association between a 
splice-site variant (rs3812718) in the SCN1A gene and maximal doses of CBZ and PHT,103  and later 
described an association of the same variant with PHT serum concentrations at maintenance dose.181 
Like LTG, these drugs exert their anticonvulsant effects by inhibition of the VGSC and thus an 
association might have been anticipated. The current study did not genotype the rs3812718 SNP 
directly, but it was tagged by rs922224 (r2 = 1.0) (Appendix Table 5), which failed to show a significant 
association with LTG dose (p = 0.061) even before correction for multiple testing. This failure to 
confirm a previous observation, even indirectly, can be explained by differences in study design and 
patient populations. Tate et al explored maximal rather than maintenance doses and in doing so, 
they focused more on the limit of tolerability than on drug effectiveness. In addition, a significant 
proportion of their study population was taking multiple AEDs and they failed to consider the 
possible influence of drug interactions on doses of PHT and CBZ, compounds which are well-known 
for their interaction potential. To avoid the possible confounding influence of drug interactions, the 
current study included patients on LTG monotherapy alone. These differences alone would be 
sufficient to explain the discrepant findings. However, there also remains the possibility that the 
original report was a false positive association. Indeed, a study by Zimprich and colleagues did not 
find a significant difference in the average CBZ doses between genotypes for the SCN1A splice-site 
variant (rs3812718), and failed to even report a trend in the same direction as the original study.184 
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The notion of a false-positive association is more in keeping with the current study, particularly when 
the multivariate analysis of SCN1A SNPs failed to detect a single significant model, suggesting that 
variation in this gene has no bearing on the dose requirement of LTG. 
SCN2A 
Univariate analyses identified seven SNPs in SCN2A that were significantly associated with LTG 
maintenance dose before correction for multiple comparisons (Table 3.5). These were all intronic 
SNPs, and cumulatively tagged an additional 23 polymorphisms (Appendix Table 6). A stepwise linear 
regression model was constructed using the 51 available SNP genotypes in the SCN2A gene, 
generating a dose-predictive model (Table 3.20) containing a single intronic SNP (rs20119067) that 
did not tag any additional genetic variants. This model associated with 9.4% of the observed variation 
in LTG maintenance dose (p=0.010), however the explanatory capacity of the equation derived from 
observed and expected doses was poor (Spearman’s correlation coefficient = 0.219, p=0.032). A 
report by Sills et al previously identified a weak association between a non-synonymous 
polymorphism in SCN2A (rs17183814, R19K) and response to AED treatment.170 The present study 
directly genotyped this SNP, but an association with LTG maintenance dose requirement was not 
identified (p=0.892, Appendix Table 10). A more recent study showed an association between 
genotype at an intronic SNP locus (rs2304016) and resistance to AED treatment in a cohort of 471 
Chinese participants.185 This polymorphism is not present in Caucasian populations and its influence 
on LTG maintenance dose requirement could not, therefore, be assessed in the present study. 
Previous studies have demonstrated a modest contribution of variation in SCN2A to heterogeneity in 
the response to AED therapy. The results of the present study indicate that variation in SCN2A might 
also be associated with maintenance dose requirement of sodium channel blocking drugs, although 
again its relative importance appears to be limited. 
SCN3A 
Univariate analyses of genetic variation in SCN3A identified significant association between an 
intronic SNP (rs11903851) and maintenance dose requirement of LTG (Table 3.5). This association did 
not, however, remain significant after correction for multiple comparisons. The rs11903851 SNP was 
found to tag an additional 15 polymorphisms (Appendix Table 7); 14 further intronic SNPs and one in 
the coding region of the gene (rs16850131) but which did not alter the amino acid sequence (L481L). 
As a result, it is debatable whether this SNP, or indeed any that it tags, has functional relevance. 
Three stepwise linear regression models were constructed using genetic variation in SCN3A (Table 
3.21). The last of these models comprised three SNP genotypes, (rs11903851, rs1982208 and 
rs17829596) that collectively associated with 23.5% of the observed variation in LTG maintenance 
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dose (p<0.01). However, the explanatory capacity of the equation built on SCN3A genotypes and 
derived from observed and expected doses was poor (Spearman’s correlation coefficient = 0.246, 
p=0.016). Overall, the results of these univariate and multivariate analyses suggest that genetic 
variation in SCN3A may contribute towards LTG maintenance dose requirement. However, given that 
the association with rs11903851 was not significant after correction, that the variant genotypes do 
not appear to have functional consequences, and that the multivariate model had limited 
explanatory ability, the extent of this contribution, if genuine, is likely to be modest. 
 
Combined multivariate analyses 
SCN1A, SCN2A, SCN3A 
A multivariate model was constructed to determine whether genetic variation across all three 
sodium channel genes investigated in this study could accurately predict LTG maintenance dose 
requirements when considered together. This was deemed to be a reasonable approach as it isolated 
genetic influences on LTG pharmacodynamics from those on its pharmacokinetics and also because 
these three genes are located together on chromosome 2 and, as such, there may be an element of 
LD across all three. The optimal multivariate model included four SNPs from SCN3A and two from 
SCN2A and associated with 45.0% of the observed variability in LTG maintenance dose (Table 3.22). 
All of the SNPs that directly comprised the model were intronic and they tagged an additional 16 
SNPs in SCN3A (Appendix Table 7). The dosing equation derived from this model had a moderate 
explanatory capability (0.626, p<0.001) indicating that combined genetic variation in SCN2A and 
SCN3A may be important factors in determining LTG maintenance dose. This would support the 
observations made in the analysis of these two genes in isolation and also serves to confirm that the 
SCN1A gene does not have a significant influence on maintenance dose requirements of LTG.  
SCN1A, SCN2A, SCN3A, UGT1A4, SLC22A1 
Finally, multivariate models were constructed using stepwise linear regression to determine whether 
genetic variation across all five genes can be combined to accurately predict maintenance dose. All 
173 SNP genotypes and the five non-genetic variables were included in the analysis, with the optimal 
model associating with 60.6% of the observed variation in LTG maintenance dose (Table 3.23). This 
model comprised four SNPs from SLC22A1, two from SCN2A (which tagged six additional SNPs, 
Appendix Table 6), two from SCN3A (which tagged one further SNP, Appendix Table 7), and one SNP 
from SCN1A. All of these SNPs were intronic, with the exception of the known missense 
polymorphism in SLC22A1 (rs34059508, G465R) discussed above. The dosing equation derived from 
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this multivariate model showed moderate explanatory capabilities (Spearman’s correlation 
coefficient = 0.686, p<0.001) indicating that, if employed in an alternative cohort, the model may 
potentially provide reasonably accurate dose predictions based on genotypes of the nine SNP 
variants included. Of all the multivariate analyses undertaken in this project, this model associated 
with the greatest amount of observed variation in maintenance dose (60.6%). Overall, this model 
suggests that genetic variation in SLC22A1, SCN3A, SCN2A, and to a lesser extent SCN1A, is 
responsible for determining LTG maintenance dose requirement, whereas variation in the UGT1A4 
gene does not appear influential. 
 
Summary of results 
Overall, five demographic variables and 173 sites of genetic variation across five candidate genes 
have been analysed to investigate associations with LTG maintenance dose. None of the univariate 
analyses remained significant after correction for multiple comparisons using FDR, which is perhaps 
unsurprising given the number of tests undertaken. None of the demographic variables appeared to 
associate with LTG maintenance dose, suggesting that age, sex, epilepsy-type, etc, do not impact on 
dosing of LTG. This is somewhat intriguing, as there is evidence for other AEDs that dose 
requirements are higher in males (due to higher body weight), decrease with age (due to decline of 
hepatic metabolism) and are lower in generalised epilepsies (mechanism unknown). Of the genetic 
variants found to be significant before FDR correction, seven were in SCN2A, six were in SLC22A1, 
and one was in SCN3A. Of these, the putatively functional missense SNP in SLC22A1 that results in a 
G465R amino acid substitution is of particular note. Interestingly, polymorphisms in the UGT1A4 or 
SCN1A genes did not appear to associate with dose, despite the fact that these genes encode 
proteins which might have been expected a priori to play a prominent role in LTG pharmacokinetics 
and pharmacodynamics, respectively. 
Multivariate analyses were undertaken to determine whether combinations of genetic variants and 
non-genetic factors could explain the observed variation in LTG maintenance dose requirement. Of 
all the multivariate models that were generated, the one which associated with the greatest amount 
of variation in LTG maintenance dose incorporated polymorphisms from four of the five candidate 
genes; SLC22A1, SCN3A, SCN2A, and SCN1A. The model appeared to explain 60.6% of the observed 
variation in LTG maintenance dose, and the dose equation derived from this model showed stronger 
explanatory capabilities than the other models (Spearman’s correlation coefficient = 0.686, p<0.01). 
Of the four genes which comprise this model, variation in SLC22A1 appears to influence dose 
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requirements to the greatest degree, contributing four of nine SNPs to the model. The effect of 
variation in SLC22A1 on maintenance dose requirement is further highlighted from the multivariate 
analysis of SLC22A1 alone; 31.0% of the variation in maintenance dose was explained by four SNPs, 
and the model demonstrated reasonable explanatory properties (Spearman’s correlation coefficient 
= 0.403).  
Genetic variation in SCN2A and SCN3A also appeared to contribute to LTG maintenance dose 
requirements. Multivariate models were constructed for each gene individually and associated with 
24.2% and 23.5% of the variation in dose, respectively. However, both of these models showed poor 
explanatory capabilities when observed and predicted doses were correlated (Spearman’s 
correlation coefficients: 0.219 for SCN2A, 0.246 for SCN3A). In contrast, when the genetic variation 
across SCN1A, SCN2A and SCN3A was analysed collectively in a combined stepwise linear regression 
model, the optimal model appeared to associate with 45.0% of the variation in dose and showed a 
moderate explanatory capacity (Spearman’s correlation coefficient 0.626). This combined sodium 
channel model incorporated four SNPs from SCN3A and two from SCN2A, with no contribution from 
SCN1A. Thus, inter-individual differences in LTG dose also appear to be dependent, at least in part, 
on genetic variation in SCN2A and SCN3A genes and this association is most evident when variation 
across the genomic region rather than single genes is considered. 
  
 83 
 
Limitations 
Design of study 
There are several stages where confounders may have been introduced to this study. The analysis 
itself was retrospective and employed DNA samples and clinical information that had been collected 
as part of a previous clinical trial. However, the data in that trial were collected prospectively and, as 
such, can be assumed to be reliable and unbiased. Nevertheless, the SANAD trial was not designed 
with a pharmacogenetic analysis in mind and so, in some aspects, the case report forms were less 
than adequate. One of the principal concerns, in this regard, is the use of concomitant medication 
and its reliable reporting in the trial notes. Patients were specifically excluded from this analysis if it 
was known that they were being treated with multiple AEDs, even where those drugs might not be 
expected to interact with LTG. Some established AEDs are well known for their ability to affect LTG 
pharmacokinetics; sodium valproate decreases LTG clearance by approximately 60%, and PHT and 
CBZ increase LTG clearance by 125% and 30-50%, respectively.69 Co-administration with these agents 
would clearly have had an impact on LTG dose requirements. Unfortunately, it was not possible to 
exclude the possible confounding effects of co-medication with other drugs as this was not routinely 
recorded in the SANAD study notes. For example, recent studies have demonstrated that LTG serum 
levels are significantly reduced by the ethinyl estradiol component of the oral contraceptive pill.74, 75 
Fifty-percent of participants in this analysis were female and many of those were of child-bearing 
age. The use of oral contraceptives in this sub-population could, in theory, have affected LTG dose 
requirement but without knowledge of contraceptive use, this potential confounder could not be 
excluded nor controlled for. 
Further significant shortcomings in the patient notes included the absence of patient weight and/or 
body mass index (BMI) and information regarding smoking status. Both of these demographic 
variables have the potential to influence LTG dosing requirements. Persons with higher BMIs are 
likely to require higher doses of LTG to achieve similar volume-distribution and steady concentrations 
to those with ‘normal’ BMIs; the opposite is likely to be true for participants with low BMI. In any 
future studies of genetic influence on AED dose requirement, it is imperative that body mass is 
included in the multivariate analysis or controlled for by reporting serum drug concentrations. In the 
present study, although the relationship between LTG dose and serum concentration is linear, 
serum-LTG concentration would have provided a more accurate outcome measure and arguably 
negated the need to account for patient BMI. Smoking status should also be included as a non-
genetic variable; a recent preliminary study by Reinsberger and colleagues demonstrated that 
smokers have a significantly lower serum level-to-dose ratio for LTG than non-smokers (p=0.0014).186 
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The mechanism for this association is not yet certain, although it is thought to be reflective of 
tobacco smoke and nicotine inducing glucuronidation enzymes for which LTG is a substrate. Although 
this study was relatively small (n=44) and recruited predominantly females, it highlights another 
possible shortcoming of the current analysis and reflects the limitations of undertaking retrospective 
pharmacogenetic analysis on clinical data which was not collected for that purpose.  
Implementation of study 
In addition to unavoidable confounding factors arising from the clinical data, there are several 
potential limitations to the methodology. Patients were included in the analysis if they achieved 
seizure freedom for a period of at least 12 consecutive months on a stable dose of LTG monotherapy. 
The rationale for this was to include only those patients who responded to LTG monotherapy so that 
a maintenance dose could be established. However, from a pragmatic perspective, this might be 
considered an overly conservative approach as it effectively excluded all patients who experienced a 
significant reduction in their seizure frequency and who opted to continue treatment with LTG as a 
result. Anyone with a high pre-treatment seizure frequency which was reduced to almost zero was 
excluded and yet, arguably, these individuals were optimally controlled and receiving a maintenance 
dose of LTG. Their exclusion undoubtedly had an effect on the power of the study.  
Another possible confounder is the introduction of selection bias on the basis of seizure type. If, as 
discussed above, the study favoured patients with relatively low pre-treatment seizure frequency, 
then it may have preferentially included those with partial-onset and primary generalised tonic-clonic 
seizures at the expense of patients with more frequent absence or myoclonic events. Patients with 
primary generalised epilepsies tend to require lower doses of AEDs for effective or optimal seizure 
control, which could have skewed the overall dataset if they were unknowingly recruited with 
preference. In the present study the distribution of participants between the IGE, LRE and UNC 
seizure groups was 11.5%, 61.5% and 27.0%, respectively. Although the proportion of LRE is 
reasonable given the cohort was largely an adult population, a higher proportion of IGE and a lower 
proportion of UNC might have been expected in the final analysis, the reasons for which are unclear. 
There is evidence to suggest that LTG is not efficacious in the treatment of generalised-seizures, 
which may provide an explanation for the observed distribution of epilepsy types in the present 
study. Conversely, it could be that patients with UNC epilepsy may respond particularly well to LTG 
monotherapy, or equally the observed trend may be a combination of both these factors. Aside from 
seizure type, the participants included in the analysis of this study were a good representation of the 
SANAD cohort as a whole for other variables such as age and gender distribution. Overall, even 
though the present trial has analysed a minority of the two-thousand four-hundred and thirty-seven 
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participants enrolled on the SANAD trial, the analysed participants show characteristics well matched 
to the original study. The apparent discrepancy between the observed and expected epilepsy-type 
distribution is likely a reflection of LTGs different efficacy toward epilepsy-types, and, given that 
epilepsy type failed to show a significant association with Ln dose in both univariate (ANOVA p = 
0.105) and multivariate analyses, the influence of this selection bias is likely to be slight. 
There are some possible shortcomings in the SNP selection process employed in this study, 
specifically relating to the inclusion of putatively functional polymorphisms. In an effort to minimise 
the required number of genotypings, tSNPs were only included in the analysis if they had a MAF of 
greater than 5% in a Caucasian population. For putatively functional SNPs, the MAF cut-off was 
lowered to 1%. In hindsight, however, it might have been more appropriate to include all known 
functional SNPs (except those not represented in a Caucasian population) irrespective of their MAF. 
This would have captured more of the important variation across each candidate gene and permitted 
the inclusion of potentially informative polymorphisms that do not have widely reported allele 
frequencies. An example of such a SNP is the non-synonymous rs2011425 in UGT1A4 that has 
recently been shown in a Turkish study181 to be associated with plasma concentrations of LTG but 
which, at the time of SNP selection, did not have a published MAF. A caveat to the inclusion of rarer 
SNPs is that, since only 96 participants were included in the final analyses, this study was not 
sufficiently powered to detect associations at the required level of certainty (p < 0.05). In retrospect, 
given that the number of participants available for inclusion was determined at the outset, it may 
have been appropriate to undertake a power calculation to determine a suitable MAF threshold for 
inclusion/exclusion of SNPs. However, this approach would have resulted in the exclusion of many 
functional SNPs from the analysis, and therefore the inclusion of rarer SNPs and relying upon 
subsequent validation studies to confirm/reject apparent associations was arguably appropriate in 
this instance. 
As previously discussed, using LTG serum concentration as an outcome measure may have been 
more appropriate than maintenance dose requirement. Not only would this have gone some way 
towards accounting for identified confounders such as patient BMI, smoking status, and concomitant 
medication use, but could also have eliminated the inherent bias from using an outcome measure 
that combines efficacy and tolerability. The candidate genes selected for this study were based upon 
the pharmacokinetic and pharmacodynamic profiles of LTG, with polymorphisms in these genes likely 
to influence both efficacy and tolerability to varying degrees. In contrast, genetic variation in 
alternative genes is unlikely to influence the efficacy of LTG; however it is quite conceivable that the 
tolerability aspect of LTG dosing could be affected by polymorphisms in alternative genes such as 
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those encoding the HLA-proteins, resulting in a phenotype with a predisposition to hypersensitivity 
reactions. Although such patients would have been excluded from the current analysis, this serves to 
illustrate that, in an ideal scenario, the efficacy and tolerability aspects of LTG should be considered 
separately.  
 
Impact of this study 
This study has sought to determine the impact of genetic variation on LTG maintenance dose 
requirements when successfully employed as monotherapy in the treatment of epilepsy. Through a 
candidate gene approach, it has shown that variation in SLC22A1, SCN2A and SCN3A influences LTG 
dose requirement. This is a novel finding and therefore represents an important addition to the 
existing knowledgebase on AED pharmacogenetics. As part of the analysis, stepwise linear regression 
allowed the development of a dose-predictive equation for LTG maintenance dose which can explain 
up to 61% of inter-individual variability in LTG dose requirement when used as monotherapy in newly 
or recently-diagnosed epilepsy. Although validation of these results is required in an independent 
and substantially larger cohort, the data presented here have the potential to form the basis of a 
predictive algorithm for LTG dosing in clinical practice. 
 
Future work 
The results reported in this study require validation in a large, independent cohort. The validation 
study should be undertaken in a prospective manner to ensure that the confounding factors 
acknowledged above, including patient BMI, smoking status and concomitant medication use, are 
appropriately accounted for. Assuming the results withstand validation, it may then be appropriate 
to undertake a prospective clinical trial to assess whether LTG maintenance dose prediction can 
improve upon current clinical practice. In theory, participants could be randomised to receive LTG 
monotherapy via one of two dosing regimens; a dose-predicted regimen based on genotype or the 
standard dosing regimen currently employed clinically. Comparisons could be made on the basis of 
efficacy (time to first seizure, time to X months remission), tolerability (time to withdrawal due to 
adverse effects), or overall effectiveness (time to treatment discontinuation) of the two dosing 
regimens. Such a study would allow an indication of whether a priori dose-prediction can improve or 
optimise the use of LTG in newly-diagnosed epilepsy. If so, it would have the potential to influence 
prescribing practice with LTG, validate the use genetic-based dose-prediction models for AEDs, and 
mark the first step towards personalised-prescribing for epilepsy. 
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Another avenue for future research is the systematic assessment of the relationship between OCT1 
and LTG. Findings of the present study were in keeping with recent data from the Department of 
Pharmacology at the University of Liverpool which suggest that LTG is subject to OCT1-dependent 
transport. However, the functional significance (if any) of LTG transport at the level of both 
hepatocytes and the BBB remains to be clarified. Without an adequate understanding of the 
anatomical distribution of OCT1 and its relative expression at different cell membranes, it is difficult 
to draw robust conclusions about the influence of genetic variation in SLC22A1 on LTG maintenance 
dose requirement. In particular, the impact of two recognised missense polymorphisms in SLC22A1 
(rs34059508 and rs628031) on the transport of LTG by OCT1 needs to be established using site-
directed mutagenesis and drug transport assays. The trends reported by this study would suggest 
that these variants have a potentially significant effect on LTG pharmacokinetics, even though the 
mechanisms by which this might occur are yet to be elucidated. 
There are no previous reports of transport of LTG, or indeed any AED, by OCT1 or other members of 
the SLC transporter super-family. This is potentially a novel area of investigation for epilepsy 
therapeutics. It remains unclear whether LTG transport is specific to OCT1 or if it is also a substrate 
for other OCT isoforms. OCT1 and OCT2 have previously shown overlapping specificity for various 
substrate drugs, including cimetidine, quinine and metformin.118,120, 121 It is possible that LTG is also 
transported by OCT2 and this would require detailed characterisation and assessment of its 
functional significance. It would be reasonable to extend these studies to the wider SLC-transporter 
family, which remains relatively under-investigated with respect to its influence on therapeutics in 
general. If nothing else, it is essential that all clinically relevant pharmacokinetic and 
pharmacodynamic pathways are explored as we move towards an era of personalised medicine. 
Finally, it may be beneficial to return to the SANAD dataset and identify participants who failed 
treatment with LTG monotherapy. As discussed in the introduction, there is possibility that some of 
these failures arose as a result of a “one-size-fits-all” dosing strategy, with exquisitely sensitive 
patients being over-dosed and withdrawing from treatment due to adverse effects and relatively 
insensitive patients being under-dosed and withdrawing due to perceived lack of efficacy. In these 
cases, it may be possible to retrospectively calculate the individual LTG dose requirement based on 
genotype and to compare that to the actual doses employed. This would add validation to the dose 
predictive model and provide insight into whether LTG treatment failures in the SANAD study were 
genuine or a consequence of the relatively inflexible dosing and titration schedules that are currently 
used in the treatment of epilepsy.  
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Concluding remarks 
LTG is one of the most commonly employed AED agents in the developed world with proven efficacy 
for the treatment of various epilepsy types.3 The dose of LTG required to achieve seizure freedom 
varies considerably between patients; this study aimed to determine whether the observed variation 
in dose requirement could at least partially be explained by inter-individual variation in 
pharmacokinetic and pharmacodynamic profiles. We have assessed whether LTG maintenance dose 
requirement is associated with variation in five candidate genes; SLC22A1, UGT1A4, SCN1A, SCN2A 
and SCN3A. 
Multivariate stepwise linear regression analysis generated a model that appeared to explain 60.6% of 
the observed variation in LTG maintenance dose through incorporation of polymorphisms in 
SLC22A1, SCN1A, SCN2A and SCN3A. The dose equation derived from this model showed a moderate 
association between observed and predicted doses (Spearman’s correlation coefficient = 0.686, 
p<0.01). 
The results show that genetic variation in SLC22A1, SCN3A, SCN2A, and to a lesser extent SCN1A, 
influence LTG maintenance dose requirement. Although these results require validation in a larger, 
independent cohort, these findings potentially form the basis for a predictive algorithm for LTG 
maintenance dose requirement.   
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Appendix I 
Study Number of 
participants 
LTG 
Group 
Control 
Group 
Dose Regimen, 
Assessments and 
Study Duration 
Study Type Inclusion Criteria Exclusion Criteria Outcome 
Measure 
Dropouts / 
Withdrawals 
(?Accounted For) 
Observations Conclusions 
Brodie et 
al
76
 
260 LTG 
150mg, 
n=131 
CBZ 
600mg, 
n=129 
4-week planned, fixed 
dose escalation. 
Assessed every 2-
weeks until 12-weeks, 
then every 6-weeks. 
Dose altered if seizures 
persist, AE, or blood 
concentration not 
adequate. 48-weeks 
total duration. 
Double-blind, 
randomised, 
parallel-group 
comparison. 
Patients stratified 
according to 
seizure type. 
> 13-years old. 
Newly diagnosed 
epilepsy. 
Previous AED use. TTW, 
proportion of 
patients 
seizure-free at 
24 and 40-
weeks 
151/260 
participants 
completed the 
study. 27 patients 
from the LTG 
group withdrew, 
and 38 patients 
from the CBZ 
group. All 
withdrawals 
accounted for. 
Higher seizure 
frequency before 
treatment predisposed 
to further seizures after 
6-week treatment 
period. LTG less 
dropouts than CBZ. 
Difference in AEs 
between groups. Similar 
efficacy 
No difference in efficacy 
between LTG and CBZ in 
the treatment of partial 
seizures (with or without 
secondary generalisation). 
Bias between groups due 
to non-matching of seizure 
frequency.  Statistically 
significant difference in 
AEs & ‘sleepiness’ – lower 
in LTG group. 
Reunanen 
et al77 
343 LTG 
100mg, 
n=115 
 
LTG 
200mg, 
n=111 
CBZ  
600mg, 
n=117 
4-week escalation 
period. Dose adjusted 
if persistent seizures / 
significant AE. 
Reassessed at end of 
weeks 2, 6, 12 and 30. 
30 weeks total 
duration. 
Blinded 
randomisation, 
open treatment. 
> 12-years old. 
Newly diagnosed 
or current 
epilepsy. No 
concurrent 
medications 
More than 2 doses 
of AED in prior 6-
months. History of 
status epilepticus. 
Significant organic / 
psychiatric disease. 
Abnormal 
laboratory values. 
Pregnancy, 
lactation, or 
exposure to risk of 
pregnancy. 
TTW, 
proportion of 
patients 
seizure-free at 
30-weeks. 
LTG-100, n=23 
 
LTG-200, n=10 
 
CBZ-600, n=29 
 
All accounted for. 
Higher proportion of 
LTG-200 seizure free at 
30-weeks (60.4%) than 
LTG-100 (51.3%) and 
CBZ-600 (54.7%). More 
AEs on CBZ-600 (66%) 
than LTG-100 (53%) & 
LTG-200 (58%). 
No statistically significant 
difference between 
groups. LTG appeared 
equally effective but 
better tolerated than CBZ. 
Brodie et 
al78 
150 LTG, 
n=102 
CBZ, 
n=48 
6-week planned, fixed 
dose escalation. 
Assessed at 2, 4, 6, 12 
and 24 weeks; 
unscheduled visits 
allowed as necessary. 
Dosage could be 
adjusted from week 6 
onwards while 
maintaining the blind. 
24-weeks total 
duration. 
Multicentre, 
randomised, 
randomised 
controlled trial 
> 65 years old. 
Newly diagnosed 
epilepsy. Two or 
more seizures in 
the past 12-
months, at least 
one during the 
past 6-months. 
 Rate of drop 
out due to 
adverse 
events, time to 
first seizure, 
proportion of 
patients 
completing the 
study. 
92/150 
participants 
completed the 
study. 30 patients 
from the LTG 
group withdrew, 
and 28 patients 
from the CBZ 
group. All 
accounted for. 
Main difference was 
rate of drop-out due to 
adverse effects (LTG 
18%, CBZ 42%). No 
difference between 
drugs in time to first 
seizure. More patients 
continued on treatment 
with LTG than CBZ (LTG 
71%, CBZ 42%, p<0.001). 
HR for withdrawal 2.4 
(95% CI 1.4-4.0) 
LTG can be regarded as an 
acceptable choice as initial 
treatment for elderly 
patients with newly 
diagnosed epilepsy. 
  
  
 
1
0
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Steiner 
et al79 
181 LTG 
(modal 
daily dose 
150mg, 
maximal 
daily dose 
400mg), 
n=81 
PHT 
(modal 
daily dose 
300mg, 
maximal 
daily dose 
600mg), 
n=93 
Reassessed at 
clinic at 2, 4, 6, 8, 
12, 18, 24, 36, and 
48 weeks. 
48-weeks total 
duration 
Double-blind, 
parallel-group study. 
Assessed at entry, 
stratified according 
to seizure type, then 
randomised within 
strata to receive 
either LTG or PHT 
14-75 years old. ≥2 
seizures in past 6-
months, at least one in 
previous 3-months. 
Previous AED use, absence 
seizures, significantly 
abnormal laboratory values, 
other chronic medical 
disorders, severe mental 
sub-normality, 
alcohol/substance abuse, 
pregnancy / risk of 
becoming pregnant. 
Percentage of 
patients 
remaining on 
treatment and 
seizure free. 
Number of 
seizures within 
last 24 and 40-
weeks 
Seven protocol 
violators; all 
accounted for. 
Percentages of patients 
remaining on treatment 
and seizure free 
differed little between 
treatments at 24 and 
40-weeks. >50% 
patients discontinued 
from both groups. 
PHT and LTG appear 
comparable of the 
primary efficacy 
index of percentage 
of patients 
remaining seizure-
free 
Brodie 
et al
81
 
309 LTG, 
n=143 
GBP, 
n=143 
GBP 600mg/day, 
titrated up to 
1200mg/day over 
2-weeks. 
LTG 25mg/day, 
titrated up to 
100mg/day over 6-
weeks. 
Dose adjusted 
according to 
seizures / AE. 
30-weeks total 
duration. 
Multicentre, double-
blind, randomised 
parallel-group study. 
Seizures classified, 
adverse events 
recorded, physical 
and neurological 
examinations at 
baseline and final 
week / at withdrawal 
≥ 16-yearsold. Partial 
seizures with/without 
secondary 
generalisation or 
primary generalised 
seizures. Newly 
diagnosed epilepsy. At 
least 2-seizures in past 
12-months. Untreated 
patients must have had 
a seizure in past 3-
months. 
Absence/myoclonic seizure 
type, history of status 
epilepticus, progressive CNS 
disease, or seizures related 
to alcohol, acute mental 
illness or head-trauma.  
Previous treatment with LTG 
or GBP, pregnancy,  
TTW 291/309 
patients 
included in 
evaluable 
population. 19-
patients in each 
group had an 
exit event. All 
accounted for. 
Median TTW 69-days 
for GBP, 48-days for 
LTG. 71.6% of GBP and 
67.1% of LTG 
populations completed 
study. 80/106 (75.5%) 
of GBP and 73/96 (76%) 
of LTG patients 
remained seizure free 
during final 12-weeks. 
8.9% of GBP and 9.9% 
of LTG withdrew citing 
AEs. 
GBP and LTG were 
similarly effective 
and well tolerated in 
patients with newly 
diagnosed epilepsy. 
Marson 
et al2 
1721 LTG, 
n=378 
CBZ, 
n=378. 
GBP, 
n=377. 
OXC, 
n=210. 
TPM, 
n=378 
As per clinical 
judgment, aim to 
control seizures 
with minimum 
effective dose. 
Followed up at 3, 
6, 12, and yearly 
intervals. More-
regular if clinically 
indicated 
Unblinded, 
randomised, 
multicentre, 
controlled trial. 
Stratified according 
to centre, sex, 
treatment history. 
History of two or more 
clinically definite 
unprovoked epileptic 
seizures in previous 
year. CBZ deemed 
better standard 
treatment option 
compared with VPA 
(Arm B) 
Previous failed 
monotherapy for one of the 
AEDs in the study arm. 
Patient / clinician deemed 
treatment contraindicated. 
All seizures acute and 
symptomatic. 4-years old or 
younger. History of 
progressive neurological 
disease. 
TTW, time to 
12-month 
remission. 
71 deaths, all 
patient 
withdrawals 
accounted for. 
For TTF: LTG 
significantly better than 
CBZ (HR 0.78 [95% CI 
0.63-0.97]), GBP (0.65 
[0.52-0.79]) and 
showed a non-
significant advantage 
for OXC (1.15 [0.86-
1.54]). 
For time to 12-0-month 
remission, CBZ has a 
non-significant 
advantage versus LTG 
(0.91 [0.77-1.09]) 
LTG is clinically 
better than CBZ in 
terms of TTF. Given 
its non-inferiority in 
comparison to CBZ 
for time to 12-month 
remission, it is 
therefore a cost-
effective alternative 
for patients 
diagnosed with 
partial onset 
seizures. 
LTG = lamotrigine; CBZ = carbamazepine; AE = adverse effects; AED = antiepileptic drugs; TTW = time-to-withdrawal; PHT = phenytoin; GBP = gabapentin; OXC = oxcarbazepine; TPM = topiramate; HR = hazard ratio. 
Appendix Table 1: Summary of LTG monotherapy trials in the treatment of partial-onset seizures 
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Appendix II 
Appendix Table 2: Amino acid and codon table187 
Amino Acid Abbreviation DNA Codons 
Isoleucine I ATT, ATC, ATA 
Leucine L CTT, CTC, CTA, CTG, TTA, TTG 
Valine V GTT, GTC, GTA, GTG 
Phenylalanine F TTT, TTC 
Methionine M ATG 
Cysteine C TGT, TGC 
Alanine A GCT, GCC, GCA, GCG 
Glycine G GGT, GGC, GGA, GGG 
Proline P CCT, CCC, CCA, CCG 
Threonine T ACT, ACC, ACA, ACG 
Serine S TCT, TCC, TCA, TCG, AGT, AGC 
Tyrosine Y TAT, TAC 
Tryptophan W TGG 
Glutamine Q CAA, CAG 
Asparagine N AAT, AAC 
Histidine H CAT, CAC 
Glutamic acid E GAA, GAG 
Aspartic acid D GAT, GAC 
Lysine K AAA, AAG 
Arginine R CGT, CGC, CGA, CGG, AGA, AGG 
Stop codons Stop TAA, TAG, TGA 
  
 
1
0
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Appendix III  
SLC22A1 
Appendix Table 3: SLC22A1 haploview output - tSNPs 
Test Alleles Captured 
rs2297374 rs9295124, rs3798164, rs9295125, rs9295123, rs1443844, rs3818678, rs9347386, rs1382785, rs9347388, rs2297374, rs9295122 
rs4709400 rs3822841, rs1867351, rs4709399, rs4709400, rs3798173, rs6935207, rs7769472 
rs1871389 rs2083867, rs1871389, rs4709403, rs7744238, rs10455780 
rs3798168 rs1867350, rs1871388, rs3798168 
rs1564348 rs11753995, rs1564348, rs662138 
rs609468 rs609468, rs622591 
rs622342 rs650284, rs622342 
rs594709 rs628031, rs594709 
rs3101826 rs3101826 
rs9457843 rs9457843 
rs2197296 rs2197296 
rs6455682 rs6455682 
rs9456505 rs9456505 
rs3798167 rs3798167 
rs6937722 rs6937722 
rs7773429 rs7773429 
rs3798174 rs3798174 
rs461473 rs461473 
rs10455864 rs10455864 
rs644992 rs644992 
rs3777392 rs3777392 
rs683369 rs683369 
rs456598 rs456598 
rs10455868 rs10455868 
rs4646283 rs4646283 
rs651164 rs651164 
rs619598 rs619598 
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UGT1A4 
Appendix Table 4: UGT1A4 haploview output - tSNPs 
Test Alleles Captured 
rs3806591 rs2013030, rs3806591 
rs3755319 rs871514, rs7597496, rs4663333, rs2221198, rs4663965, rs10179091, rs4663967, rs3755319, rs3806597, rs4663969, rs4148326, 
rs10929301, rs6431628, rs6741669, rs7556676, rs6715325, rs3806596, rs4663971, rs4663963, rs7574296, rs4294999, rs4399719, 
rs2008595, rs4124874 
rs6714634 rs17864701, rs6744284, rs4148325, rs4148324, rs6742078, rs11695484, rs6714634, rs17862875, rs6722076, rs887829, rs10929302 
rs2018985 rs7604115, rs2018985, rs869283, rs11673726, rs11891311, rs1875263, rs10178992, rs11888459, rs7564935, rs1983023 
rs28899189 rs28898621, rs17862878, rs12463641, rs3796088, rs10929293, rs904855, rs1018124, rs4663964, rs904856, rs28898615, rs17864705, 
rs28899186, rs12468543, rs12468356, rs12466997, rs4663968, rs12479045, rs12466779, rs17863798, rs28899187, rs12052787, 
rs12479208, rs28899189 
rs6431632 rs1042640, rs1500482, rs8330, rs1587493, rs10199525, rs6431632, rs4663972, rs6431631, rs10929303 
rs11568318 rs11568318, rs17863800, rs17868341, rs17863795, rs6755571, rs28898590, rs17874945, rs17862874 
rs10199882 rs4663335, rs9287649, rs7586006, rs4663973, rs11563250, rs10199882 
rs6719561 rs6719561, rs6728520, rs6728940, rs6746002, rs10209214 
rs6717546 rs4148329, rs6717546, rs10199512 
rs11563251 rs11563251, rs6431630, rs11888492 
rs929596 rs13009407, rs929596 
rs3771342 rs3771342, rs2003569 
rs12475068 rs3755321, rs17868334, rs3806594, rs17863791, rs12477216, rs2013021, rs3732221, rs4556969, rs2013018, rs4663327, rs28898605, 
rs3732218, rs3806593, rs3806595, rs17862870, rs12475068, rs4233633, rs17874943, rs3732220, rs28946885, rs5020121, rs3892170, 
rs28898596, rs3893334, rs17863792, rs4663945, rs2885295 
rs4148328 rs4148328 
rs2302538 rs2302538 
rs2011404 rs2011404 
rs10203853 rs10203853 
rs6431633 rs6431633 
rs28946889 rs28946889 
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SCN1A 
Appendix Table 5: SCN1A haploview output - tSNPs 
 
  
Test Alleles Captured 
rs4667867 rs4667867, rs2390322, rs552878, rs545331, rs492299, rs2859817, rs10167228, rs7580482, rs504059, rs1841547, rs7423423, rs490317, 
rs13421166, rs4667503, rs2114760, rs2126152, rs508585, rs536744, rs545238, rs7601520, rs1834840, rs6432860, rs1461202, rs577306, 
rs565348, rs13006006, rs7598539, rs7574618, rs4667862, rs7606888, rs5006656, rs568141, rs567652, rs1461193, rs523119, rs3812719, 
rs2298771, rs4667861, rs496571, rs10930201 
rs4667866 rs4667866, rs16851381, rs2020035, rs16822821, rs16851356, rs12614431, rs16851327, rs1427651, rs12613942, rs994398, rs16851400, 
rs10497276, rs16851332, rs11674130, rs1381108, rs12998913, rs10497275, rs11686142, rs16851478, rs10930202 
rs7607629 rs4667869, rs7607455, rs484926, rs1841548, rs2169312, rs10497278, rs13405797, rs1020852, rs13383881, rs7607543, rs1841549, 
rs2162600, rs6731591, rs7607629 
rs1461197 rs1824551, rs967614, rs1461197, rs1381105, rs11691355, rs10202285, rs2217198, rs6722462, rs1381109, rs1824549, rs991716 
rs1841550 rs3812718, rs1542484, rs2195143, rs7609055, rs1841550, rs1972445, rs922224, rs1841546, rs10192608, rs13398150 
rs10168027 rs10188577, rs10197430, rs11692675, rs557222, rs11691603, rs10168027 
rs17744737 rs12999293, rs17744737, rs11884723 
rs10182473 rs6749076, rs1020853, rs10182473 
rs498631 rs498631, rs478389 
rs10176603 rs10176603 
rs1461195 rs1461195 
rs16851382 rs16851382 
rs17791817 rs17791817 
rs13406905 rs13406905 
rs13397210 rs13397210 
rs12151636 rs12151636 
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SCN2A 
Appendix Table 6: SCN2A haploview output - tSNPs 
Test Alleles Captured 
rs4667484 rs12467383, rs1991774, rs12464010, rs12468128, rs4667484, rs2390210, rs2304013, rs3769948, rs2043255, rs12619626, rs12614399, rs6744911, 
rs16850430, rs16850467, rs3943809, rs2075703, rs3769941, rs12469667, rs12477385, rs6731083, rs3754963, rs4667481, rs3769932, rs16850454, 
rs12468669, rs1864885, rs11889342, rs1947114, rs3769928, rs16850433, rs12619604, rs12618468, rs12612104, rs4667812, rs6718242, rs4667808, 
rs16850426 
rs12692768 rs4566378, rs7580734, rs7589423, rs10167223, rs2390258, rs764660, rs10204322, rs2116658, rs2163708, rs12692767, rs17245688, rs7581427, 
rs1368236, rs3769943, rs12692768, rs10199969, rs1579865, rs10203729 
rs7593568 rs353138, rs6432820, rs7596560, rs13023748, rs2075704, rs7593568, rs3769938, rs777138, rs13012293, rs1965757, rs1838847, rs11885321, rs2121371, 
rs4667805, rs10497259, rs1816918, rs7592445 
rs2304010 rs10930160, rs2043254, rs16850532, rs2304012, rs4667485, rs2304010, rs1432545, rs2892961, rs4667810, rs1007722, rs1821223, rs1368237, 
rs10181853, rs4296442, rs1469649, rs1821225 
rs4667807 rs10191771, rs17185905, rs2043256, rs6716702, rs7589614, rs10203424, rs4667807, rs4667809, rs7578237, rs4480996, rs935403, rs3769950, rs7596027, 
rs2060198, rs10930162, rs2116659 
rs4667802 rs10174400, rs10197716, rs10182570, rs7589211, rs13432006, rs16850290, rs10192208, rs4667802, rs1470089, rs6709306, rs1866604 
rs168478 rs353120, rs353115, rs353118, rs353119, rs353129, rs353121, rs353111, rs168478, rs353122 
rs12993173 rs12993173, rs7581811, rs1867864, rs353139, rs997508, rs1371466, rs7607897, rs6432817 
rs1966633 rs4303727, rs2390163, rs3769944, rs1966633, rs6738837, rs3769947, rs2304014 
rs17182982 rs17182645, rs6755708, rs17182714, rs1439804, rs2390162, rs17182982, rs6736704 
rs3769931 rs3769934, rs4387807, rs7567616, rs3769931, rs7586412, rs997507 
rs9287858 rs10209034, rs9287857, rs13413719, rs9287856, rs9287858 
rs2028892 rs1866603, rs1446579, rs2028892, rs1439805, rs1898970 
rs6740895 rs6740895, rs16850311, rs7561826 
rs6721613 rs6721613, rs12997787 
rs353112 rs353112, rs6741147 
rs13387970 rs13387970, rs3769949 
rs17182784 rs17182784, rs6718960 
rs17183814 rs1529668, rs17183814 
rs10207911 rs2119068, rs10207911 
rs353116 rs353128, rs353116 
rs7573433 rs7573433 
rs6705474 rs6705474 
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rs13025009 rs13025009 
rs7600082 rs7600082 
rs2119067 rs2119067 
rs353123 rs353123 
rs10497258 rs10497258 
rs10184275 rs10184275 
rs2060199 rs2060199 
rs16850317 rs16850317 
rs1368234 rs1368234 
rs17242693 rs17242693 
rs7566636 rs7566636 
rs17184707 rs17184707 
 
  
  
 
1
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SCN3A 
Appendix Table 7: SCN3A haploview output - tSNPs 
Test Alleles Captured 
rs16850191 rs4667793, rs3754962, rs7556825, rs11885920, rs16850188, rs4667789, rs7573017, rs11903523, rs16822785, rs4667795, rs16850191, rs4667787, 
rs3754961, rs16850192, rs1446576, rs6711595, rs16850186, rs4145346, rs6717810, rs7586796, rs7579000, rs2304710, rs4667790 
rs17829650 rs1982208, rs11903851, rs2289401, rs1439807, rs17829626, rs1982212, rs16850136, rs16850131, rs1439808, rs1899013, rs17829759, rs1982213, 
rs16850134, rs10930152, rs17829650, rs2028363 
rs11686777 rs10930151, rs10930149, rs1439993, rs1347992, rs11686777, rs1550385, rs3816195, rs10930148 
rs3731760 rs4667786, rs3731760, rs6432812, rs1158135, rs7598098, rs10048748 
rs17829560 rs17829596, rs17829560, rs10930150, rs13015737 
rs6755352 rs7572969, rs12464762, rs6755352, rs10497257, rs11898238, rs12615864, rs1583762 
rs11677254 rs11677254, rs11894144 
rs6719780 rs6719780, rs16850230 
rs2028891 rs2028891, rs6727857 
rs7571512 rs7571512, rs7574918 
rs6756406 rs6756406, rs1439806 
rs7596422 rs7596422 
rs1946892 rs1946892 
rs3213904 rs3213904 
rs4667792 rs4667792 
rs2028364 rs2028364 
rs2165208 rs2165208 
rs13011371 rs13011371 
rs2043932 rs2043932 
rs2390165 rs2390165 
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Appendix IV 
Screen-shot of GWAS database detailing the SNPs genotyped on Chromosome 2, position of each 
SNP, and the minor and major allele possibilities at each locus. 
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Screen-shot of GWAS database detailing the SNPs genotyped on Chromosome 6, position of each 
SNP, and the minor and major allele possibilities at each locus. 
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Appendix V 
Plate Design 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A EPI5821 SIEPI 045 AJC SIEPI 060 AJC SIEPI 020 AJC SIEPI 023 AJC EPI9497 BLANK EPI30169 BLANK EPI34419 EPI5584 EPI5107 
B EPI9500 EPI4618 EPI5290 EPI5113 EPI5659 EPI5731 BLANK EPI5911 EPI10106 EPI34446 EPI32099 EPI30454 
C BLANK EPI4747 EPI10070 EPI30169 EPI5911 EPI9701 SIEPI 045 AJC EPI9701 EPI17578 BLANK EPI34572 BLANK 
D EPI10172 EPI5566 EPI4777 EPI5938 EPI10196 EPI9410 BLANK BLANK BLANK EPI34530 EPI34212 EPI32015 
E EPI16975 EPI4753 EPI9662 EPI9710 EPI10106 EPI17578 SIEPI 020 AJC EPI10172 EPI31132 EPI45499 EPI5362 EPI32507 
F EPI31117 EPI31132 BLANK EPI5344 EPI30457 EPI10127 BLANK EPI5566 EPI5344 EPI5653 EPI44863 EPI101368 
G EPI34464 EPI45574 EPI30955 EPI34560 EPI34434 EPI34425 SIEPI 023 AJC EPI4777 EPI30457 EPI101395 EPI101122 EPI101167 
H EPI34419 EPI34446 EPI34530 EPI45499 EPI5653 EPI101395 EPI9497 EPI5938 BLANK EPI121932 EPI4984 EPI100942 
I EPI121932 EPI121719 EPI31973 EPI32297 EPI32522 EPI34239 EPI4618 EPI10196 EPI10127 EPI121719 BLANK EPI101368 
J EPI45466 EPI16972 EPI5584 EPI32099 EPI34572 EPI34212 BLANK BLANK EPI34464 EPI31973 EPI201462 EPI201462 
K EPI5362 EPI44863 EPI101122 EPI4984 EPI201462 EPG183957 EPI5113 BLANK EPI45574 BLANK EPG183957 EPI32060 
L EPI9479 EPI32060 EPI5800 EPI10058 EPI30499 EPI9791 BLANK EPI16975 EPI30955 EPI32297 EPI9479 EPI34572 
M EPI5107 EPI30454 BLANK EPI32015 EPI32507 EPI101368 BLANK EPI4753 BLANK EPI32522 EPI32060 BLANK 
N EPI101167 EPI100942 EPI5821 SIEPI 060 AJC EPI5659 EPI10070 EPI5731 EPI9662 EPI34560 EPI34239 EPI5800 EPI34434 
O EPI9701 EPI9410 EPI31117 EPI10127 EPI45574 BLANK EPI4747 EPI9710 EPI34434 EPI16972 EPI10058 EPI45499 
P EPI32507 EPI34446 EPI101395 EPI34239 EPI9479 EPI100942 BLANK BLANK EPI34425 BLANK EPI9791 EPI34464 
Plex 2 shown in grey 
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Appendix VI 
SLC22A1: 
 
 
  
Appendix Table 8: SLC22A1 one-way ANOVAs 
SNP (Minor 
allele) 
F-
Statistic 
Degrees of Freedom p-
value 
p-value 
rank 
FDR-corrected p-
value 
  Between 
Groups 
Within 
Groups 
   
rs3798173 (A) 5.102 2 92 0.008 1 1.424 
rs628031 (A) 4.567 2 93 0.013 4 0.579 
rs456598 (A) 4.264 2 93 0.017 5 0.605 
rs806383 (A) 3.393 2 93 0.038 12 0.564 
rs2197296 (A) 2.646 2 93 0.076 21 0.644 
rs1564348 (G) 2.306 2 93 0.105 31 0.603 
rs3798167 (A) 1.679 2 93 0.192 50 0.684 
rs622342 (C) 1.503 2 93 0.228 52 0.780 
rs654993 (A) 1.494 2 93 0.230 54 0.758 
rs3818678 (C) 0.940 2 93 0.394 80 0.877 
rs683369 (C) 0.801 2 93 0.452 88 0.914 
rs2297374 (A) 0.741 2 93 0.480 90 0.949 
rs3101826 (A) 0.719 2 93 0.490 92 0.948 
rs1443844 (G) 0.698 2 93 0.500 96 0.927 
rs10455868 (T) 0.447 2 67 0.641 116 0.984 
rs651164 (A) 0.308 2 93 0.735 137 0.955 
rs3798164 (A) 0.231 2 91 0.794 147 0.961 
rs10455864 (T) 0.168 2 67 0.846 157 0.959 
rs6455682 (A) 0.165 2 92 0.848 158 0.955 
rs4646275 (A) 0.155 2 93 0.856 160 0.952 
rs619598 (T) 0.155 2 68 0.857 161 0.947 
rs3798174 (A) 0.127 2 93 0.881 163 0.962 
rs1871389 (A) 0.112 2 93 0.894 167 0.953 
rs2083867 (G) 0.112 2 93 0.894 167 0.953 
rs4646283 (G) 0.085 2 92 0.919 174 0.940 
rs622591 (A) 0.062 2 93 0.940 176 0.951 
rs6937722 (A) 0.039 2 93 0.962 177 0.967 
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Appendix Table 9: SLC22A1 Student's t-tests 
Variable t-
statistic 
Degrees of 
freedom 
p-
value 
Mean 
difference 
95% Confidence 
interval for mean 
difference 
p-
value 
rank 
FDR-
corrected 
p-value 
Lower Upper 
rs461473 
(A) 
-2.575 67 0.012 -0.36837 -0.65394 -0.08280 3 0.712 
rs34059508 
(A) 
-2.151 69 0.035 -0.55731 -1.07413 -0.04049 11 0.566 
rs3777392 
(A) 
1.689 94 0.095 0.18918 -0.03325 0.41161 28 0.604 
rs4646272 
(C) 
-0.799 94 0.427 -0.10934 -0.38120 0.16251 84 0.905 
rs9457839 
(A) 
-0.680 94 0.498 -0.15965 -0.62559 0.30629 95 0.933 
rs9456505 
(A) 
0.601 69 0.549 0.08618 -0.19965 0.37200 100 0.977 
rs4646273 
(A) 
-0.470 94 0.640 -0.07564 -0.39548 0.24419 114 0.999 
rs3798168 
(A) 
-0.470 94 0.640 -0.07564 -0.39548 0.24419 114 0.999 
rs3798169 
(C) 
-0.427 93 0.671 -0.06845 -0.38707 0.25018 124 0.963 
rs9457843 
(A) 
-0.334 94 0.739 -0.03737 -0.25930 0.18457 138 0.953 
rs35956182 
(A) 
0.118 67 0.906 0.02519 -0.40073 0.45112 173 0.932 
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UGT1A4: 
 
 
Appendix Table 10: UGT1A4 one-way ANOVAs 
SNP (Minor 
allele) 
F-
Statistic 
Degrees of Freedom p-
value 
p-value 
rank 
FDR-corrected p-
value Between 
Groups 
Within 
Groups 
rs10209214 (G) 2.880 2 93 0.061 17 0.639 
rs6717546 (A) 2.642 2 93 0.077 22 0.623 
rs6431631 (C) 2.385 2 93 0.098 29 0.602 
rs6719561 (A) 2.323 2 93 0.104 30 0.617 
rs8330 (C) 2.140 2 92 0.124 39 0.566 
rs4148329 (G) 1.418 2 91 0.248 56 0.788 
rs4148325 (A) 0.543 2 93 0.583 101 1.027 
rs6742078 (A) 0.543 2 93 0.583 101 1.027 
rs887829 (A) 0.543 2 93 0.583 101 1.027 
rs3771341 (A) 0.463 2 93 0.631 109 1.030 
rs4148324 (C) 0.455 2 92 0.636 110 1.029 
rs2013018 (G) 0.438 2 93 0.647 117 0.984 
rs3755321 (G) 0.438 2 93 0.647 117 0.984 
rs4663945 (A) 0.438 2 93 0.647 117 0.984 
rs2221198 (A) 0.427 2 93 0.654 120 0.970 
rs4124874 (C) 0.417 2 92 0.660 122 0.963 
rs2008595 (A) 0.388 2 93 0.679 125 0.967 
rs3755319 (C) 0.388 2 93 0.679 125 0.967 
rs4148326 (G) 0.388 2 93 0.679 125 0.967 
rs4663327 (A) 0.387 2 92 0.680 129 0.938 
rs2018985 (G) 0.382 2 93 0.684 130 0.937 
rs4294999 (G) 0.294 2 92 0.746 139 0.955 
rs4663963 (C) 0.294 2 92 0.746 139 0.955 
rs6744284 (A) 0.274 2 93 0.761 141 0.961 
rs4148328 (A) 0.225 2 93 0.799 148 0.961 
rs3806591 (G) 0.174 2 68 0.840 156 0.958 
rs4663335 (A) 0.137 2 93 0.872 162 0.958 
rs1018124 (G) 0.111 2 93 0.895 169 0.943 
rs4663968 (G) 0.111 2 93 0.895 169 0.943 
rs11563251 (A) 0.102 2 93 0.903 171 0.940 
Appendix Table 11: UGT1A4 Student's t-tests 
Variable t-
statistic 
Degrees of 
freedom 
p-
value 
Mean 
difference 
95% Confidence 
interval for mean 
difference 
p-
value 
rank 
FDR-
corrected 
p-value 
Lower Upper 
rs17862884 
(A) 
-1.136 94 0.259 -0.26543 -0.72934 0.19849 60 0.768 
rs6431633 
(A) 
0.627 67 0.533 0.07426 -0.16198 0.31049 98 0.968 
rs2302538 
(G) 
-0.293 92 0.770 -0.03246 -0.25268 0.18775 144 0.952 
rs11568318 
(A) 
-0.215 92 0.830 -0.02985 -0.30536 0.24566 154 0.959 
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SCN1A: 
 
 
 
  
Appendix Table 12: SCN1A one-way ANOVAs 
SNP (Minor 
allele) 
F-
Statistic 
Degrees of Freedom p-
value 
p-value 
rank 
FDR-corrected p-
value Between 
Groups 
Within 
Groups 
rs922224 (G) 2.889 2 93 0.061 17 0.639 
rs478389 (C) 1.952 2 67 0.150 42 0.636 
rs10176603 (A) 1.498 2 93 0.229 53 0.769 
rs484926 (G) 1.380 2 93 0.257 58 0.789 
rs6731591 (G) 1.380 2 93 0.257 58 0.789 
rs13397210 (A) 1.324 2 93 0.271 62 0.778 
rs1841548 (G) 1.324 2 93 0.271 62 0.778 
rs10183551 (G) 1.253 2 93 0.290 64 0.807 
rs7607455 (G) 1.143 2 93 0.323 68 0.846 
rs16851382 (A) 1.134 2 93 0.326 71 0.817 
rs11692675 (G) 0.995 2 93 0.374 74 0.900 
rs10497275 (G) 0.815 2 93 0.446 86 0.923 
rs10497276 (A) 0.815 2 93 0.446 86 0.923 
rs12998913 (G) 0.709 2 93 0.495 93 0.947 
rs536744 (A) 0.539 2 92 0.585 104 1.001 
rs6722462 (G) 0.498 2 93 0.609 106 1.023 
rs577306 (A) 0.485 2 93 0.617 107 1.026 
rs1020853 (A) 0.476 2 93 0.623 108 1.027 
rs13421166 (C) 0.455 2 93 0.636 110 1.029 
rs1834840 (G) 0.455 2 93 0.636 110 1.029 
rs4667867 (A) 0.455 2 93 0.636 110 1.029 
rs1381109 (A) 0.388 2 93 0.679 125 0.967 
rs1824549 (C) 0.359 2 93 0.700 131 0.951 
rs545331 (A) 0.268 2 93 0.766 142 0.960 
Appendix Table 13: SCN1A Student's t-tests 
Variable t-
statistic 
Degrees of 
freedom 
p-
value 
Mean 
difference 
95% Confidence 
interval for mean 
difference 
p-
value 
rank 
FDR-
corrected 
p-value 
Lower Upper 
rs17791817 
(T) 
1.568 68 0.122 0.21626 -0.05897 0.49149 38 0.571 
rs12151636 
(C) 
1.125 69 0.264 0.23459 -0.18137 0.65054 61 0.770 
rs7606193 
(G) 
0.236 94 0.814 0.07769 -0.57561 0.73099 151 0.960 
rs9678982 
(G) 
0.236 94 0.814 0.07769 -0.57561 0.73099 151 0.960 
rs6735544 
(G) 
-0.148 94 0.883 -0.06848 -0.98767 0.85071 164 0.958 
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SCN2A: 
 
Appendix Table 14: SCN2A one-way ANOVAs 
SNP (Minor 
allele) 
F-
Statistic 
Degrees of Freedom p-
value 
p-value 
rank 
FDR-corrected p-
value Between 
Groups 
Within 
Groups 
rs12993173 (C) 4.256 2 92 0.017 5 0.605 
rs1439805 (C) 4.184 2 93 0.018 7 0.458 
rs9287856 (A) 3.724 2 93 0.028 8 0.623 
rs9287857 (G) 3.724 2 93 0.028 8 0.623 
rs1866603 (G) 3.629 2 93 0.030 10 0.534 
rs17184707 (A) 3.384 2 93 0.039 13 0.534 
rs10174400 (A) 3.108 2 91 0.049 14 0.623 
rs10182570 (C) 3.040 2 93 0.053 15 0.629 
rs10184275 (G) 2.894 2 93 0.060 16 0.668 
rs7607897 (A) 2.861 2 92 0.062 19 0.581 
rs10207911 (G) 2.760 2 93 0.068 20 0.605 
rs353119 (A) 2.622 2 93 0.078 23 0.604 
rs353121 (G) 2.622 2 93 0.078 23 0.604 
rs1439804 (A) 2.453 2 93 0.092 27 0.607 
rs353111 (C) 2.290 2 93 0.107 33 0.577 
rs2119067 (G) 2.208 2 93 0.116 37 0.558 
rs6741147 (T) 2.003 2 68 0.143 40 0.636 
rs353123 (A) 1.912 2 93 0.154 43 0.637 
rs353139 (G) 1.734 2 93 0.182 49 0.661 
rs13025009 (G) 1.676 2 93 0.193 51 0.674 
rs7600082 (T) 1.429 2 68 0.247 55 0.799 
rs3769941 (G) 1.411 2 93 0.249 57 0.778 
rs2304010 (A) 1.142 2 93 0.324 69 0.836 
rs2892961 (A) 1.142 2 93 0.324 69 0.836 
rs1965757 (G) 1.089 2 93 0.341 73 0.831 
rs10497259 (A) 0.963 2 93 0.385 75 0.914 
rs1838847 (A) 0.963 2 93 0.385 75 0.914 
rs3769931 (G) 0.966 2 93 0.385 75 0.914 
rs7573433 (G) 0.909 2 68 0.408 81 0.897 
rs4667481 (G) 0.858 2 93 0.427 84 0.905 
rs13387970 (A) 0.793 2 93 0.456 89 0.912 
rs12469667 (A) 0.689 2 92 0.505 97 0.927 
rs6718960 (G) 0.619 2 92 0.541 99 0.973 
rs10497258 (G) 0.533 2 93 0.589 105 0.998 
rs1368234 (C) 0.418 2 68 0.660 122 0.963 
rs764660 (C) 0.333 2 93 0.718 133 0.961 
rs10203729 (C) 0.319 2 93 0.728 134 0.967 
rs10204322 (A) 0.319 2 93 0.728 134 0.967 
rs2116658 (A) 0.319 2 93 0.728 134 0.967 
rs2116659 (A) 0.268 2 93 0.766 142 0.960 
rs10930162 (G) 0.261 2 93 0.771 145 0.946 
rs4480996 (G) 0.261 2 93 0.771 145 0.946 
rs17183814 (A) 0.115 2 68 0.892 166 0.956 
rs6740895 (G) 0.100 2 93 0.905 172 0.937 
rs2060199 (A) 0.016 2 68 0.984 178 0.984 
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SCN3A: 
 
  
Appendix Table 15: SCN2A Student's t-tests 
Variable t-
statistic 
Degrees of 
freedom 
p-
value 
Mean 
difference 
95% Confidence 
interval for mean 
difference 
p-
value 
rank 
FDR-
corrected 
p-value 
Lower Upper 
rs2304016 
(G) 
1.400 93 0.165 0.63869 -0.26702 1.54339 44 0.668 
rs13424762 
(G) 
1.379 94 0.171 0.63196 -0.27818 1.54211 46 0.662 
rs6714217 
(G) 
1.379 94 0.171 0.63196 -0.27818 1.54211 46 0.662 
rs10803795 
(G) 
0.242 94 0.810 0.04366 -0.31522 0.40253 150 0.961 
rs17242693 
(A) 
-0.189 94 0.850 -0.02913 -0.33461 0.27636 159 0.952 
rs4303727 
(G) 
-0.146 94 0.884 -0.01456 -0.21235 0.18341 165 0.954 
Appendix Table 16: SCN3A one-way ANOVAs 
SNP (Minor 
allele) 
F-
Statistic 
Degrees of Freedom p-
value 
p-value 
rank 
FDR-corrected p-
value Between 
Groups 
Within 
Groups 
rs11903851 (A) 5.018 2 93 0.009 2 0.801 
rs1899013 (G) 2.555 2 93 0.083 25 0.591 
rs1982208 (C) 2.555 2 93 0.083 25 0.591 
rs1946892 (A) 2.283 2 68 0.110 34 0.576 
rs11686777 (A) 2.218 2 93 0.115 35 0.585 
rs1347992 (G) 2.218 2 93 0.115 35 0.585 
rs17829596 (G) 1.989 2 93 0.143 40 0.636 
rs1439806 (A) 1.836 2 93 0.165 44 0.668 
rs11677254 (G) 1.814 2 68 0.171 46 0.662 
rs13011371 (G) 1.247 2 91 0.292 65 0.800 
rs7574918 (A) 1.204 2 93 0.304 66 0.820 
rs4667792 (G) 1.151 2 92 0.321 67 0.853 
rs13015737 (A) 0.945 2 93 0.392 78 0.895 
rs4667786 (G) 0.943 2 93 0.393 79 0.885 
rs10497257 (G) 0.867 2 93 0.423 82 0.918 
rs4145346 (G) 0.867 2 93 0.423 82 0.918 
rs6727857 (G) 0.706 2 93 0.496 94 0.939 
rs6755352 (G) 0.426 2 93 0.654 120 0.970 
rs2165208 (A) 0.219 2 93 0.803 149 0.959 
rs2043932 (A) 0.182 2 93 0.834 155 0.958 
rs2390165 (A) 0.075 2 93 0.928 175 0.944 
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Appendix VII 
SLC22A1 
rs806383 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.038, uncorrected). This intronic SNP is found in SLC22A1 and did not tag any 
additional SNPs. The homozygous-minor allele group (AA) appeared to require a higher maintenance 
dose of LTG than the homozygous-major allele group (GG) (Appendix Table 17 and Appendix Table 
18). Comparison with the heterozygous group (GA) failed to reach statistical significance but there 
was modest evidence of an allele-specific effect on dose, with carriers of the A-allele requiring higher 
maintenance doses of LTG (Figure 10). 
 
Appendix Table 17: Back transformed dose data for rs806383 
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
GG 46 176 50 500 
GA 39 183 100 500 
AA 11 259 150 675 
Total 96 187 50 675 
Appendix Table 18: Back-transformed dose data for rs806383 - between groups comparison 
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
GG GA 0.959 0.757 1.214 0.962 
AA 0.679* 0.471 0.978 0.034 
GA GG 1.043 0.823 1.321 0.962 
AA 0.708 0.489 1.026 0.076 
AA GG 1.473* 1.023 2.121 0.034 
GA 1.412 0.975 2.046 0.076 
* The mean difference is significant at the 0.05 level. 
Number of participants: GG = 46, GA = 39, AA = 11, Total = 96 
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Figure 10: Dose distribution between rs806383 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: GG = 46, GA = 39, AA = 11, Total = 96 
rs34059508 
Student’s t-test identified a significant association between maintenance dose and genotype at this 
SNP locus (p=0.035, uncorrected). This is a coding non-synonymous SNP in SLC22A1 that results in a 
G465R amino acid substitution in the OCT1 protein. It did not tag any additional SNPs. The 
heterozygous group (GA, geometric mean = 311mg/day, n=3) appeared to require a higher 
maintenance dose of LTG than the homozygous-major allele group (GG, geometric mean = 
178mg/day, n=68) (Appendix Table 19). Again, with only two genotypes at this locus, it was not 
possible to infer allele-specific effects. 
Appendix Table 19: Back-transformed dose data for rs34059508 – between groups comparison 
Variable t-
statistic 
Degrees 
of 
freedom 
Ratio of 
Geometric 
means 
95% CI of Ratio 
of Geometric 
Means 
p-
value 
p-
value 
rank 
FDR-
corrected 
p-value 
Lower Upper 
rs34059508 
(A) 
-2.151 69 0.573 0.342 0.960 0.035 3 0.712 
Number of participants: GG = 68, GA = 3, Total = 71 
 119 
 
 
 
Figure 11: Dose distribution between rs34059508 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: GG = 68, GA = 3, Total = 71 
 
SCN2A 
rs9287856 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.028, uncorrected). This intronic SNP is found in SCN2A and tagged an additional four 
SNPs (Appendix Table 6). A statistically significant difference between the individual genotype groups 
could not be identified in post-hoc tests (Appendix Table 20 and Appendix Table 21). There was some 
evidence of an allele-specific effect on dose, with carriers of the A-allele requiring higher 
maintenance doses of LTG (Figure 12). 
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Figure 12: Dose distribution between rs9287856 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: GG = 66, GA = 26, AA = 4, Total = 96 
Appendix Table 20: Back-transformed dose data for rs9287856 
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
GG 66 174 50 500 
GA 26 207 100 675 
AA 4 300 200 450 
Total 96 187 50 675 
Appendix Table 21: Back-transformed dose data for rs9287856 – between groups comparison 
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
GG GA 0.843 0.644 1.104 0.284 
AA 0.582 0.304 1.112 0.083 
GA GG 1.186 0.906 1.554 0.284 
AA 0.690 0.375 1.270 0.218 
AA GG 1.720 0.899 3.289 0.083 
GA 1.450 0.788 2.668 0.218 
Number of participants: GG = 66, GA = 26, AA = 4, Total = 96 
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rs9287857 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.028, uncorrected). This intronic SNP is found in SCN2A (Appendix Table 6) and tagged 
an additional four SNPs. A statistically significant difference between the individual genotype groups 
could not be identified in post-hoc tests (Appendix Table 22 and Appendix Table 23). There was some 
evidence of an allele-specific effect on dose, with carriers of the A-allele requiring higher 
maintenance doses of LTG (Figure 13). 
 
 
Appendix Table 22: Back-transformed dose data for rs9287857 
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
AA 66 174 50 500 
AG 26 207 100 675 
GG 4 300 200 450 
Total 96 187 50 675 
Appendix Table 23: Back-transformed dose data for rs9287857 – between groups comparison 
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
AA AG 0.843 0.656 1.083 0.272 
GG 0.582 0.333 1.016 0.059 
AG AA 1.186 0.923 1.524 0.272 
GG 0.690 0.386 1.234 0.326 
GG AA 1.720 0.985 3.003 0.059 
AG 1.450 0.810 2.593 0.326 
Number of participants: AA = 66, AG = 26, GG = 4, Total = 96 
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Figure 13: Dose distribution between rs9287857 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: AA = 66, AG = 26, GG = 4, Total = 96 
 
rs1866603 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.030, uncorrected). This intronic SNP is found in SCN2A and tagged an additional four 
SNPs (Appendix Table 6). The homozygous-minor allele group (GG) appeared to require a higher 
maintenance dose of LTG than the heterozygous group (AG) (Appendix Table 24 and Appendix Table 
25). Comparison with the homozygous-major allele group (AA) failed to reach statistical significance 
and there no was no evidence of an allele-specific effect on dose (Figure 14). 
  
Appendix Table 24: Back-transformed dose data for rs1866603 
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
AA 22 187 100 500 
AG 55 172 50 675 
GG 19 237 150 500 
Total 96 187 50 675 
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Figure 14: Dose distribution between rs1866603 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: AA = 22, AG = 55, GG = 19, Total = 96 
  
Appendix Table 25: Back-transformed dose data for rs1866603 - between groups comparison 
Compared Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
AA AG 1.087 0.827 1.429 0.839 
GG 0.790 0.563 1.109 0.256 
AG AA 0.920 0.700 1.209 0.839 
GG 0.726* 0.544 0.969 0.025 
GG AA 1.266 0.902 1.778 0.256 
AG 1.377* 1.032 1.837 0.025 
*The mean difference is significant at the 0.05 level. 
Number of participants: AA = 22, AG = 55, GG = 19, Total = 96 
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rs17184707 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.039, uncorrected). This intronic SNP is found in SCN2A and did not tag any additional 
SNPs. A statistically significant difference between the individual genotype groups could not be 
identified in post-hoc tests (Appendix Table 26 and Appendix Table 27). There was some evidence of 
an allele-specific effect on dose, with carriers of the A-allele requiring higher maintenance doses of 
LTG (Figure 15). 
 
 
Appendix Table 26: Back transformed dose data for rs17184707 
Genotype 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
GG 53 173 50 500 
GA 39 198 100 500 
AA 4 300 150 675 
Total 96 187 50 675 
Appendix Table 27: Back-transformed dose data for rs17184707 - between groups comparison 
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
GG GA 0.874 0.695 1.100 0.401 
AA 0.577 0.328 1.013 0.057 
GA GG 1.144 0.909 1.438 0.401 
AA 0.659 0.373 1.166 0.218 
AA GG 1.734 0.987 3.047 0.057 
GA 1.517 0.857 2.683 0.218 
Number of participants: GG = 53, GA = 39, AA = 4, Total = 96 
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Figure 15: Dose distribution between rs17184707 genotypes 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
Number of participants: GG = 53, GA = 39, AA = 4, Total = 96 
rs10174400 
ANOVA identified a significant association between maintenance dose of LTG and genotype at this 
SNP locus (p=0.049, uncorrected). This intronic SNP is found in SCN2A and tagged an additional ten 
SNPs (Appendix Table 6). The homozygous-minor allele group (AA) appeared to require a higher 
maintenance dose of LTG than the homozygous-major allele group (GG) (Appendix Table 28 and 
Appendix Table 29). Comparison with the heterozygous group (GA) failed to reach statistical 
significance but there was modest evidence of an allele-specific effect on dose, with carriers of the G-
allele requiring higher maintenance doses of LTG (Figure 16). 
Appendix Table 28: Back transformed dose data for rs10174400 
Genotypes 
Number of 
Participants 
Mean Dose 
(mg/day) 
Minimum Dose 
(mg/day) 
Maximum Dose 
(mg/day) 
GG 43 170 50 500 
GA 44 189 100 675 
AA 7 265 150 500 
Total 94 185 50 675 
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Figure 16: Dose distribution between rs10174400 genotypes 
Number of participants: GG = 43, GA = 44, AA = 7, Total = 94 
Appendix Table 29: Back-transformed dose data for rs10174400 - between groups comparison 
Compared 
Genotypes 
Ratio of Geometric 
Means 
95% Confidence Interval for Ratio of 
Geometric Means 
Significance Lower Boundary Upper Boundary 
GG GA 0.901 0.716 1.134 0.616 
AA 0.643* 0.415 0.997 0.048 
GA GG 1.110 0.882 1.397 0.616 
AA 0.714 0.461 1.105 0.179 
AA GG 1.554* 1.003 2.407 0.048 
GA 1.401 0.905 2.168 0.179 
*. The mean difference is significant at the 0.05 level. 
Number of participants: GG = 43, GA = 44, AA = 7, Total = 94 
 
Top box boundary = third quartile, lower boundary = first quartile, and bold line = median. Whiskers = 
values within 1.5 x inter-quartile range (IQR) outside the box. Circles = values 1.5 to 3 x IQR outside 
the box. Stars = values more than 3 x IQR outside the box. 
